WO2014031594A2 - Modulating voltage-operated calcium channels on immune cells - Google Patents
Modulating voltage-operated calcium channels on immune cells Download PDFInfo
- Publication number
- WO2014031594A2 WO2014031594A2 PCT/US2013/055711 US2013055711W WO2014031594A2 WO 2014031594 A2 WO2014031594 A2 WO 2014031594A2 US 2013055711 W US2013055711 W US 2013055711W WO 2014031594 A2 WO2014031594 A2 WO 2014031594A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- disease
- type calcium
- calcium channel
- selective
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 49
- 102000003922 Calcium Channels Human genes 0.000 title claims abstract description 30
- 108090000312 Calcium Channels Proteins 0.000 title claims abstract description 30
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 124
- 238000000034 method Methods 0.000 claims abstract description 91
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 240
- 108090000030 T-Type Calcium Channels Proteins 0.000 claims description 215
- 102000003691 T-Type Calcium Channels Human genes 0.000 claims description 214
- 210000004027 cell Anatomy 0.000 claims description 178
- 239000003795 chemical substances by application Substances 0.000 claims description 141
- 201000010099 disease Diseases 0.000 claims description 129
- 208000035475 disorder Diseases 0.000 claims description 111
- 230000000694 effects Effects 0.000 claims description 97
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 81
- 210000001519 tissue Anatomy 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 39
- 210000000056 organ Anatomy 0.000 claims description 38
- 150000003384 small molecules Chemical class 0.000 claims description 36
- 239000003112 inhibitor Substances 0.000 claims description 32
- -1 TTA-Q3 Chemical compound 0.000 claims description 27
- 230000002829 reductive effect Effects 0.000 claims description 19
- 208000023275 Autoimmune disease Diseases 0.000 claims description 17
- 108091030071 RNAI Proteins 0.000 claims description 17
- 230000024245 cell differentiation Effects 0.000 claims description 17
- 230000009368 gene silencing by RNA Effects 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 16
- 230000036407 pain Effects 0.000 claims description 16
- 210000000952 spleen Anatomy 0.000 claims description 16
- 238000011161 development Methods 0.000 claims description 15
- 230000018109 developmental process Effects 0.000 claims description 15
- 230000001404 mediated effect Effects 0.000 claims description 15
- 201000006417 multiple sclerosis Diseases 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 13
- 239000003018 immunosuppressive agent Substances 0.000 claims description 13
- GEYDMBNDOVPFJL-CYBMUJFWSA-N 2-(4-cyclopropylphenyl)-n-[(1r)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl]acetamide Chemical compound N([C@H](C)C=1N=CC(OCC(F)(F)F)=CC=1)C(=O)CC(C=C1)=CC=C1C1CC1 GEYDMBNDOVPFJL-CYBMUJFWSA-N 0.000 claims description 10
- 230000001861 immunosuppressant effect Effects 0.000 claims description 10
- 208000035473 Communicable disease Diseases 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 9
- 210000001185 bone marrow Anatomy 0.000 claims description 9
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 9
- IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 8
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 8
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 230000008499 blood brain barrier function Effects 0.000 claims description 8
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 210000001165 lymph node Anatomy 0.000 claims description 8
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 7
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 230000003111 delayed effect Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 claims description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 208000004631 alopecia areata Diseases 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 6
- 229960004438 mibefradil Drugs 0.000 claims description 6
- 239000002777 nucleoside Substances 0.000 claims description 6
- 229960001967 tacrolimus Drugs 0.000 claims description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 6
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 5
- 206010061818 Disease progression Diseases 0.000 claims description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 claims description 5
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 5
- 230000005750 disease progression Effects 0.000 claims description 5
- 229950003102 efonidipine Drugs 0.000 claims description 5
- 230000005713 exacerbation Effects 0.000 claims description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 5
- 238000012552 review Methods 0.000 claims description 5
- 210000001541 thymus gland Anatomy 0.000 claims description 5
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 claims description 4
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 4
- 229960002170 azathioprine Drugs 0.000 claims description 4
- PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 claims description 4
- 229950010231 brequinar Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 229960000681 leflunomide Drugs 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 229960001428 mercaptopurine Drugs 0.000 claims description 4
- 229960003729 mesuximide Drugs 0.000 claims description 4
- 229950000844 mizoribine Drugs 0.000 claims description 4
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 4
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- OQUXVPJVBSENGK-QXMHVHEDSA-N (z)-2,5-dicyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]pent-2-enamide Chemical compound N#CCCC(/O)=C(\C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 OQUXVPJVBSENGK-QXMHVHEDSA-N 0.000 claims description 3
- OURCOVUGQRXRTE-CQSZACIVSA-N 2-[4-(3-methylpyrazin-2-yl)phenyl]-n-[(1r)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl]acetamide Chemical compound N([C@H](C)C=1N=CC(OCC(F)(F)F)=CC=1)C(=O)CC(C=C1)=CC=C1C1=NC=CN=C1C OURCOVUGQRXRTE-CQSZACIVSA-N 0.000 claims description 3
- OVRNWJYZCIAMGV-HXUWFJFHSA-N 4-[(4s)-6-chloro-4-cyclopropyl-2-oxo-3-(2,2,2-trifluoroethyl)-1h-quinazolin-4-yl]benzonitrile Chemical compound C1([C@@]2(C3=CC(Cl)=CC=C3NC(=O)N2CC(F)(F)F)C=2C=CC(=CC=2)C#N)CC1 OVRNWJYZCIAMGV-HXUWFJFHSA-N 0.000 claims description 3
- LAMQVIQMVKWXOC-UHFFFAOYSA-N 4-methyl-n-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCOCC1 LAMQVIQMVKWXOC-UHFFFAOYSA-N 0.000 claims description 3
- JYJFNDQBESEHJQ-UHFFFAOYSA-N 5,5-dimethyloxazolidine-2,4-dione Chemical compound CC1(C)OC(=O)NC1=O JYJFNDQBESEHJQ-UHFFFAOYSA-N 0.000 claims description 3
- AGPIHNZOZNKRGT-CYBMUJFWSA-N 5-[(8ar)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine-2-carbonyl]-4-chloro-2-fluoro-n-(2-fluorophenyl)benzenesulfonamide Chemical compound FC1=CC=CC=C1NS(=O)(=O)C1=CC(C(=O)N2C[C@H]3CCCN3CC2)=C(Cl)C=C1F AGPIHNZOZNKRGT-CYBMUJFWSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 3
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 3
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 235000021318 Calcifediol Nutrition 0.000 claims description 3
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 102000006395 Globulins Human genes 0.000 claims description 3
- 108010044091 Globulins Proteins 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000003807 Graves Disease Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000000209 Isaacs syndrome Diseases 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- 101710103741 Kurtoxin Proteins 0.000 claims description 3
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 3
- 201000005505 Measles Diseases 0.000 claims description 3
- 206010028424 Myasthenic syndrome Diseases 0.000 claims description 3
- 201000002481 Myositis Diseases 0.000 claims description 3
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 claims description 3
- 206010072359 Neuromyotonia Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 3
- 201000005702 Pertussis Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- 208000003782 Raynaud disease Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 3
- 206010043376 Tetanus Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 claims description 3
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- PZDPVSFZTKORSP-UHFFFAOYSA-N [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-(3-aminobutylamino)butyl]carbamate Chemical compound CC(N)CCNCCCCNC(=O)OCC(=O)NCCCCCCNC(N)=N PZDPVSFZTKORSP-UHFFFAOYSA-N 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 3
- 208000001974 autoimmune enteropathy Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims description 3
- 201000004339 autoimmune neuropathy Diseases 0.000 claims description 3
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 claims description 3
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 claims description 3
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000029407 autoimmune urticaria Diseases 0.000 claims description 3
- 229960004669 basiliximab Drugs 0.000 claims description 3
- 229960005347 belatacept Drugs 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960004361 calcifediol Drugs 0.000 claims description 3
- 235000020964 calcitriol Nutrition 0.000 claims description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 3
- 229960005084 calcitriol Drugs 0.000 claims description 3
- 239000011612 calcitriol Substances 0.000 claims description 3
- 208000024376 chronic urticaria Diseases 0.000 claims description 3
- 238000011970 concomitant therapy Methods 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 229960002806 daclizumab Drugs 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 229950004446 dimethadione Drugs 0.000 claims description 3
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 3
- 229960002767 ethosuximide Drugs 0.000 claims description 3
- 229960000556 fingolimod Drugs 0.000 claims description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 239000000138 intercalating agent Substances 0.000 claims description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 3
- 229940070813 lymphocyte immune globulin Drugs 0.000 claims description 3
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 229960003816 muromonab-cd3 Drugs 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 229960000951 mycophenolic acid Drugs 0.000 claims description 3
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 229960004227 phensuximide Drugs 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 229960005205 prednisolone Drugs 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- 235000005875 quercetin Nutrition 0.000 claims description 3
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000006379 syphilis Diseases 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 206010043778 thyroiditis Diseases 0.000 claims description 3
- 208000009174 transverse myelitis Diseases 0.000 claims description 3
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims description 3
- 229960004453 trimethadione Drugs 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 102000009310 vitamin D receptors Human genes 0.000 claims description 3
- 108050000156 vitamin D receptors Proteins 0.000 claims description 3
- HQZBFDAIHIKVRO-CXAGYDPISA-N 3,5-dichloro-n-[[(3s,4r)-1-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl]benzamide Chemical compound F[C@@H]1CN(CCC(C)(C)C)CC[C@@H]1CNC(=O)C1=CC(Cl)=CC(Cl)=C1 HQZBFDAIHIKVRO-CXAGYDPISA-N 0.000 claims description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 2
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims description 2
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims description 2
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000016905 Hashimoto encephalopathy Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 101710183280 Topoisomerase Proteins 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 210000004324 lymphatic system Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000002123 temporal effect Effects 0.000 claims description 2
- 208000037972 tropical disease Diseases 0.000 claims description 2
- 210000002229 urogenital system Anatomy 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- DKNDOKIVCXTFHJ-HNNXBMFYSA-N 3,5-dichloro-n-[[1-[[(4s)-2,2-dimethyloxan-4-yl]methyl]-4-fluoropiperidin-4-yl]methyl]benzamide Chemical compound C1COC(C)(C)C[C@H]1CN1CCC(F)(CNC(=O)C=2C=C(Cl)C=C(Cl)C=2)CC1 DKNDOKIVCXTFHJ-HNNXBMFYSA-N 0.000 claims 3
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 claims 1
- 210000000068 Th17 cell Anatomy 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 66
- 241000282414 Homo sapiens Species 0.000 description 63
- 102000004196 processed proteins & peptides Human genes 0.000 description 63
- 229920001184 polypeptide Polymers 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 52
- 150000001413 amino acids Chemical class 0.000 description 47
- 150000007523 nucleic acids Chemical class 0.000 description 46
- 235000001014 amino acid Nutrition 0.000 description 44
- 229940024606 amino acid Drugs 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 42
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 40
- 102000039446 nucleic acids Human genes 0.000 description 35
- 108020004707 nucleic acids Proteins 0.000 description 35
- 108091006146 Channels Proteins 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 239000002773 nucleotide Substances 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 32
- 239000011575 calcium Substances 0.000 description 31
- 201000002491 encephalomyelitis Diseases 0.000 description 29
- 239000012634 fragment Substances 0.000 description 28
- 229910052791 calcium Inorganic materials 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 25
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 24
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 24
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 24
- 230000027455 binding Effects 0.000 description 24
- 239000000126 substance Substances 0.000 description 24
- 239000000427 antigen Substances 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 23
- 239000000523 sample Substances 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 229920000642 polymer Polymers 0.000 description 20
- 210000003169 central nervous system Anatomy 0.000 description 19
- 230000000875 corresponding effect Effects 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 15
- 230000007935 neutral effect Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 14
- 101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000004055 small Interfering RNA Substances 0.000 description 12
- 210000004988 splenocyte Anatomy 0.000 description 12
- 108010052285 Membrane Proteins Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 239000012190 activator Substances 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 238000001114 immunoprecipitation Methods 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 10
- 102100025482 Voltage-dependent T-type calcium channel subunit alpha-1H Human genes 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 239000013558 reference substance Substances 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 10
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 101000932785 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1I Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 102100033024 Voltage-dependent T-type calcium channel subunit alpha-1G Human genes 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000009258 tissue cross reactivity Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000003119 immunoblot Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 102000020167 Calcium release-activated calcium channel Human genes 0.000 description 7
- 108091022898 Calcium release-activated calcium channel Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000018697 Membrane Proteins Human genes 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000003185 calcium uptake Effects 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 230000002452 interceptive effect Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108090000862 Ion Channels Proteins 0.000 description 6
- 102000004310 Ion Channels Human genes 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 210000001638 cerebellum Anatomy 0.000 description 6
- 150000005829 chemical entities Chemical class 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- 229940124641 pain reliever Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000003393 splenic effect Effects 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 5
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000009460 calcium influx Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001934 delay Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000007783 downstream signaling Effects 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000011285 therapeutic regimen Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- NWGGKKGAFZIVBJ-UHFFFAOYSA-N antrafenine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCOC(=O)C=3C(=CC=CC=3)NC=3C4=CC=C(C=C4N=CC=3)C(F)(F)F)CC2)=C1 NWGGKKGAFZIVBJ-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101150084750 1 gene Proteins 0.000 description 3
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 201000005866 Exanthema Subitum Diseases 0.000 description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- 206010016946 Food allergy Diseases 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 3
- 102100033461 Interleukin-17A Human genes 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 208000007542 Paresis Diseases 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 229940123939 T-type calcium channel antagonist Drugs 0.000 description 3
- 102100025484 Voltage-dependent T-type calcium channel subunit alpha-1I Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003659 bee venom Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 235000020932 food allergy Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 210000005211 primary lymphoid organ Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- JWQYZECMEPOAPF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1=CC=C2CC(O)CCC2=C1 JWQYZECMEPOAPF-UHFFFAOYSA-N 0.000 description 2
- MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 description 2
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- UVPCKMJVJLKETQ-UHFFFAOYSA-N 7-[[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-2-(2-hydroxyethylamino)-4-propan-2-ylcyclohepta-2,4,6-trien-1-one Chemical compound O=C1C(NCCO)=CC(C(C)C)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 UVPCKMJVJLKETQ-UHFFFAOYSA-N 0.000 description 2
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 description 2
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 229940124638 COX inhibitor Drugs 0.000 description 2
- WRLFSJXJGJBFJQ-WPUCQFJDSA-N Calcifediol monohydrate Chemical compound O.C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C WRLFSJXJGJBFJQ-WPUCQFJDSA-N 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 description 2
- 108010036941 Cyclosporins Proteins 0.000 description 2
- 102100028203 Cytochrome c oxidase subunit 3 Human genes 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 229940127337 Glycine Antagonists Drugs 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000861034 Homo sapiens Cytochrome c oxidase subunit 3 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027925 Monoparesis Diseases 0.000 description 2
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 description 2
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 2
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 108010070503 PAR-2 Receptor Proteins 0.000 description 2
- 102000032628 PAR-2 Receptor Human genes 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 208000036485 Roseola Diseases 0.000 description 2
- 208000006045 Spondylarthropathies Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 229940126495 T-type calcium channel blocker Drugs 0.000 description 2
- 108010062740 TRPV Cation Channels Proteins 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229950004064 antrafenine Drugs 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 2
- 229960004916 benidipine Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125400 channel inhibitor Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000013104 docking experiment Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000002792 enkephalinase inhibitor Substances 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 2
- 229960003667 flupirtine Drugs 0.000 description 2
- 229960003532 fluspirilene Drugs 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002706 gusperimus Drugs 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 238000010231 histologic analysis Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229950007692 lomerizine Drugs 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000010291 membrane polarization Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002274 morphinomimetic effect Effects 0.000 description 2
- 229960000751 nefopam Drugs 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960004505 penfluridol Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000164 protein isolation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000036390 resting membrane potential Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000009750 upstream signaling Effects 0.000 description 2
- 208000034280 venom allergy Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- 229960002911 zonisamide Drugs 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
- BQNIEVRILLAWHK-UHFFFAOYSA-N (4-fluoropiperidin-4-yl)methanamine Chemical compound NCC1(F)CCNCC1 BQNIEVRILLAWHK-UHFFFAOYSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- AUEKAKHRRYWONI-UHFFFAOYSA-N 1-(4,4-diphenylbutyl)piperidine Chemical class C1CCCCN1CCCC(C=1C=CC=CC=1)C1=CC=CC=C1 AUEKAKHRRYWONI-UHFFFAOYSA-N 0.000 description 1
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PTVWPYVOOKLBCG-UHFFFAOYSA-N 3-(4-phenyl-1-piperazinyl)propane-1,2-diol Chemical compound C1CN(CC(O)CO)CCN1C1=CC=CC=C1 PTVWPYVOOKLBCG-UHFFFAOYSA-N 0.000 description 1
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- UDESUGJZUFALAM-UHFFFAOYSA-N 3-methyl-3-phenylpyrrolidine-2,5-dione Chemical compound C=1C=CC=CC=1C1(C)CC(=O)NC1=O UDESUGJZUFALAM-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- WCIBOXFOUGQLFC-UHFFFAOYSA-N 4-[4-(4-fluorobenzoyl)piperidin-1-yl]-1-(4-fluorophenyl)butan-1-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(C(=O)C=2C=CC(F)=CC=2)CC1 WCIBOXFOUGQLFC-UHFFFAOYSA-N 0.000 description 1
- LMMLLWZHCKCFQA-UGKPPGOTSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-prop-1-ynyloxolan-2-yl]pyrimidin-2-one Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C#CC)O[C@H](CO)[C@@H](O)[C@H]1O LMMLLWZHCKCFQA-UGKPPGOTSA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000002485 Adiposis dolorosa Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000001839 Antisynthetase syndrome Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 201000002827 Balo concentric sclerosis Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001608562 Chalazion Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010252 Concentric sclerosis Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000024134 Diffuse cutaneous systemic sclerosis Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101100232351 Homo sapiens IL12RB1 gene Proteins 0.000 description 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 1
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 1
- 101001044883 Homo sapiens Interleukin-22 receptor subunit alpha-1 Proteins 0.000 description 1
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 208000029470 Hughes-Stovin syndrome Diseases 0.000 description 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 1
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 description 1
- 102100022723 Interleukin-22 receptor subunit alpha-1 Human genes 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000009777 Majeed syndrome Diseases 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101000846105 Mus musculus Short transient receptor potential channel 6 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical class CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029229 Neuralgic amyotrophy Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 102000004059 R-Type Calcium Channels Human genes 0.000 description 1
- 108090000583 R-Type Calcium Channels Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 102000004094 Stromal Interaction Molecule 1 Human genes 0.000 description 1
- 108090000532 Stromal Interaction Molecule 1 Proteins 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- 208000002286 Susac Syndrome Diseases 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 108050003979 Two pore domain potassium channels Proteins 0.000 description 1
- 102000014103 Two pore domain potassium channels Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- CAWBRCOBJNWRLK-UHFFFAOYSA-N acetyloxymethyl 2-[4-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-3-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-1h-indole-6-carboxylate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C=2NC3=CC(=CC=C3C=2)C(=O)OCOC(C)=O)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O CAWBRCOBJNWRLK-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940054053 antipsychotics butyrophenone derivative Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940059756 arava Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 229940092117 atgam Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- GRHLMSBCOPRFNA-UHFFFAOYSA-M azanide 2-oxidoacetate platinum(4+) Chemical compound N[Pt]1(N)OCC(=O)O1 GRHLMSBCOPRFNA-UHFFFAOYSA-M 0.000 description 1
- 229950003616 azaperone Drugs 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 229940022777 azasan Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- 229960002507 benperidol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229940112133 busulfex Drugs 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000000801 calcium channel stimulating agent Substances 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229940107810 cellcept Drugs 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229950007971 clopimozide Drugs 0.000 description 1
- JCZYXTVBWHAWLL-UHFFFAOYSA-N clopimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC(Cl)=CC=C32)=O)CC1 JCZYXTVBWHAWLL-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 201000003056 complement component 2 deficiency Diseases 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 108010019249 cyclosporin G Proteins 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical compound CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 description 1
- 229960002947 dapiprazole Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960004722 dropropizine Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- MAFNAHULLMXPPI-UHFFFAOYSA-N ethyl 3-bromo-4-[[2-[4-(2,4-dichlorophenyl)thiadiazol-5-yl]sulfanylacetyl]amino]benzoate Chemical compound BrC1=CC(C(=O)OCC)=CC=C1NC(=O)CSC1=C(C=2C(=CC(Cl)=CC=2)Cl)N=NS1 MAFNAHULLMXPPI-UHFFFAOYSA-N 0.000 description 1
- IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 description 1
- 229960005437 etoperidone Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000037440 gene silencing effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010085650 interferon gamma receptor Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229950005692 larotaxel Drugs 0.000 description 1
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
- 229950008108 lenperone Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- PTVWPYVOOKLBCG-ZDUSSCGKSA-N levodropropizine Chemical compound C1CN(C[C@H](O)CO)CCN1C1=CC=CC=C1 PTVWPYVOOKLBCG-ZDUSSCGKSA-N 0.000 description 1
- 229960002265 levodropropizine Drugs 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001861 melperone Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- DOTIMEKVTCOGED-UHFFFAOYSA-N mepiprazole Chemical compound N1C(C)=CC(CCN2CCN(CC2)C=2C=C(Cl)C=CC=2)=N1 DOTIMEKVTCOGED-UHFFFAOYSA-N 0.000 description 1
- 229950004808 mepiprazole Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940083410 myfortic Drugs 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 229950005705 naftopidil Drugs 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- RSKQGBFMNPDPLR-UHFFFAOYSA-N niaprazine Chemical compound C=1C=CN=CC=1C(=O)NC(C)CCN(CC1)CCN1C1=CC=C(F)C=C1 RSKQGBFMNPDPLR-UHFFFAOYSA-N 0.000 description 1
- 229960002686 niaprazine Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 229950001094 ortataxel Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229960002841 oxypertine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000005580 palindromic rheumatism Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229960004403 pixantrone Drugs 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
- 229960000214 pralatrexate Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940112971 protopic Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 102220160729 rs745863047 Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940021506 stye Drugs 0.000 description 1
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229950009016 tesetaxel Drugs 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229940100411 torisel Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- 229940111528 trexall Drugs 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 229960002341 trifluperidol Drugs 0.000 description 1
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 description 1
- 190014017283 triplatin tetranitrate Chemical compound 0.000 description 1
- 229950002860 triplatin tetranitrate Drugs 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Definitions
- Undesirable or inappropriate lymphocyte activity contributes to a variety of diseases, disorders, and conditions, including particularly various inflammatory, infectious, and/or proliferative diseases, disorders, and/or conditions such as autoimmune disorders and cancer.
- diseases, disorders, and conditions including particularly various inflammatory, infectious, and/or proliferative diseases, disorders, and/or conditions such as autoimmune disorders and cancer.
- the present invention encompasses the finding that T-type voltage-gated calcium channels operate on immune cells (e.g., T lymphocytes).
- the present invention further demonstrates that modulation of such T-type voltage-gated calcium channels can impact immune cell development, differentiation, and/or activity.
- the invention provides systems (e.g., compositions and methods) for identifying, characterizing, and/or using appropriate modulating agents that are selective T-type calcium channel modulators.
- modulating agents modulate T-type calcium channels active in or on immune cells.
- modulating agents are selective for (e.g., exhibit preferential activity with respect to) T-type calcium channels in cells when membrane potential is relatively depolarized.
- such modulating agents exhibit preferential activity for cells when membrane potential is above about -70 mV, for example in the range of about -55 mV to about -65 mV, or about -55 mV to about -60 mV, as is observed with resting T cells whose average resting membrane potentials can range from -60 mV to -55 mV, a range which is depolarized relative to the approximate average resting potential of neurons (-70 mV) and cardiac muscle (-90 mV).
- modulating agents are selective and/or specific for T-type calcium channels (e.g., for one or more of Cav3.1, Cav3.2, or Cav3.3 channels) as compared with other calcium channels, and/or for T-type calcium channels on immune cells as compared with T-type calcium channels on other cell types.
- modulating agents are selective and/or specific for a particular T-type calcium channel as compared with other T-type calcium channels (e.g., for Cav3.1 channels as compared with Cav3.2 and/or Cav3.3 channels), even in some instances as compared with other T-type calcium channels in or on immune cells.
- modulating agents are or comprise inhibitors.
- the invention provides methods identifying and/or characterizing one or more agents for activity as a selective T-type calcium channel modulator by contacting the agent with a system comprising a T-type calcium channel active on lymphocyte cells; and detecting a selective and/or specific effect (e.g., relative to absence of the agent and/or to level or type of activity of the agent with respect to one or more other calcium channels and/or to one or more calcium channels on other cell types) of the agent on level or activity of the T-type channel.
- the system comprises lymphocyte cells on which the T-type calcium channel is active.
- relevant immune cells are or comprise T lymphocytes (i.e, T cells).
- relevant immune cells are or comprise Thl7 cells.
- relevant immune cells are or comprise naive T cells.
- the relevant immune cells are present in a tissue or organ.
- the tissue or organ is or comprises the spleen.
- the tissue or organ is or comprises bone marrow.
- compositions comprising modulating agents as described herein, as well as methods of using them (e.g., including diagnostic and/or therapeutic methods), or of otherwise diagnosing, monitoring, and/or treating certain lymphocyte -related diseases, disorders, and/or conditions.
- diseases, disorders, and/or conditions may be selected from inflammatory, autoimmune, infectious, and/or proliferative diseases, disorders, or conditions.
- the invention features a method of treating a subject suffering from or susceptible to a relevant lymphocyte -related diseases, disorder, or condition, the method including administering to the subject a selective T-type calcium channel modulator in an amount sufficient to treat the disease, disorder, or condition.
- the lymphocyte-related disease, disorder, or condition (and/or those aspects of it treated by administration of a T-type calcium channel modulator [e.g., a selective T-type calcium modulator] as described herein) involves cells, tissues, organs and/or systems other than the CNS; in some such embodiments, it does not significantly involve CNS cells, tissues, organs and/or systems. In some particular embodiments, neurons are not involved.
- provided methods reduce the frequency of clinical exacerbations, and/or delay or prevent disease progression, rather than reduce the degree (e.g., severity and/or frequency of incidence of) of pain or of other clinical manifestations (e.g., fatigue) associated with the particular relevant disease, disorder, or condition.
- provided treatment methods further include administering to the subject a second agent, wherein the selective T-type calcium channel modulator and the second agent together are present in an amount sufficient to treat the condition.
- provided treatment methods further include administering to the subject a second agent that reduces the frequency or severity, and/or delays onset, of one or more symptoms or manifestations of the disease, disorder, or condition that is not significantly affected by administration of the selective T-type calcium channel modulator alone; in some such embodiments, the one or more symptoms or manifestations is or comprises pain.
- the invention features a method for assessing development, progression and/or treatment of a relevant lymphocyte-associated disease, disorder or condition, in a subject, for example by determining level and/or activity of a T-type calcium channel in or on immune cells (e.g., T cells such as Thl7 cells) and/or of Thl7 cells in the subject by analyzing a sample obtained from the subject.
- the sample is obtained prior to, concurrent with, or subsequent to administration of one or more doses of a T-type calcium channel modulator as described herein.
- such analyzing is performed on a plurality of samples from the subject, wherein different samples in the plurality were obtained at different points in time.
- one or more doses of a T-type calcium channel modulator as described herein may be administered between such different points in time.
- a decrease in level and/or activity of the relevant T-type calcium channel (e.g., of a CaV3.1 channel) and/or of Thl7 cells is indicative of slowed progression and/or effective treatment of the disease, disorder, or condition.
- the invention provides methods for assessing the treatment of a lymphocyte-associated disease, disorder, or condition as described herein, by administering a selective T-type calcium channel modulator to a subject suffering from or susceptible to the disease, disorder, or condition and determining whether, after such
- the frequency and/or severity of clinical exacerbations was reduced, extent of disease progression was delayed or prevented, and/or frequency and/or magnitude of one or more doses of a concomitant therapy (e.g., of another selective T-type calcium channel modulator, antioxidant, immunosuppressant, or anticancer agent) was reduced.
- a concomitant therapy e.g., of another selective T-type calcium channel modulator, antioxidant, immunosuppressant, or anticancer agent
- the present invention contemplates combination therapy of a modulating agent (e.g., a T-type calcium channel blocker, and particularly a selective T-type calcium channel modulator as described herein) with at least one additional therapeutic agent (i.e., at least one second agent).
- a modulating agent e.g., a T-type calcium channel blocker, and particularly a selective T-type calcium channel modulator as described herein
- at least one additional therapeutic agent i.e., at least one second agent.
- the second agent is or comprises another selective T-type calcium channel modulator, an antioxidant, an immunosuppressant, or an anticancer agent.
- the second agent is or comprises a pain reliever (e.g., an analgesic).
- the antioxidant is selected from the group consisting of: vitamin
- the immunosuppressant is selected from the group consisting of: a calcineurin inhibitor, tacrolimus, an mTor inhibitor, fingolimod, myriocin, alemtuzumab, rituximab, an anti-CD4 monoclonal antibody, an anti-LFAl monoclonal antibody, an anti-LFA3 monoclonal antibody, an anti-CD45 antibody, an anti-CD 19 antibody, monabatacept, belatacept, indolyl-ASC; azathioprine, lymphocyte immune globulin and anti-thymocyte globulin [equine], mycophenolate mofetil,
- the anticancer agent is selected from the group consisting of: a chemotherapeutic agent, an antiangiogenic agent, a mitotic inhibitor, a nucleoside analog, a DNA intercalating agent, and a topoisomerase analog.
- a modulating agent e.g., a T-type calcium channel modulator, and particularly a selective T-type calcium modulator
- a pain reliever such as, for example, acetaminophen/paracetomol, one or more nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, opiates, morphinomimetics, flupirtine, tricyclic antidepressants, (e.g., amitriptyline), nefopam, anticonvulsants (e.g., carbamazepine, gabapentin, pregabalin), dual LOX/COX inhibitors, cannabinoid receptor antagonists, neurokinin antagonists, PAR2 receptor antagonists, iNOS inhibitors, vanilloid/TRPVl/capsaicin receptor antagonists, calcitonin gene- related antagonists, COX3 inhibitors, glycine antagonists, N-acetylcholine receptor
- a pain reliever such as, for example, aceta
- the lymphocyte-related disease, disorder or condition is a T cell-mediated disease, disorder, or condition such as, for example, allergic asthma, allergy (e.g., bee venom allergy or food allergy), erythematosus, alopecia areata, atherosclerosis, bipolar disease, graft-versus-host disease, hay fever, rejection of a transplanted organ or tissue, schizophrenia, T cell lymphoma expressing ICOS.
- the lymphocyte-related disease, disorder or condition is a T cell-mediated disease, disorder, or condition such as, for example, allergic asthma, allergy (e.g., bee venom allergy or food allergy), erythematosus, alopecia areata, atherosclerosis, graft-versus- host disease, hay fever, rejection of a transplanted organ or tissue, T cell lymphoma expressing ICOS.
- a T cell-mediated disease, disorder or condition is a Thl7-mediated autoimmune disease.
- the lymphocyte-related disease, disorder or condition is an autoimmune disease, for example selected from the group consisting of: amyotrophic lateral sclerosis, multiple sclerosis, rheumatoid arthritis, systemic lupus, psoriasis, diabetes mellitus type 1 , sympathetic ophthalmia, thrombocytopenia, inflammatory bowel disease (Crohn's disease, ulcerative colitis), Grave's disease, Hajimoto's thyroiditis, Sjogren's syndrome, autoimmune aplastic anemia, autoimmune cardiomyopathy, autoimmune enteropathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune myocarditis, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune urticaria, and autoimmune uveitis, acute disseminated
- encephalopathy idiopathic thrombocytopenic purpura, inflammatory myopathy, Kawasaki's disease, Lambert-Eaton myasthenic syndrome, myasthenia gravis, neuromyelitis optica (Devic's disease), neuromyotonia, osteoarthritis, pemphigus vulgaris, pernicious anaemia, polymyositis, primary biliary cirrhosis, progressive inflammatory neuropathy, psoriatic arthritis, Raynaud phenomenon, relapsing polychondritis, restless leg syndrome, sarcoidosis, scleroderma, stiff person (man) syndrome, temporal (giant cell) arteritis, transverse myelitis, undifferentiated connective tissue disease, vasculitis, vitiligo, Wegener's granulomatosis, and combinatios thereof.
- the lymphocyte -related disease, disorder or condition is an infectious disease, for example selected from the group consisting of: lower respiratory infections, HIV/AIDS, diarrheal diseases, tuberculosis, malaria, measles, pertussis, tetanus, meningitis, syphilis, hepatitis B, tropical diseases, and combinations thereof.
- the lymphocyte -related disease, disorder or condition is a, for example selected from multiple myeloma, T cell leukemia and T cell lymphoma.
- the modulating agent is or comprises a selective T-type calcium channel modulator that selectively targets T-type calcium channels.
- the selective T-type calcium channel modulator selectively targets CaV3.1.
- the selective T-type calcium channel modulator selectively targets CaV3.1 in T cells.
- the modulating agent is or comprises a selective T-type calcium channel modulator that modulates T cell differentiation.
- the modulating agent is or comprises a selective T-type calcium channel modulator that does not preferentially cross the blood-brain barrier (i.e., the T-type calcium channel modulator has a CSF:plasma concentration ratio less than one).
- the modulating agent is or comprises a selective T-type calcium channel modulator that does not substantially cross the blood brain barrier (e.g., the T-type calcium channel modulator is not detected above background in a CNS sample such as a CSF sample).
- the modulating agent is or comprises a selective T-type calcium channel modulator that is preferentially distributed to part or all of the immune system, such as for example to bone marrow, thymus, lymphatic system, lymph nodes, spleen, and/or mucosal and cutaneous lymphoid tissues in the gastrointestinal tract, respiratory system, genitourinary system, and/or skin.
- a selective T-type calcium channel modulator that is preferentially distributed to part or all of the immune system, such as for example to bone marrow, thymus, lymphatic system, lymph nodes, spleen, and/or mucosal and cutaneous lymphoid tissues in the gastrointestinal tract, respiratory system, genitourinary system, and/or skin.
- modulating agent is or comprises a selective T-type calcium channel modulator selected from the group consisting of: ethosuximide, phensuximide, and
- methsuximide methyl-phenyl-succinimide
- R isomer of efonidipine, trimethadione, dimethadione, mibefradil, TTA-A2, TTA-A8, TTA-Pl, TTA-P2, TTA-Q3, TTA-Q6, MK-8998, Z941, Z944, ABT-639, TTL-1 177, KYSO5044, N C 55-0396 dihydrochloride, kurtoxin, and combinations thereof.
- the modulating agent is or comprises a selective
- the modulating agent is a selective T-type calcium channel blocker that is administered according to a dosing regimen that is sufficient to treat a particular lymphocyte-related disease, disorder or condition (e.g., multiple sclerosis) in that its use in a population of subjects suffering from multiple sclerosis shows a statistically significant correlation with a reduction in the frequency and/or severity, and/or with a delay in onset, of one or more symptoms or manifestations of the disease, disorder, or condition, across the population.
- a lymphocyte-related disease, disorder or condition e.g., multiple sclerosis
- Activator is meant an agent whose presence in a system comprising a T- type calcium channel or gene correlates with increased expression and/or activity of the T-type calcium channel as compared with that observed under otherwise comparable conditions in its absence.
- an activator acts by direct interaction (i.e., binding) with a T-type calcium channel.
- an activator acts by indirect effect (e.g., on expression or activity of a gene or transcript encoding a T-type calcium channel, or on a protein regulator thereof.
- activators can include reversible activators (e.g., that reversibly interact with a T-type calcium channel or regulator thereof).
- inhibitors can comprise irreversible inhibitors, for example which covalently modify the T-type calcium channel or regulator thereof.
- activators can be agonists and/or positive allosteric regulators of T-type calcium channels or regulators thereof.
- Administration refers to the administration of a composition to a subject. Administration may be by any appropriate route.
- administration may be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal and vitreal.
- amino acid in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds.
- an amino acid has the general structure H2N- C(H)(R)-COOH.
- an amino acid is a naturally-occurring amino acid.
- an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid.
- Standard amino acid refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides.
- Nonstandard amino acid refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source.
- an amino acid, including a carboxy- and/or amino-terminal amino acid in a polypeptide can contain a structural modification as compared with the general structure above.
- an amino acid may be modified by methylation, amidation, acetylation, and/or substitution as compared with the general structure.
- such modification may, for example, alter the circulating half life of a polypeptide containing the modified amino acid as compared with one containing an otherwise identical unmodified amino acid. In some embodiments, such modification does not significantly alter a relevant activity of a polypeptide containing the modified amino acid, as compared with one containing an otherwise identical unmodified amino acid.
- amino acid is used to refer to a free amino acid; in some embodiments it is used to refer to an amino acid residue of a polypeptide.
- Amount sufficient By “amount sufficient" of an agent (e.g., a modulating agent) it is meant an amount of the agent sufficient to effect a beneficial or desired result (e.g., treatment of a relevant disease, disorder or conditionas described herein).
- the beneficial or desired result is or comprises increase or reduction in level and/or activity of T-type calcium channels on immune cells and/or of Thl7 cells and/or of iNKT cells, as compared to that observed under otherwise comparable conditions absent the agent.
- an amount sufficient is an amount that, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, is effective to achieve treatment of the disease, disorder, and/or condition (e.g., is effective to reduce the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition).
- an amount can be considered to be an "amount sufficient" even when it does not in fact achieve successful treatment upon administration to a particular individual. Rather, so long as the relevant amount provides a particular desired outcome in a significant number of subjects when administered to a population thereof, it may be considered an "amount sufficient".
- a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable.
- reference to amount sufficient may be a reference to an amount as measured in one or more relevant tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc).
- relevant tissues e.g., a tissue affected by the disease, disorder or condition
- fluids e.g., blood, saliva, serum, sweat, tears, urine, etc.
- an amount sufficient may be formulated and/or administered in a single dose.
- an amount sufficient may be formulated and/or administered in a plurality of doses, for example, as part of a therapeutic regimen.
- Analog refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an “analog” shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways.
- an analog a substance that can be generated from the reference substance by chemical manipulation of the reference substance.
- an analog is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance.
- an analog is or can be generated through performance of a synthetic process different from that used to generate the reference substance.
- Animal As used herein, the term “animal” refers to any member of the animal kingdom.
- animal refers to humans, at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development. In some embodiments, the non- human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically-engineered animal, and/or a clone.
- Antibody refers to a polypeptide that includes canonical immunoglobulin sequence elements sufficient to confer selective and/or specific binding to a particular target antigen.
- intact antibodies as produced in nature are approximately 150 kD tetrameric agents comprised of two identical heavy chain polypeptides (about 50 kD each) and two identical light chain polypeptides (about 25 kD each) that associate with each other into what is commonly referred to as a "Y-shaped" structure.
- Each heavy chain is comprised of at least four domains (each about 1 10 amino acids long) an amino-terminal variable (VH) domain (located at the tips of the Y structure), followed by three constant domains: CHI, CH2, and the carboxy-terminal CH3 (located at the base of the Y's stem).
- VH amino-terminal variable
- CH2 amino-terminal variable
- CH3 carboxy-terminal CH3
- Each light chain is comprised of two domains - an amino-terminal variable (VL) domain, followed by a carboxy-terminal constant (CL) domain, separated from one another by another "switch".
- Intact antibody tetramers are comprised of two heavy chain-light chain dimers in which the heavy and light chains are linked to one another by a single disulfide bond; two other disulfide bonds connect the heavy chain hinge regions to one another, so that the dimers are connected to one another and the tetramer is formed.
- Naturally-produced antibodies are also glycosylated, typically on the CH2 domain.
- Each domain in a natural antibody has a structure characterized by an "immunoglobulin fold" formed from two beta sheets (e.g., 3-, 4-, or 5-stranded sheets) packed against each other in a compressed antiparallel beta barrel.
- Each variable domain contains three hypervariable loops known as "complement determining regions” (CDRl, CDR2, and CDR3) and four somewhat invariant "framework" regions (FR1, FR2, FR3, and FR4).
- the FR regions form the beta sheets that provide the structural framework for the domains, and the CDR loop regions from both the heavy and light chains are brought together in three- dimensional space so that they create a single hypervariable antigen binding site located at the tip of the Y structure.
- Amino acid sequence comparisons among antibody polypeptide chains have defined two light chain ( ⁇ and ⁇ ) classes, several heavy chain (e.g., ⁇ , ⁇ , ⁇ , ⁇ ) classes, and certain heavy chain subclasses (al, a2, ⁇ , ⁇ 2, ⁇ 3, and ⁇ 4).
- Antibody classes are defined based on the class of the utilized heavy chain sequences.
- any polypeptide or complex of polypeptides that includes sufficient immunoglobulin domain sequences as found in natural antibodies can be referred to and/or used as an "antibody", whether such polypeptide is naturally produced (e.g., generated by an organism reacting to an antigen), or produced by recombinant engineering, chemical synthesis, or other artificial system or methodology.
- an antibody is monoclonal; in some embodiments, an antibody is monoclonal. In some embodiments, an antibody has constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, an antibody sequence elements are humanized, primatized, chimeric, etc, as is known in the art.
- an antibody as used herein, will be understood to encompass (unless otherwise stated or clear from context) can refer in appropriate embodiments to any of the art-known or developed constructs or formats for capturing antibody structural and functional features in alternative presentation.
- the term can refer to bi- or other multi-specific (e.g., zybodies, etc) antibodies, Small Modular ImmunoPharmaceuticals ("SMIPsTM”), single chain antibodies, cameloid antibodies, and/or antibody fragments.
- SMIPsTM Small Modular ImmunoPharmaceuticals
- an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally.
- an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload [e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc], or other pendant group [e.g., poly-ethylene glycol, etc]
- a covalent modification e.g., attachment of a glycan, a payload [e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc]
- other pendant group e.g., poly-ethylene glycol, etc
- Antibody fragment includes a portion of an intact antibody, such as, for example, the antigen-binding or variable region of an antibody.
- antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; triabodies; tetrabodies; linear antibodies; single-chain antibody molecules; and CDR-containing moieties included in multi-specific antibodies formed from antibody fragments.
- antibody fragment does not imply and is not restricted to any particular mode of generation.
- An antibody fragment may be produced through use of any appropriate methodology, including but not limited to cleavage of an intact antibody, chemical synthesis, recombinant production, etc..
- Anticancer is meant an agent or compound that reduces, prevents, or interferes with uncontrolled growth of cells, invasion and/or metastasis.
- Anti-T-type calcium channel antibody is meant an antibody (e.g., murine monoclonal antibody, chimeric, humanized monoclonal antibody, or human monoclonal antibody) that selectively and/or specifically binds to a T-type calcium channel.
- an anti-T-type calcium channel antibody may prevent binding of the T-type calcium channel to its natural ligand, preventing downstream signaling events, and/or stimulate the immune system to attack the T-type calcium channel to which it is bound, including in some embodiments by killing cells that express the T-type calcium channel.
- the term “approximately” and “about” is intended to encompass normal statistical variation as would be understood by those of ordinary skill in the art as appropriate to the relevant context.
- the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 1 1%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
- Two events or entities are "associated" with one another, as that term is used herein, if the presence, level and/or form of one is correlated with that of the other.
- a particular entity e.g., polypeptide
- two or more entities are physically "associated” with one another if they interact, directly or indirectly, so that they are and remain in physical proximity with one another.
- two or more entities that are physically associated with one another are covalently linked to one another; in some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another but are non-covalently associated, for example by means of hydrogen bonds, van der Waals interaction, hydrophobic interactions, magnetism, and combinations thereof.
- biologically active refers to a substance that has activity in a biological system (e.g., in a cell (e.g., isolated, in culture, in a tissue, in an organism), in a cell culture, in a tissue, in an organism, etc.).
- a substance that, when administered to an organism, has a biological effect on that organism is considered to be biologically active.
- a biologically active substance is required (e.g., is necessary and sufficient) for the activity to be present; in such circumstances, that portion or fragment is considered to be a "biologically active" portion or fragment.
- Characteristic sequence element refers to a sequence element found in a polymer (e.g., in a polypeptide or nucleic acid) that represents a characteristic portion of that polymer. In some embodiments, presence of a characteristic sequence element correlates with presence or level of a particular activity or property of the polymer. In some embodiments, presence (or absence) of a characteristic sequence element defines a particular polymer as a member (or not a member) of a particular family or group of such polymers.
- characteristic sequence element typically comprises at least two monomers (e.g., amino acids or nucleotides).
- a characteristic sequence element includes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, or more monomers (e.g., contiguously linked monomers).
- a characteristic sequence element includes at least first and second stretches of continguous monomers spaced apart by one or more spacer regions whose length may or may not vary across polymers that share the sequence element.
- Combination therapy refers to those situations in which a subject is simultaneously exposed to two or more therapeutic agents. In some embodiments, such agents are administered simultaneously; in some embodiments, such agents are administered sequentially; in some embodiments, such agents are administered in overlapping regimens.
- Comparable refers to two or more agents, entities, situations, sets of conditions, etc that may not be identical to one another but that are sufficiently similar to permit comparison therebetween so that conclusions may reasonably be drawn based on differences or similarities observed. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc to be considered comparable.
- corresponding to is often used to designate the position/identity of a residue in a polymer, such as an amino acid residue in a polypeptide or a nucleotide residue in a nucleic acid.
- residues in such a polymer are often designated using a canonical numbering system based on a reference related polymer, so that a residue in a first polymer "corresponding to" a residue at position 190 in the reference polymer, for example, need not actually be the 190 th residue in the first polymer but rather corresponds to the residue found at the 190 th position in the reference polymer; those of ordinary skill in the art readily appreciate how to identify "corresponding" amino acids, including through use of one or more commercially-available algorithms specifically designed for polymer sequence comparisons.
- Decreased Level of Activity By “decreased level of activity” of CaV3.1 is meant a decrease in CaV3.1 gene expression, protein expression, or activity (e.g., permeability to Ca 2+ , channel opening, and/or up-regulation of gene expression), as compared to a control or reference (e.g., from a normal cell or normal tissue).
- a control or reference e.g., from a normal cell or normal tissue.
- such decrease is at least 2-fold, e.g., from about 2- fold to about 150-fold, e.g., from 5-fold to 150-fold, from 5-fold to 100-fold, from 10-fold to 150-fold, from 10-fold to 100-fold, from 50-fold to 150-fold, from 50-fold to 100-fold, from 75-fold to 150-fold, or from 75-fold to 100-fold, as compared to a control or a normal reference sample.
- Decrease level of activity of ion channels can be determined using any useful methods known in the art.
- Derivative refers to a structural analogue of a reference substance. That is, a “derivative” is a substance that shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways.
- a derivative is a substance that can be generated from the reference substance by chemical manipulation.
- a derivative is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance.
- the term "designed” refers to an agent (i) whose structure is or was selected by the hand of man; (ii) that is produced by a process requiring the hand of man; and/or (iii) that is distinct from natural substances and other known agents.
- Docking refers to orienting, rotating, translating a chemical entity in the binding pocket, domain, molecule or molecular complex or portion thereof based on distance geometry or energy. Docking may be performed by distance geometry methods that find sets of atoms of a chemical entity that match sets of sphere centers of the binding pocket, domain, molecule or molecular complex or portion thereof. See Meng et al. J. Comp. Chem. 4: 505-524 (1992). Sphere centers are generated by providing an extra radius of given length from the atoms (excluding hydrogen atoms) in the binding pocket, domain, molecule or molecular complex or portion thereof. Real-time interaction energy calculations, energy minimizations or rigid-body minimizations (Gschwend et al., J. Mol.
- Recognition 9: 175- 186 (1996)) can be performed while orienting the chemical entity to facilitate docking.
- interactive docking experiments can be designed to follow the path of least resistance. If the user in an interactive docking experiment makes a move to increase the energy, the system will resist that move. However, if that user makes a move to decrease energy, the system will favor that move by increased responsiveness. (Cohen et al., J. Med. Chem. 33:889-894 (1990)). Docking can also be performed by combining a Monte Carlo search technique with rapid energy evaluation using molecular affinity potentials. See Goodsell and Olson, Proteins: Structure, Function and Genetics 8: 195-202 (1990).
- Dosage form refers to a physically discrete unit of a therapeutic agent for administration to a subject. Each unit contains a predetermined quantity of active agent. In some embodiments, such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen).
- Dosing regimen refers to a set of unit doses
- a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses.
- a dosing regimen comprises a plurality of doses each of which are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses.
- a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).
- Engineered refers to the aspect of having been manipulated by the hand of man.
- a polynucleotide is considered to be “engineered” when two or more sequences, that are not linked together in that order in nature, are manipulated by the hand of man to be directly linked to one another in the engineered polynucleotide.
- an engineered polynucleotide comprises a regulatory sequence that is found in nature in operative association with a first coding sequence but not in operative association with a second coding sequence, is linked by the hand of man so that it is operatively associated with the second coding sequence.
- a cell or organism is considered to be "engineered” if it has been manipulated so that its genetic information is altered ⁇ e.g., new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or deletion mutation, or by mating protocols).
- new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or deletion mutation, or by mating protocols.
- progeny of an engineered polynucleotide or cell are typically still referred to as "engineered” even though the actual manipulation was performed on a prior entity.
- expression refers to one or more of the following events: (1) production of an RNA template from a DNA sequence ⁇ e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and/or 3' end formation); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
- Fragment A "fragment" of a material or entity as described herein has a structure that includes a discrete portion of the whole, but lacks one or more moieties found in the whole. In some embodiments, a fragment consists of such a discrete portion. In some embodiments, a fragment consists of or comprises a characteristic structural element or moiety found in the whole.
- a polymer fragment comprises or consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 1 10, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more monomeric units (e.g., residues) as found in the whole polymer.
- monomeric units e.g., residues
- a polymer fragment comprises or consists of at least about 5%, 10%, 15%, 20%, 25%, 30%, 25%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the monomeric units (e.g., residues) found in the whole polymer.
- the whole material or entity may in some embodiments be referred to as the "parent" of the whole.
- homology refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules.
- polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical.
- polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% similar (e.g., containing residues with related chemical properties at corresponding positions).
- certain amino acids are typically classified as similar to one another as “hydrophobic” or “hydrophilic”amino acids, and/or as having "polar” or “non-polar” side chains. Substitution of one amino acid for another of the same type may often be considered a
- the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence.
- the nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position; when a position in the first sequence is occupied by a similar nucleotide as the corresponding position in the second sequence, then the molecules are similar at that position.
- the percent homology between the two sequences is a function of the number of identical and similar positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences.
- Representative algorithms and computer programs useful in determining the percent homology between two nucleotide sequences include, for example, the algorithm of Meyers and Miller (CABIOS, 1989, 4: 1 1 - 17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- the percent homology between two nucleotide sequences can, alternatively, be determined for example using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.
- Identity refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules.
- polymeric molecules are considered to be “substantially identical” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical.
- the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence.
- the nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences.
- Representative algorithms and computer programs useful in determinng the percent identity between two nucleotide sequences include, for example, the algorithm of Meyers and Miller (CABIOS, 1989, 4: 1 1- 17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- the percent identity between two nucleotide sequences can, alternatively, be determined for example using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.
- Immune Cells are cells involved in the immune system. In many embodiments, immune cells consist of or comprise
- immune cells consist of or comprise T lymphocytes (i.e., T cells).
- immune cells relevant to the present invention consist of or comprise Thl7 cells.
- immune cells relevant to the present invention consist of or comprise naive T cells.
- immune cells relevant to the present invention consist of or comprise iNKT cells.
- immune cells are utilized in vitro.
- immune cells are utilized in vivo.
- immune cells are provided and/or utilized in context of a tissue or organ.
- such a tissue or organ is or comprises a primary lymphoid organ (e.g., spleen), for example in which T- cell differentiation occurs.
- a tissue or organ is or comprises bone marrow.
- immune cells consist of or comprise peripheral immune cells. In some embodiments, immune cells are not and/or do not include peripheral immune cells.
- Immunosuppressant By “immunosuppressant” is meant an agent or compound that induces immunosuppression, (i.e., it reduces, e.g., prevents or interferes with the development of an immunological response, e.g., cellular or humoral).
- Inhibitor By “inhibitor” is meant an agent whose presence in a system comprising a T- type calcium channel or gene correlates with reduced expression and/or activity of the T-type calcium channel as compared with that observed under otherwise comparable conditions in its absence. In some embodiments, an inhibitor acts by direct interaction (i.e., binding) with a T-type calcium channel.
- an inhibitor acts by indirect effect (e.g., on expression or activity of a gene or transcript encoding a T-type calcium channel, or on a protein regulator thereofln some embodiments, inhibitors can include reversible inhibitors (e.g., competitive inhibitors, uncompetitive inhibitors, mixed inhibitors, non-competitive inhibitors). In some embodiments, inhibitors can comprise irreversible inhibitors, for example which covalently modify the T-type calcium channel or regulator thereof.
- reversible inhibitors e.g., competitive inhibitors, uncompetitive inhibitors, mixed inhibitors, non-competitive inhibitors.
- inhibitors can comprise irreversible inhibitors, for example which covalently modify the T-type calcium channel or regulator thereof.
- Ion Channel Blocker an agent or compound that disrupts the movement of ions (e.g., Na 2+ , Ca 2+ , K + , and CI " ) through ion channels (e.g., voltage-gated calcium channels, e.g., L-type, P-type/Q-type, N-type, R-type, or T-type, e.g., ligand-gated calcium channels, e.g., IP 3 receptor, ryanodine receptor, two-pore channels, cation channels of sperm, or store- operated channels, e.g., voltage-gated potassium channels, calcium-activated potassium channels, two- pore domain potassium channels, voltage-gated sodium channels, and/or chloride channels).
- ions e.g., Na 2+ , Ca 2+ , K + , and CI "
- ion channels e.g., voltage-gated calcium channels, e.g., L-type, P-type/Q-type, N-
- Isolated refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) designed, produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which they were initially associated.
- isolated agents are about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure.
- a substance is "pure” if it is substantially free of other components.
- a substance may still be considered “isolated” or even “pure”, after having been combined with certain other components such as, for example, one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such embodiments, percent isolation or purity of the substance is calculated without including such carriers or excipients.
- isolation involves or requires disruption of covalent bonds (e.g., to isolate a polypeptide domain from a longer polypeptide and/or to isolate a nucleotide sequence element from a longer oligonucleotide or nucleic acid).
- Isomer As is known in the art, many chemical entities (in particular many organic molecules and/or many small molecules) can exist in a variety of structural and/or optical isomeric forms. In some embodiments, as will be clear to those skilled in the art from context, depiction of or reference to a particular compound structure herein is intended to encompass all structural and/or optical isomers thereof.
- compositions including a chemical entitiy that can exist in a variety of isomeric forms include a plurality of such forms; in some embodiments such compositions include only a single form.
- compositions including a chemical entity that can exist as a variety of optical isomers include a racemic population of such optical isomers; in some embodiments such compositions include only a single optical isomer and/or include a plurality of optical isomers that together retain optical activity.
- Modulator is used to refer to an entity whose presence in a system in which an activity of interest is observed correlates with a change in level and/or nature of that activity as compared with that observed under otherwise comparable conditions when the modulator is absent.
- a modulator is an activator, in that activity is increased in its presence as compared with that observed under otherwise comparable conditions when the modulator is absent.
- a modulator is an inhibitor, in that activity is reduced in its presence as compared with otherwise comparable conditions when the modulator is absent.
- a modulator interacts directly with a target entity whose activity is of interest.
- a modulator interacts indirectly (i.e., directly with an intermediate agent that interacts with the target entity) with a target entity whose activity is of interest.
- a modulator affects level of a target entity of interest; alternatively or additionally, in some embodiments, a modulator affects activity of a target entity of interest without affecting level of the target entity.
- a modulator affects both level and activity of a target entity of interest, so that an observed difference in activity is not entirely explained by or commensurate with an observed difference in level.
- Modulates T Cell Differentiation By “modulates T cell differentiation” is meant that the agent or compound affects upstream or downstream signaling events that are involved in
- the agent or compound may affect activation of antigen-presenting cells (APCs), the gene or protein expression of cytokine receptors (e.g., IL23R, IL22R, IL4R, IL12R, or IL17), cytokines (e.g., IL4, IL23, IL22, IL17, or IL12), interferon receptors (e.g., IFNGR1, or IFNGR2), and interferons (e.g., IFN, IL17, etc).
- APCs antigen-presenting cells
- cytokine receptors e.g., IL23R, IL22R, IL4R, IL12R, or IL17
- cytokines e.g., IL4, IL23, IL22, IL17, or IL12
- interferon receptors e.g., IFNGR1, or IFNGR2
- interferons e.g., IFN, IL17, etc
- nucleic acid refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain.
- a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage.
- nucleic acid refers to individual nucleic acid residues (e.g., nucleotides and/or nucleosides); in some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues.
- a "nucleic acid” is or comprises RNA; in some embodiments, a “nucleic acid” is or comprises DNA.
- a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues.
- a nucleic acid is, comprises, or consists of one or more nucleic acid analogs.
- a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone.
- a nucleic acid is, comprises, or consists of one or more "peptide nucleic acids", which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention.
- a nucleic acid has one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds.
- a nucleic acid is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine).
- adenosine thymidine
- guanosine guanosine
- cytidine uridine
- deoxyadenosine deoxythymidine
- deoxyguanosine deoxycytidine
- a nucleic acid is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5- methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5- fluorouridine, C5-iodouridine, C5 -propynyl-uridine, C5 -propynyl-cytidine, C5-methylcytidine, 2- aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)- methylguanine, 2-thiocytidine, methylated bases, intercalated bases,
- a nucleic acid comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'- deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids.
- a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or protein.
- a nucleic acid includes one or more introns.
- nucleic acids are prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), reproduction in a recombinant cell or system, and chemical synthesis.
- a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long.
- Peptide modulator is meant an peptide that modulates T-type calcium channel active in lymphocyte cells as described herein, sometimes compared to a control or reference (e.g., baseline).
- a peptide modulator is or comprises an endogenous or synthetic peptide that has structural homology or conserved sequences to the subunits of the T-type calcium channel (e.g., al, ⁇ 2 ⁇ , ⁇ , and/or ⁇ subunit(s)) and/or transmembrane domains of the T-type calcium channel (e.g., TM1, TM2, TM3, TM4, TM5, and TM6) that are effective in activating and/or inhibiting T-type calcium channel activity (e.g., low voltage-activated calcium current, high voltage- activated calcium current, calcium flux across the plasma membrane, and alteration of surface expression).
- T-type calcium channel activity e.g., low voltage-activated calcium current, high voltage- activated calcium current, calcium flux across the plasma membrane, and alteration of surface expression
- compositions that, within the scope of sound medical judgment, are suitable for use in contact with tissues of human beings and/or animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- composition a composition containing an active agent as described herein, formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal.
- Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gel cap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other formulation described herein.
- Polypeptide generally has its art-recognized meaning of a polymer of at least three amino acids, linked to one another by peptide bonds.
- the term is used to refer to certain functional classes of polypeptides, such as, for example, autoantigen polypeptides, nicotinic acetylcholine receptor polypeptides, alloantigen polypeptides, etc.
- the present specification provides several examples of amino acid sequences of known exemplary polypeptides within the class; in some embodiments, such known polypeptides are reference polypeptides for the class.
- polypeptide refers to any member of the class that shows significant sequence homology or identity with a relevant reference polypeptide. In many embodiments, such member also shares significant activity with the reference polypeptide.
- a member polypeptide shows an overall degree of sequence homology or identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more and/or includes at least one region (i.e., a conserved region, often including a characteristic sequence element) that shows very high sequence identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99%.
- Such a conserved region usually encompasses at least 3-4 and often up to 20 or more amino acids; in some embodiments, a conserved region encompasses at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15 or more contiguous amino acids.
- a useful polypeptide as described herein may comprise or consist of a fragment of a parent polypeptide.
- a useful polypeptide as described herein may comprise or consist of a plurality of fragments, each of which is found in the same parent polypeptide in a different spatial arrangement relative to one another than is found in the polypeptide of interest (e.g., fragments that are directly linked in the parent may be spatially separated in the polypeptide of interest or vice versa, and/or fragments may be present in a different order in the polypeptide of interest than in the parent), so that the polypeptide of interest is a derivative of its parent polypeptide.
- Protein refers to a polypeptide (i.e., a string of at least two amino acids linked to one another by peptide bonds). Proteins may include moieties other than amino acids (e.g., may be glycoproteins, proteoglycans, etc.) and/or may be otherwise processed or modified. Those of ordinary skill in the art will appreciate that a “protein” can be a complete polypeptide chain as produced by a cell (with or without a signal sequence), or can be a characteristic portion thereof. Those of ordinary skill will appreciate that a protein can sometimes include more than one polypeptide chain, for example linked by one or more disulfide bonds or associated by other means.
- Polypeptides may contain L-amino acids, D-amino acids, or both and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, e.g., terminal acetylation, amidation, methylation, etc.
- proteins may comprise natural amino acids, non- natural amino acids, synthetic amino acids, and combinations thereof.
- the term "peptide” is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids.
- proteins are antibodies, antibody fragments, biologically active portions thereof, and/or characteristic portions thereof.
- Reference is often used herein to describe a standard or control agent or value against which an agent or value of interest is compared.
- a reference agent is tested and/or a reference value is determined substantially simultaneously with the testing or determination of the agent or value of interest.
- a reference agent or value is a historical reference, optionally embodied in a tangible medium.
- a reference agent or value is determined or characterized under conditions comparable to those utilized to determine or characterize the agent or value of interest.
- Refractory As used herein, the term “refractory” refers to any subject that does not respond with an expected clinical efficacy following the administration of provided compositions as normally observed by practicing medical personnel.
- RNAi Agen By “R Ai agent” is meant any agent or compound that exerts a gene silencing effect by hybridizing a target nucleic acid.
- RNAi agents include any nucleic acid molecules that are capable of mediating sequence-specific RNAi (e.g., under stringent conditions), for example, a short interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically- modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and Dicer-substrate RNA
- siRNA short interfering RNA
- dsRNA double-stranded RNA
- miRNA microRNA
- shRNA short hairpin RNA
- sample typically refers to a biological sample obtained or derived from a source of interest, as described herein.
- a source of interest comprises an organism, such as an animal or human.
- a biological sample comprises biological tissue or fluid.
- a biological sample may be or comprise bone marrow; blood; blood cells; ascites; tissue or fine needle biopsy samples; cell-containing body fluids; free floating nucleic acids; sputum; saliva; urine; cerebrospinal fluid, peritoneal fluid; pleural fluid; feces; lymph; gynecological fluids; skin swabs; vaginal swabs; oral swabs; nasal swabs; washings or lavages such as a ductal lavages or broncheoalveolar lavages; aspirates; scrapings; bone marrow specimens; tissue biopsy specimens; surgical specimens; feces, other body fluids, secretions, and/or excretions; and/or cells therefrom, etc.
- a biological sample is or comprises cells obtained from an individual.
- obtained cells are or include cells from an individual from whom the sample is obtained.
- obtained cells are or include microbial cells of an individual's microbiome.
- a sample is a "primary sample" obtained directly from a source of interest by any appropriate means.
- a primary biological sample is obtained by methods selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of body fluid (e.g., blood, lymph, feces etc.), etc.
- sample refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane.
- processing e.g., by removing one or more components of and/or by adding one or more agents to
- a primary sample For example, filtering using a semi-permeable membrane.
- Such a “processed sample” may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and/or purification of certain components, etc.
- An agent that is "selective" is one that produces a desired effect on one target entity and/or in one cell, one compartment of the body, while to a lesser degree influencing and/or creating adverse effects on other potential target entities (in some embodiments including subtype and/or variants of the target entity) and/or in other cells, tissues, organs, and/or compartments of the body.
- a selective agent is an agent that acts specifically and/or preferentially on a particular target or set of targets.
- selectivity can be determined by binding kinetics (e.g., degree of interaction between an agent with its target and/or with a particular cell, cell type, tissue, organ, and/or compartment of the body).
- an agent is selective if it shows an elevated affinity and/or decreased dissociation constant (K D ) of 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30- fold, 100-fold, or 200-fold for its target (and/or for a particular cell, cell type, tissue, organ, and/or compartment of the body) as compared with for a non-target competitor.
- K D dissociation constant
- an agent is selective if it exerts a particular biologic effect on its target (and/or on or in a particular cell, cell type, tissue, organ, and/or compartment of the body) at a dose that is lower (e.g., by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more) than is required for the agent to exert an analogous effect on a potential alternative target (or particular cell, cell type, tissue, organ, and/or compartment of the body ), and/or for an alternative comparable reference agent to exhibit an analogous effect on the target (and/or on or in the particular cell, cell type, tissue, organ, and/or compartment of the body).
- a dose that is lower (e.g., by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or
- selectivity can also be a measure of local accumulation of an agent in association with the target entity and/or on or in the particular cell, cell type, tissue, organ, and/or compartment of the body compared to accumulation in association with other potential target entities and/or target and/or cells, cell types, tissues, organs, and/or compartments of the body.
- a selective agent demonstrates an increase in accumulation that is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% at or with the target entity and/or on or in the particular cell, cell type, tissue, organ, and/or compartment of the body as compared with an alternative comparable reference entity and/or cell, cell type, tissue, organ, and/or compartment of the body
- selectivity can be based on efficacy and/or potency of an agent.
- an agent that is selective shows an efficacy or potency that is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% more than that of a reference agent with respect to a particular activity or event.
- Small molecule means a low molecular weight organic and/or inorganic compound.
- a "small molecule” is a molecule that is less than about 5 kilodaltons (kD) in size.
- a small molecule is less than about 4 kD, 3 kD, about 2 kD, or about 1 kD.
- the small molecule is less than about 800 daltons (D), about 600 D, about 500 D, about 400 D, about 300 D, about 200 D, or about 100 D.
- a small molecule is less than about 2000 g/mol, less than about 1500 g/mol, less than about 1000 g/mol, less than about 800 g/mol, or less than about 500 g/mol. In some embodiments, a small molecule is not a polymer. In some embodiments, a small molecule does not include a polymeric moiety. In some embodiments, a small molecule is not a protein or polypeptide (e.g., is not an oligopeptide or peptide). In some embodiments, a small molecule is not a polynucleotide (e.g., is not an oligonucleotide). In some embodiments, a small molecule is not a polysaccharide.
- a small molecule does not comprise a polysaccharide (e.g., is not a glycoprotein, proteoglycan, glycolipid, etc.). In some embodiments, a small molecule is not a lipid. In some embodiments, a small molecule is a modulating agent. In some embodiments, a small molecule is biologically active. In some embodiments, a small molecule is detectable (e.g., comprises at least one detectable moiety). In some embodiments, a small molecule is a therapeutic.
- Small Molecule Modulator is meant any small molecule (e.g., naturally occurring, or synthesized organic and/or inorganic compound) that modulates a T-type calcium channel active in lymphocyte cells as described herein, sometimes compared to a control or reference (e.g., baseline). In some embodiments, such increase or decrease is by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, as compared to the control or reference. Small molecule modulators can be activators or inhibitors and can be identified and/or characterized by any useful methods or can be known in the art.
- Solid form As is known in the art, many chemical entities (in particular many organic molecules and/or many small molecules) can adopt a variety of different solid forms such as, for example, amorphous forms and/or crystalline forms (e.g., polymorphs, hydrates, solvates, etc). In some embodiments, such entities may be utilized in any form, including in any solid form. In some embodiments, such entities are utilized in a particular form, for example in a particular solid form.
- the agent or entity does not detectably bind to the competing alternative target under conditions of binding to its target. In some embodiments, the agent or entity binds with higher on-rate, lower off-rate, increased affinity, decreased dissociation, and/or increased stability to its target as compared with the competing alternative target(s).
- Stable when applied to compositions herein, means that the compositions maintain one or more aspects of their physical structure and/or activity over a period of time under a designated set of conditions.
- the period of time is at least about one hour; in some embodiments the period of time is about 5 hours, about 10 hours, about one (1) day, about one (1) week, about two (2) weeks, about one (1) month, about two (2) months, about three (3) months, about four (4) months, about five (5) months, about six (6) months, about eight (8) months, about ten (10) months, about twelve (12) months, about twenty- four (24) months, about thirty-six (36) months, or longer.
- the period of time is within the range of about one (1) day to about twenty-four (24) months, about two (2) weeks to about twelve (12) months, about two (2) months to about five (5) months, etc.
- the designated conditions are ambient conditions (e.g., at room temperature and ambient pressure).
- the designated conditions are physiologic conditions (e.g., in vivo or at about 37 °C for example in serum or in phosphate buffered saline).
- the designated conditions are under cold storage (e.g., at or below about 4 °C, -20 °C, or -70 °C).
- the designated conditions are in the dark.
- Subject By “subject” it is meant a mammal (e.g., a human, in some embodiments including prenatal human forms). In some embodiments, a subject is suffering from a relevant disease, disorder or condition. In some embodiments, a subject is susceptible to a disease, disorder, or condition. In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder or condition. In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition. In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. In some embodiments, a subject is an individual to whom therapy is administered.
- substantially refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest.
- One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result.
- Susceptible to An individual who is "susceptible to" a disease, disorder, or condition is at risk for developing the disease, disorder, or condition. In some embodiments, such an individual is known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition does not display any symptoms of the disease, disorder, or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition has not been diagnosed with the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition is an individual who has been exposed to conditions associated with development of the disease, disorder, or condition. In some embodiments, a risk of developing a disease, disorder, and/or condition is a population-based risk (e.g., family members of individuals suffering from allergy, etc.
- a population-based risk e.g., family members of individuals suffering from allergy, etc.
- Symptoms are reduced: According to the present invention, "symptoms are reduced” when one or more symptoms of a particular disease, disorder or condition is reduced in magnitude (e.g., intensity, severity, etc.) and/or frequency. For purposes of clarity, a delay in the onset of a particular symptom is considered one form of reducing the frequency of that symptom.
- T cells By "T cells” is meant a group of white blood cells that play a role in immune responses and contain a T cell receptor at the cell surface. T cells maybe of the subset of helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, and/or gamma delta T cells.
- Therapeutic agent refers to any agent that has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect, when administered to a subject.
- an agent is considered to be a therapeutic agent if its administration to a relevant population is statistically correlated with a desired or beneficial therapeutic outcome in the population, whether or not a particular subject to whom the agent is administered experiences the desired or beneficial therapeutic outcome.
- therapeutically effective amount means an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and/or condition.
- a therapeutically effective amount is one that reduces the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition.
- therapeutically effective amount does not in fact require successful treatment be achieved in a particular individual.
- a therapeutically effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment. It is specifically understood that particular subjects may, in fact, be “refractory” to a “therapeutically effective amount.” To give but one example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable.
- reference to a therapeutically effective amount may be a reference to an amount as measured in one or more relevant tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc).
- a therapeutically effective amount may be formulated and/or administered in a single dose. In some embodiments, a therapeutically effective amount may be formulated and/or administered in a plurality of doses, for example, as part of a dosing regimen.
- Therapeutic regimen refers to a dosing regimen whose administration across a relevant population is correlated with a desired or beneficial therapeutic outcome.
- Three dimensional representation refers to converting the lists of structure coordinates into structural models or graphical representation in three-dimensional space.
- the three dimensional structure may be displayed or used to performing computer modeling or fitting operations.
- the structure coordinates themselves, without the displayed model may be used to perform computer-based modeling and fitting operations.
- Treating By “treating” it is meant obtaining beneficial or desired results, such as clinical results.
- beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or manifestations of a disease, disorder, or condition;
- treating involves administering an agent as described herein, according to a therapeutic regimen that partially or completely alleviates, ameliorates, relieves, inhibits, delays onset of, reduces severity of, and/or reduces frequency, incidence or severity of one or more symptoms, features, and/or causes of a relevant disease, disorder, and/or condition.
- Such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition. Alternatively or additionally, such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition. In some embodiments, treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject who is susceptible to the disease, disorder, or condition in that s/he is known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
- T-t pe Calcium Channel Modulator By "T-type calcium channel modulator” it is meant an agent that increases or decreases a level and/or activity of a T-type calcium channel, for example by altering one or more of gene expression (including transcription, post-transcriptional processing, transcript localization or packaging, etc), protein expression (including translation, folding, degradation, post-translational processing or modification, localization, etc), and/or activity (e.g., ability to transport calcium across the plasma membrane, to achieve membrane polarization, and/or to initiate or maintain downstream signaling), compared to an appropriate control or reference.
- gene expression including transcription, post-transcriptional processing, transcript localization or packaging, etc
- protein expression including translation, folding, degradation, post-translational processing or modification, localization, etc
- activity e.g., ability to transport calcium across the plasma membrane, to achieve membrane polarization, and/or to initiate or maintain downstream signaling
- T-type calcium channel modulators include activators or inhibitors of T-type calcium channels.
- T-type calcium channel modulators can be identified, tested, and/or characterized by any useful methods in the art and/or described herein.
- T-t pe Calcium Channel By "T-type calcium channel” is meant a type of voltage- operated calcium channel wherein the length of channel activation is transient and the channel contains an l subunit which determines the properties of the channel.
- Voltage-Operated Calcium Channel By "voltage-operated calcium channel” is meant a calcium channel activated by voltage, distinct from a ligand-gated calcium channel and synonymous with a voltage-activated calcium channel and a voltage-gated calcium channel.
- Figures 1A-1E show CaV3.1 expression in T cells and localization to the plasma membrane.
- Figures 1A-B show CaV3.1 expression as measured by quantitative RT-PCR in CD4+ T cells isolated from murine lymph nodes, spleen and thymus, in EL-4 T cells, in murine splenic CD4+ T cells, cerebrum, and cerebellum.
- Figure 1C shows CaV3.1 protein detection in pooled splenic and lymph node CD4+ T cells as a band of the expected size (-250 kD) by cell lysis, immunoprecipitation and immunoblotting with an anti-CaV3.1 antibody (anti-CaV3.1).
- Figure ID shows CaV3.1 expression at the surface of splenic CD4+ T cells by biotinylation of intacT cells followed by purification on avidin beads, then blotting with anti-CaV3.1 Ab (upper panel) or anti-GATA-3 as control for a strictly intracellular protein (lower panel).
- B indicates the biotinylated cell surface fraction isolated on avidin beads;
- N indicates the non-labeled flow-through fraction.
- Figure IE shows relative expression of the CaV3.1, CaV3.2, and CaV3.3 message in wild-type, CaV3.1 -/- and CaV3.1 ⁇ mice. CaV3.1 deletion induces compensation with increased expression of CaV3.2 and CaV3.3 in CD4+ T cells, as assessed by quantitative RT-PCR.
- Figures 2A-2E are results showing that the signature current for T-type channels is present in wild-type CD4+ T cells and reduced in constitutively CaV3.1 -/- CD4+ T cells.
- Figure 2B are representative recordings at the -30 mV voltage step displayed for all conditions. Currents were 13.3 ⁇ 1.38 pA in wild-type versus 6.95 ⁇ 1.10 pA in CaV3.1 -/- cells at -30 mV without mibefradil.
- Figure 2C is a plot showing the time constant ( ⁇ ) of voltage-dependent inactivation of currents in CD4+ T cells elicited by voltage steps from a holding potential of -90 mV. Data represent means ⁇ SEM from 7 wild-type and 8 CaV3.1 -/- cells.
- FIG. 2D is a plot showing that store operated Ca 2+ entry triggered by treatment with thapsigargin (TG; 2 ⁇ ) is unaffected in CaV3.1 deficient CD4+ cells.
- Cells were loaded with Fluo-4 AM and analyzed on a Flipr 96-well imaging system (means + SEM from 16 wells for each genotype from 3 independenT cell preparations).
- Figure 2E is a plot showing that calcium entry induced by TCR engagement is not affected by CaV3.1 deficiency.
- CD4+ T cells were stimulated with an anti-CD3 antibody and no differences in the amplitude or time course of calcium influx were observed between cells from wild-type and CaV3.1 ⁇ animals.
- CD4+ T cells from CaV3.1 ⁇ and wild-type littermates were loaded with indo-1 AM and biotinylated anti-CD3. The cells were analyzed by flow cytometry at baseline and after activation with streptavidin.
- FIGs 3A-3D show that CaV3.1 -/- and CaV3.1 ⁇ animals are resistant to experimental autoimmune encephalomyelitis (EAE).
- EAE experimental autoimmune encephalomyelitis
- Figure 3A is a plot showing the EAE score and Figure 3B is a plot showing the body weight measured daily (means +/- SEM).
- Figure 3C is a plot showing the EAE score and Figure 3D is a plot showing the body weight measured daily (means +/- SEM).
- Figures 4A-4D show the reduction in Thl7 cell population and in RORyt expression in
- Figures 5A-5C shows that anti-CaV3.1 antibody recognizes CaV3.1.
- Figure 5A are blots showing full-length CaV3.1 or vector control myc -tagged cDNAs transiently transfected into 293 cells. Overexpressed proteins are detected in whole cell lysates via immunoprecipitation and
- FIG. 5B are blots showing the specificity of the anti-CaV3.1 antibody confirmed using cerebellum and cerebrum isolated from CaV3.1 -/- and wild-type littermate mice.
- Figure 5C is a blot showing that no shorter splice variant is present in cerebellum from CaV3.1 deficient mice. Total protein tissue lysates of cerebellum from wild-type and CaV3.1 -/- cerebellum were analyzed by immunoblotting with anti-CaV3.1 antibody or anti-GAPDH antibodies to verify equal protein loading.
- Figures 6A-6C show the generation of constitutive CaV3.1 -deficient mice.
- Figure 6A are schematics showing a targeting construct designed to knockout the pore region of CaV3.1 using a neomycin cassette to replace exons 1 1 to 13.
- Figure 6B shows targeted disruption of the CaV3.1 gene verified by Southern blotting
- Figure 6C shows a PCR gel of genomic DNA isolated from candidate mice.
- Figures 7A-7C show that the signature current for CaV3 channels is present in wild-type
- FIGS. 7A-7B are plots showing the current/voltage (I/V) relationships of currents recorded from 17 wild-type cells and 19 CaV3.1-/- cells.
- Figure 7C is a graph showing peak currents (means ⁇ SEM) recorded from 17 wild-type cells, and 19 CaV3.1-/- cells.
- Figure 8 shows a plot of the voltage-dependent kinetics of activation.
- Data represent means ⁇ SEM from 7 wild-type and 8 CaV3.1 -/- cells.
- Figures 9A-9B show that thymic and splenic T cells isolated from CaV3.1 -/- mice display normal development and have similar rates of proliferation compared to wild-type cells.
- Thymocytes and splenocytes were isolated from wild-type and CaV3.1 -/- mice and analyzed by flow cytometry for surface expression of various T cell specific antigens.
- Figure 9A are plots showing that the percent of CD4+ CD8+ and CD4+ CD8- thymocytes are indistinguishable between wild-type and CaV3.1 -/- mice.
- Figure 9B are plots showing that CD4+ cells from wild-type and CaV3.1 -/-spleens had similar rates of proliferation. Results are representative of 6 wild-type and 6 CaV3.1 -/- mice.
- Figures 10A-10D show that CaV3.1 -/- mice are equally sensitive in an asthma model.
- Figure 10A shows an anti-OVA serum IgE response in OVA immunized wild-type and CaV3.1 -/- mice induced with asthma by challenge with OVA or saline.
- Figure 10B shows pulmonary resistance (PR) after acetylcholine challenge
- Figure IOC shows broncho-alveolar lavage cellularity
- Figures 11A-11B are histologic analyses of EAE mice showing minimal lesions in
- Figure 11A is a histologic analysis by hematoxylin and eosin staining of spinal cords (upper panels) and cerebellum (lower panels) in wild- type (left) and CaV3.1 -/- (right) mice.
- Figure 1 IB is a histologic analysis of spinal cords in wild-type (left) and CaV3.1 ⁇ (right) mice.
- the panel on the right is an enlarged view of the framed area in the left image. Characteristic perivascular inflammatory infiltrates were observed in both sets of wild-type animals.
- Figure 13 shows an exemplary timecourse of mRNA expression of Cav3.1 during Thl7 differentiation at 3, 6, 12, 24, 48 and 96 hours.
- Figure 14 depicts an exemplary dose response curve showing a T-type calcium channel antagonist, here TTA-A2, inhibiting T-type calcium current as a function of antagonist concentration.
- Figure 15 shows an exemplary graph demonstrating the pharmacological effects of a T- type calcium channel modulator in an animal model of multiple sclerosis, EAE.
- the present invention encompasses the recognition that the source of a problem in the development of therapeutic modalities for the treatment of lymphocyte-associated diseases, disorders and conditions is the limited knowledge of appropriate druggable targets active on immune (e.g., lymphocyte) cells.
- the present invention solves this problem by identifying certain T-type calcium channels (e.g., Cav3.1 and/or Cav3.2 and/or Cav3.3 channels) as present and active on particular lymphocytes (e.g., T cells and specifically na ' ive T cells and Thl7 cells).
- the present invention further specifically demonstrates ability of T-type calcium channel modulators (e.g., selective T-type calcium modulators as described herein) to impact level and/or activity of T-type calcium channels on immune cells in tissues and/or organs (e.g., spleen).
- T-type calcium channel modulators e.g., selective T-type calcium modulators as described herein
- the present invention encompasses the specific recognition of a problem associated with treating diseases, disorders and conditions associated with activity of Thl7 cells.
- Thl7 cells are thought to play a key role in autoimmune diseases (such as multiple sclerosis, psoriasis, autoimmune uveitis, juvenile diabetes, rheumatoid arthritis, and Crohn's disease in particular), and specifically to play a role in inflammation and tissue injury in these conditions.
- Thl7 cell activity can cause severe autoimmune diseases, but is also important for maintaining anti-microbial immunity, particularly at epithelial / mucosal barriers.
- Thl7 cells produce cytokines (such as interleukin 22) which stimulate epithelial cells to produce anti-microbial proteins to clear out certain types of microbe (such as Candida and
- Thl7 cell differentiation and/or activity may leave the host susceptible to opportunistic infections.
- the present invention encompasses the recognition that one source of a problem associated with treating such diseases, disorders, and conditions associated with Thl7 cell activity is the substantial absence of identified targets involved Thl7 cell differentiation and/or activity.
- the present invention appreciates that, while the Retinoic Acid Receptor gamma (RORy) transcription factor is known to participate in Thl7 cell differentiation and/or activity, it is difficult target safely and/or effectively.
- the present recognition defines and appreciates a need for draggable target(s) in or on na ' ive T cells and/or Thl7 cells, preferably on the surface of such cells.
- the present invention solves this problem and addresses this need by demonstrating, among other things, that certain T-type calcium channels (e.g., Cav3.1 and/or Cav3.2 and/or Cav3.3 channels) are present and active on na ' ive T cells and Thl7 cells, and furthermore are involved in Thl7 cell differentiation.
- the present invention therefore provides compositions and methods relevant to modulating (e.g., specifically modulating) T-type calcium channels active in na ' ive T cells and Thl7 cells, and therefore unexpectedly provides technologies relevant to Thl7- associated diseases, disorders and conditions including, for example, multiple sclerosis, psoriasis, multiple myeloma, etc.
- the present invention also specifically demonstrates that modulation of T-type calcium channel activity can achieve therapeutically relevant effects in models of lymphocyte-associated diseases disorders and conditions (e.g., in an EAE model of multiple sclerosis).
- the present disclosure particularly establishes relevance of modulating Cav3.1 channels (whose activity is shown herein to be dominant relative to other T-type calcium channels such as, e.g., Cav3.2 and Cav3.3, at least on lymphocyte cells such as T cells, e.g., na ' ive T cells and/or Thl7 cells).
- CRAC channels are known to play a role in the activity of certain T cells; they are not believed to be involved in helper T cell differentiation (see, for example, Shaw et al Front Biosci (Elite Ed). 2012 Jan 1 ;4:2253, Jan 2012). The activity of CRAC channels is not voltage-dependent.
- T-type calcium channel activity on lymphocyte cells is particularly valuable and beneficial because, prior to the present disclosure, T-type calcium channel activity was thought to be most relevant in CNS cells and events.
- T-type calcium channel modulators have previously been pursued by others, efforts have typically been focused on agents that cross the blood brain barrier and/or that are effective in the treatment of CNS disorders such as epilepsy and pain (see, for example, Zhang et al Biochim Biophys Acta 1828(7): 1550, July 2013; Uslaner et al., Neuropharmacology 62(3): 1413, March 2012).
- T-type calcium channel modulators for use in accordance with the present invention need not (and in many embodiments do not, or are administered such that they do not) cross the blood brain barrier and/or have any significant therapeutic effect with respect to pain, epilepsy, schizophrenia, and/or sleep disorders.
- the present invention therefore surprisingly establishes uses for T-type calcium channel modulators that do not cross the blood- brain barrier and/or do not have any significant therapeutic effect with respect to CNS disorders such as, for example, pain, epilepsy, schizophrenia, and/or sleep disorders.
- the present invention provides and/or utilizes T-type calcium channel modulators that do not reach and/or are not active with respect to CNS cells, and thus surprisingly teaches compositions and methods specific to non-CNS T-type calcium channels and/or to lymphocyte -related diseases, disorders or conditions that do not involve (or whose features that are treated herein do not involve) neurons and/or CNS cells, tissues, organs and/or systems.
- the present invention also surprisingly establishes methods and compositions for using T-type calcium channel modulators in non-CNS (e.g., peripheral) and/or non-neuronal settings, including particularly methods and compositions for peripheral (e.g., not-CNS targeted) delivery, including local delivery of such modulators.
- the specific utility demonstrated herein for modulation of only the CaV3.1 subtype of T- type calcium channels is particularly surprising and unexpected in light of prior art focus on Cav3.2 modulation, which is thought to be relevant to treatment of pain, for example.
- the invention surprisingly overcomes various challenges often associated with detection, characterization, and or modulation of voltage-dependent channels, and particularly of T- type voltage-gated calcium channels (e.g., Cav3.1 channels).
- the technical difficulty that can be associated with electrophysiologically recording activity of such channels in cells is recognized in the field, which includes at least one published report of a researcher driven to fabricate
- CaV3.1 channel is expressed and functional as a channel in T cells, carrying the dominant current relative to the other T-type channels, CaV3.2 and CaV3.3.
- Further surprising findings include that targeted reduction of CaV3.1 channel expression in T cells inhibits the autoimmune response in the experimental autoimmune encephalomyelitis model.
- Still further surprising findings include that this targeted CaV3.1 deficiency leads to a lower proportion of Thl7 cells and a reduction in the expression of RORyt, a transcription factor critical to Thl7 differentiation, in CaV3.1 -deficient cells stimulated in Thl7-favoring conditions, whereas no effects of CaV3.1 deficiency were observed on TCR-mediated calcium entry.
- Still further surprising findings include demonstrated effects of T-type channel modulation in immune cells in organs, specifically spleen.
- These data provide, among other things, the first evidence of T-type calcium channels in immune cells, identify the unanticipated predominance of the CaV3.1 subtype, identify an unanticipated role for CaV3.1 in T cell differentiation into the Thl7 subset, and show the existence of a TCR-independent, CaV3.1 -mediated source of calcium influx in T cells that is active in the range of resting membrane potentials.
- the present invention thererefore establishes, among other things, that a potential therapeutic approach for autoimmune and other diseases and conditions is through T-type calcium channels of subtype CaV3.1.
- T-type calcium channels are uniquely characterized by their low activation thresholds. T- type currents typically activate at about -70 mV, and inactivate rapidly ( ⁇ of about 15-30 ms) (see, for example, review by Perez-Reyes Physiol Rev 88 : 1 17, 2003 , incorporated herein by reference in its entirety).
- T-type calcium channels have focused on their roles in neuronal cells and pathways, including in pain signal transmission and in brain rhythms involved in sleep and in certain forms of epilepsy (see review by Cheong and Shin Physiol Rev 93:961, 2013).
- the present invention encompasses the insight that the T-type calcium channel activation threshold of about -70 mV is near the resting potential of lymphocytes, whose average membrane potential has been measured to be between -60 and -55 mV.
- the present invention establishes, among other things, that T-type calcium channels are in fact present and active on lymphocyte cells, and in particular on T cells such as naive T cells and Thl7 cells. Moreover, the present invention establishes that modulation of T- type calcium receptor activity, and particularly of CaV3.1 activity, is relevant in a certain lymphocyte- associated diseases, disorders and conditions, including particularly in multiple sclerosis.
- lymphocyte cell e.g., T cell
- autoimmune diseases are typically attributable to action of lymphocytes against host cells, tissues, or components.
- Many inflammatory diseases, disorders, or conditions similarly are associated with and/or caused by lymphocyte activity.
- Certain infectious diseases may also be exacerbated by inappropriate or ineffective lymphocyte action; the same is true for a variety of cancers.
- some cancers e.g., T cell cancers
- lymphocytes could be stimulated or otherwise encouraged or supported to attack them.
- modulation i.e., increase or decrease
- Any such disease, disorder or condition may be considered to be a lymphocyte-associated disease, disorder, or condition in certain embodiments of the present invention.
- lymphocyte -related diseases, disorders, or conditions (and/or those aspects of it treated by administration of a T-type calcium channel modulator [e.g., a selective T- type calcium modulator] as described herein) relevant to the present disclosure involve cells, tissues, organs and/or systems other than the CNS; in some such embodiments, such diseases, disorders, or conditions do not significantly involve CNS cells, tissues, organs and/or systems.
- a T-type calcium channel modulator e.g., a selective T- type calcium modulator
- T-type calcium channel modulators utilized as described herein do not affect, and/or are administered so that an effective amount is not delivered to, neurons and/or to one or more CNS cells, tissues, organs and/or systems. In other embodiments, however, T-type calcium channel modulators utilized as described herein do affect, and/or are administered so that an effective amount is delivered to, neurons and/or to one or more CNS cells, tissues, organs and/or systems.
- lymphocyte -related diseases, disorders, or conditions (and/or those aspects of it treated by administration of a T-type calcium channel modulator [e.g., a selective T- type calcium modulator] as described herein) relevant to the present disclosure involve immune cells in the spleen.
- a T-type calcium channel modulator e.g., a selective T- type calcium modulator
- lymphocyte-associated diseases, disorders or conditions relevant to the present disclosure are autoimmune diseases, particularly diseases characterized by or associated with uncontrolled or inappropriate Thl7 activation, such as arthritis, multiple sclerosis, psoriasis, and lupus.
- Non-limiting examples of autoimmune diseases include, acute disseminated encephalomyelitis (ADEM), Addison's disease, agammaglbulinemia, alopecia areata, amyotrophic lateral sclerosis, ankylosing spondylitis, antiphospholipid syndrome, antisynthetase syndrome, atopic allergy, atopic dermatitis, autoimmune aplastic anemia, autoimmune cardiomyophathy, autoimmune enteropathy, autoimmunehemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune
- ADAM acute disseminated encephalomyelitis
- Addison's disease agammaglbulinemia
- alopecia areata
- amyotrophic lateral sclerosis ankylosing spondylitis
- thrombocytopenic purpura autoimmune urticaria, autoimmune uveitis, Balo concentric sclerosis, Behcet's disease, Berger's disease, Bickerstaff s encephalitis, Blau syndrome, bullous pemphigoid, Castleman's disease, celiac disease, Chagas disease, chronic inflammatory demyelinating
- spondyloarthropathy stiff person syndrome, subacute bacterial endocarditis, Susac's syndrome, Sweet's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis, thrombocytopenia, Tolosa- Hunt syndrome, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease, undifferentiated spondyloarthropathy, vitiligo, and Wegener's granulomatosis.
- lymphocyte-associated diseases, disorders or conditions relevant to the present disclosure are not classically considered autoimmune diseases.
- Non-limiting examples include: allergic asthma, hay fever, bee venom, allergy, food allergy, sarcoidosis, ankylosing, spondylitis, erythematosus, inflammatory bowel disease (e.g., ulcerative colitis), vasculitis, T cell lymphoma expressing ICOS, rejection of a transplanted organ or tissue, alopecia areata, atherosclerosis, bipolar disorder, schizophrenia, and graft-versus-host disease.
- lymphocyte-associated diseases, disorders or conditions relevant to the present disclosure are infectious diseases.
- Infectious diseases can be of fungal, viral, bacterial, and/or parasitic in origin.
- viral infectious diseases include, but are not limited to: HPV, AIDS, SARS, rabies, rubella, roseola, mumps, measles, norovirus, Lassa fever, yellow fever, poliomyelitis, conjunctivitis, viral hepatitis, dengue fever, common cold, influenza, viral meningitis, West Nile virus, viral pneumonia, viral encephalitis, smallpox, Colorado tick fever, viral gastroenteritis, roseola sixth disease, hepes simplex, cytomegalovirus infection, and Ebola haemorrhagic fever.
- bacterial infectious diseases include, but are not limited to: stye, MRS A, E.coli, typhus, plague, tetanus, cholera, anthrax, syphilis, pink eye, impetigo, botulism, tularemia, trachoma, chalazion, listeriosis, diphtheria, gonorrhea, Chlamydia, shigellosis, scarlet fever, tuberculosis, legionellosis, typhoid fever, Lyme disease, bacterial meningitis, and pertussis whopping cough.
- fungal infectious diseases include, but are not limited to: candidiasis, aspergillosis, blastomycosis, histoplasmosis, cryptococcosis, tinea cruris, tinea capitis, and tinea pedis.
- parasitic infectious diseases include, but are not limited to: malaria, scabies, filariasis, amebiasis, ascariasis, babesiosis, pediculosis, trichinellosis, leishmaniasis, toxoplasmosis, trichomoniasis, Chagas disease, schistosomiasis, trypanosomiasis, and cryptosporidiosis.
- lymphocyte-associated diseases, disorders or conditions relevant to the present disclosure are cancers.
- cancers include: bladder cancer, breast cancer, colon and rectal cancer, endometrial cancer, kidney or renal cell cancer, leukemia, lung cancer, melanoma, Non-Hodgkin lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer.
- animal models are available for a variety of lymphocyte-associated diseases, disorders and conditions; such models can be utilized to identify and/or characterize useful T-type calcium channel modulators as described herein, and particularly to assess their usefulness in treatment of the particular lymphocyte-associated diseases, disorders or conditions to which the particular model is relevant.
- EAE experimental autoimmune encephalomyelitis
- Exemplary other relevant models include, for example, animal models of relapsing-remitting multiple sclerosis (see, for example, McRae et al., J.
- the present invention provides, among other things, various methods and compositions that relate to and/or include T-type calcium channel modulators.
- T-type calcium channel modulators are active with respect to T-type calcium channels on immune cells (e.g., on T cells such as na ' ive T cells and Thl7 cells).
- T-type calcium channel modulators are active with respect to T-type calcium channels in one or more primary lymphoid organs (e.g., the spleen).
- primary lymphoid organs e.g., the spleen
- such T-type calcium channel modulators are active with respect to T-type calcium channels in bone marrow.
- T-type calcium channel modulators for use in accordance with the present invention are selective T-type calcium channel modulators.
- such modulators are selective and/or specific for (e.g., exhibit preferential activity with respect to) T-type calcium channels (e.g., for one or more of Cav3.1, Cav3.2, or Cav3.3 channels) as compared with other calcium channels, and/or for T-type calcium channels on immune cells (e.g., T cells such as na ' ive T cells and/or Thl7 cells) as compared with T-type calcium channels on other cell types (e.g., on CNS cells).
- T-type calcium channels e.g., for one or more of Cav3.1, Cav3.2, or Cav3.3 channels
- immune cells e.g., T cells such as na ' ive T cells and/or Thl7 cells
- such modulators are selective and/or specific for T-type calcium channels on certain immune cells (e.g., in primary lymphoid organs) as compared with other immune cells (e.g., peripheral immune cells). In some embodiments, such modulators are selective and/or specific for a particular T- type calcium channel as compared with other T-type calcium channels (e.g., for Cav3.1 channels as compared with Cav3.2 and/or Cav3.3 channels), even in some instances as compared with other T-type calcium channels in or on immune cells. In some embodiments, T-type calcium channel modulators are selective for T-calcium channels as compared with other voltage-gated channels (e.g., such as L-type, N- type, P/Q-type, and/or R-type calcium channels).
- voltage-gated channels e.g., such as L-type, N- type, P/Q-type, and/or R-type calcium channels.
- T-type calcium channel modulators are selective for cells, tissues, organs and/or systems other than the CNS; in some such embodiments, T-type calcium channel modulators do not significantly involve CNS cells, tissues, organs and/or systems. In some particular embodiments, T-type calcium channel modulators do not selectively or specifically impact neurons. In some embodiments, however, T-type calcium channel modulators do impact neurons and/or CNS cells, tissues, organs and/or systems if contacted therewith.
- such T-type calcium channel modulators are delivered to subjects via a route, regimen, modality, or mechanism that does not achieve delivery of an effective amount (e.g., and amount sufficient to alter level and/or activity of a T-type calcium channel therein so that a significant biological effect is observed).
- an effective amount e.g., and amount sufficient to alter level and/or activity of a T-type calcium channel therein so that a significant biological effect is observed.
- T-type calcium channel modulators are or comprise inhibitors. In some embodiments, T-type calcium channel modulators are or comprise activators.
- T-type calcium channel modulators as described herein have activities and/or are administered such that one or more effects (e.g., analgesia, pain relief) on neurons and/or CNS cells, tissues, organs and/or systems is not observed.
- effects e.g., analgesia, pain relief
- T-type calcium channel modulators for use in accordance with the present invention may be identified and/or characterized with respect to their activity (including, for example, with respect to the specificity, magnitude, and/or nature of their effect(s), for example relative to one or more appropriate references or controls) on T-type calcium channels as described herein.
- one or more candidate T-type calcium channel modulating agents is contacted with a system comprising in which one or more T-type calcium channels found in or on lymphocyte cells is active, and assessing impact of the agent on level and/or activity of the T-type calcium channel, typically relative to an appropriate reference or control (e.g., absence of the agent, presence of a different known modulator, specificity, magnitude, and/or nature of effect by the agent on a different calcium channel such as a different T-type calcium channel, for example active in or on different cells).
- an appropriate reference or control e.g., absence of the agent, presence of a different known modulator, specificity, magnitude, and/or nature of effect by the agent on a different calcium channel such as a different T-type calcium channel, for example active in or on different cells.
- T-type calcium channel modulators are identified from collections or pools of candidate agents, for example including sets of candidate agents that are structural variants of one another.
- members of such collections or pools may be designed, for example, to share one or more structural features of a known T- type calcium channel modulator and/or to contain moieties in three dimensional space positioned appropriately for interaction with certain known target moieties (e.g., as determined with reference to three-dimensional structural models for example according to principles of structure based drug design).
- selective T-type calcium channel modulators may share certain structural attributes with agents or compounds that are not in and of themselves selective for T-type calcium channels.
- agents or compounds that are not themselves selective are nonetheless useful in various embodiments of the invention that require or benefit from selectivity, as such agents may be utilized in a way (e.g., via local delivery) that permits them to perform with appropriate selectivity and/or specificity in context (e.g., because they are not exposed to their own competing targets).
- agents or compounds that are not in and of themselves selective for relevant T-type calcium channels may be used as references in the design, identification, and/or characterization of selective compounds that share one or more structural features with them.
- T-type calcium modulators in accordance with the present invention are or include antibodies or fragments thereof.
- Antibodies against T-type calcium channels can be made, e.g., using any of the methods for making antibodies to membrane proteins known in the art.
- antibodies can be generated by immunization with whole cells over-expressing the target protein.
- Membrane proteins can be displayed in their native conformation without mechanical or detergent disruption.
- stable murine cells expressing a human membrane protein are used to immunize mice. Improvements to this approach can involve selecting cells that have the highest expression level of the membrane protein of interest.
- membrane proteins can be solubilized and reconstituted in its structurally intact form into phospholipid vesicles and used as an immunogen in mice.
- simple peptides can be effective immunogens for deriving antibodies against linear epitopes.
- a variation to this approach known as chemical linkage of peptides onto scaffolds (CLIPS), uses peptides to recreate individual conformational epitopes for immunization and is described in Timmerman et al., J Mol Recognit 20:283- 299, 2007. By constraining linear epitope sequences using cysteine linkages to mimic certain structured conformations that better represent the native proteins. Conformational antibodies to, for example, follicle-stimulating hormone (FSH) and G-protein coupled receptor CXCR7 have been generated using this method. As an alternate, Integral Molecular (Philadelphia, PA) has developed a method of presenting native membrane protein immunogens as Lipoparticle (Willis et al., Biochemistry 47:6988-6990, 2008).
- FSH follicle-stimulating hormone
- CXCR7 G-protein coupled receptor CXCR7
- Lipoparticles are virus-like particles that incorporate high concentrations of target membrane proteins in their native conformation.
- the particles are produced from mammalian cells by co-expressing the retroviral structural core polyprotein, Gag, along with a desired membrane protein.
- the lipoparticles are approximately 150 nm in diameter, therefore are readily suspended in aqueous solutions that can be used for inoculation.
- monoclonal antibodies can then be produced by standard hybridoma cell production. Once produced, monoclonal antibodies can also be tested for specific recognition by Western blot or immunoprecipitation analysis.
- Antibodies selective and/or specific for the T-type calcium channel can be generated using the approach described in Naylor et al., The Open Drug Discovery Journal 1 :36-42, 2009. Briefly, the target T-type calcium channel (e.g., CaV3.1, Cav3.2, and Cav3.3) is selected and the amino acid sequence of the channel is obtained including information on any splice variants. A peptide, at least 20mer in length (e.g., 20mer, 25mer, 30mer, 35mer, 40mer, etc) based on the extracellular E3 loop, which maintains the position of the ion selectivity filter, is identified.
- the target T-type calcium channel e.g., CaV3.1, Cav3.2, and Cav3.3
- a peptide, at least 20mer in length e.g., 20mer, 25mer, 30mer, 35mer, 40mer, etc
- the peptide sequence can be further selected to eliminate antigenicity and cross-species similarities (e.g., by comparing sequences between CaV3.1 , Cav3.2, and Cav3.3).
- An N- or C-terminal cysteine is added to the peptide if not naturally present in order to conjugate a support (e.g., KLH protein) to aide in affinity purification.
- the peptide is then used in standard immunization protocol, and antibody titre is determined by ELISA. Functional assays are then used to test the blocking activity of the antibody relative to controls such as preimmune antisera or peptide-adsorbed antibody.
- Antibodies with blocking effects are then tested for off-target effects on other ion transport mechanisms to validate any effects on cellular or tissue responses using independent methods (e.g., R Ai).
- Examples of polyclonal antibodies generated using this approach include, but are not limited to polyclonal antibodies targeted to the voltage-gated K + channel Kvl .2 and Kv3.1, NESOpAb, targeted to voltage-gated sodium channel Navl.5, and D-III, pAb targeted to N- and P/Q- type voltage-gated calcium channels.
- monoclonal antibodies generated using the above approach include, but are not limited to the monoclonal antibody mAb56 targeted to the voltage-gated K + channel, hEagl, and the anti-STIMl antibody targeted to the ion channel auxiliary protein STIM1.
- antibodies for use in accordance with the present invention are humanized antibodies.
- a humanized antibody can have one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain.
- Humanization can be essentially performed by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies, where substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non- human species.
- humanized antibodies are typically human antibodies in which at least some hypervariable region residues as well as other variable region residues are substituted by residues from analogous sites in rodent antibodies.
- variable domains both light and heavy
- the choice of human variable domains, both light and heavy, to be used in making the humanized antibodies can be important to reduce antigenicity.
- sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences.
- the human sequence which is closest to that of the rodent is then accepted as the human framework for the humanized antibody.
- Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies.
- antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties.
- humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
- FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
- the hypervariable region residues are directly and most substantially involved in influencing antigen binding.
- antibodies for use in accordance with the present invention are human antibodies.
- Human antibodies can be constructed by combining Fv clone variable domain sequence(s) selected from human-derived phage display libraries with known human constant domain sequences(s).
- human monoclonal antibodies of the invention can be made by the hybridoma method. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described.
- transgenic animals e.g., mice
- transgenic animals e.g., mice
- JH antibody heavy-chain joining region
- Gene shuffling can also be used to derive human antibodies from non-human, e.g., rodent, antibodies, where the human antibody has similar affinities and specificities to the starting non- human antibody.
- this method which is also called "epitope imprinting" either the heavy or light chain variable-region of a non-human antibody fragment obtained by phage display techniques as described herein is replaced with a repertoire of human V domain genes, creating a population of non- human chain/human chain scFv or Fab chimeras.
- antibodies for use in accordance with the present invention are or include anti-T-type calcium channel antibody fragments that comprise a portion of an intact antibody, preferably comprising the antigen binding region and/or one or more complement determining regions (CDRs) thereof.
- antibody fragments include Fab, Fab', F(ab')2 , and Fv fragments;
- diabodies linear antibodies; single-chain antibody molecules; and multi-specific antibodies formed from antibody fragments.
- Fab fragments, each with a single antigen-binding site, and a residual "Fc” fragment, whose name reflects its ability to crystallize readily.
- Pepsin treatment yields an F(ab')2 fragment that has two antigen- combining sites and is still capable of cross-linking antigen.
- Fv is the minimum antibody fragment which contains a complete antigen-binding site.
- a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association.
- one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure analogous to that in a two-chain Fv species. It is in this configuration that the three hypervariable regions (HVRs) of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer.
- HVRs hypervariable regions
- HVRs confer antigen- binding specificity to the antibody.
- a single variable domain or half of an Fv comprising only three HVRs specific for an antigen has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
- the Fab fragment contains the heavy- and light-chain variable domains and also contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain.
- Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region.
- Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
- F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
- Single-chain Fv or scFv antibody fragments comprise the V H and V L domains of antibody, where these domains are present in a single polypeptide chain.
- the scFv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the scFv to form the desired structure for antigen binding.
- Diabodies are antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) in the same polypeptide chain (V H -V L ).
- V H heavy-chain variable domain
- V L light-chain variable domain
- Diabodies may be bivalent or bispecific.
- Antibody fragments may be generated by traditional means, such as enzymatic digestion, or by recombinant techniques. In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead to improved access to solid tumors.
- Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies. However, these fragments can now be produced directly by recombinant hosT cells. Fab, Fv, and ScFv antibody fragments can all be expressed in and secreted from E. coli, thus allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries.
- Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments.
- F(ab')2 fragments are isolated directly from recombinant hosT cell culture.
- Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.
- T-type calcium modulators in accordance with the present invention are or include one or more RNAi agent(s) that inhibit T-type calcium channel gene expression and/or activity in a cell in vitro or in vivo (e.g., in a subject).
- RNAi agents can be or include different types of double- stranded molecules that include either RNA:RNA or
- RNA:DNA strands RNA:DNA strands.
- These agents can be introduced to (including by expression within) cells in a variety of structures, including a duplex (e.g., with or without overhangs on the 3 '-terminus), a hairpin loop, or an expression vector that express one or more polynucleotides capable of forming a double-stranded polynucleotide alone or in combination with another polynucleotide.
- RNAi agents include siRNA, shRNA, DsiRNA, and miRNA agents.
- RNAi agents are about 10 to about 40 nucleotides in length, and preferred lengths for particular RNAi agents include siRNA that are double-stranded RNA molecules of 16 to 30 nucleotides in length (e.g., 18 to 25 nucleotides, e.g., 21 nucleotides); shRNA that are single- stranded RNA molecules in which a hairpin loop structure is present and a stem length is between 19 to 29 nucleotides in length (e.g., 19 to 21 nucleotides or 25 to 29 nucleotides) or a loop size is between 4 to 23 nucleotides in length; DsiRNA that are double-stranded RNA agents of 25 to 35 nucleotides in length; and miRNA that are single- stranded RNA molecules of 17 to 25 nucleotides (e.g., 21 to 23 nucleotides) in length.
- siRNA that are double-stranded RNA molecules of 16 to 30 nucleotides in length
- an RNAi agent can have any useful nucleic acid sequence, including a nucleic acid sequence having one or more DNA molecules, RNA molecules, or modified forms (e.g., a modified backbone composition or 2'-deoxy, or 2'-0-methyl modifications) or
- an RNAi agent can contain one or more 5'- and/or 3 '-terminal modifications.
- an RNAi agent can include blunt nucleotides at one or both termini; in some embodiments, an RNAi agent can include one or more overhanging nucleotides at one or both termini.
- Exemplary terminal modifications include a 5'- dideoxythymidine overhang, such as for siRNAi; a 3'-UU or 3'-dTdT overhang, such as for shRNA; one or more G-U mismatches between the two strands of the shRNA stem; or a single-stranded nucleotide overhang at the 3 '-terminal of the antisense or sense strand of 1 to 4 nucleotides (e.g., 1 or 2 nucleotides) for DsiRNA.
- a 5'- dideoxythymidine overhang such as for siRNAi
- a 3'-UU or 3'-dTdT overhang such as for shRNA
- one or more G-U mismatches between the two strands of the shRNA stem or a single-stranded nucleotide overhang at the 3 '-terminal of the antisense or sense strand of 1 to 4 nucleotides (e.g., 1 or 2
- RNAi agents include at least one antisense nucleotide sequence that is directed to a target nucleic acid (e.g., a target gene, e.g., a T-type calcium channel gene).
- Antisense nucleotides are single strands of DNA or R A that are complementary to a chosen target sequence. In the case of antisense RNA, they prevent translation of complementary RNA strands by binding to it.
- Antisense DNA can be used to target antisense nucleotides contain from about 10 to about 40 nucleotides, more preferably about 15 to about 30 nucleotides.
- the antisense nucleotide can have up to 80%, 85%, 90%, 95%, 99%, or even 100% complementary to the desired target gene.
- RNAi agents can include commercially available agents, such as those available from
- RNAi agents can be designed to target a particular gene of interest using web-based prediction tools known in the art (e.g., Human siRNA Database (HuSiDa), and Genelink).
- T-type calcium modulators in accordance with the present invention are or include small molecules that alter level and/or activity of T-type calcium channels as described herein.
- small-molecule modulators can include one or more compound(s) that enhance or inhibit the activity (e.g., membrane polarization, influx of calcium ions into the cell, and downstream signaling) of the channel by binding to the 3 ⁇ 4 subunits (e.g., iG, iH, and ail) of various T-type calcium channels (e.g., CaV3.1, CaV3.2, CaV3.3).
- small-molecule modulators can bind to other subunits that may make up the calcium channel, such as, the ⁇ 2 ⁇ , ⁇ , and ⁇ subunits, and to different states of the channels (e.g., depolarized (inactivated) state, and polarized (activated) state, hyperpolarized (closed) state, and open state).
- T-type calcium channel small-molecule modulators may be selected from the group consisting of diphenylbutylpiperidines derivatives (e.g., pimozide, penfluridol, clopimozide, and fluspirilene), butyrophenone derivatives (e.g., haloperidol, droperidol, benperidol, triperidol, melperone, lenperone, azaperone, and domperidone), and phenylpiperazine derivatives (e.g., antrafenine, aripiprazole, ciprofloxacin, dapiprazole, dropropizine, etoperidone, itraconazole, ketoconazole, levodropropizine, mepiprazole, naftopidil, nefazodone, niaprazine, oxypertine, posaconazole, traz
- T-type calcium channel small-molecule inhibitors include dihydropyridine derivatives (e.g., manidipine, nilvadipine, benidipine, and efonidipine), flunarizine, anandamide, lomerizine, and phenytoin and zonisamide, and U-92032.
- selective T-type calcium channel small-molecule modulators may be selected from the group consisting of tetralol, tetralol derivatives (e.g., mibefradil), mibefradil derivatives (e.g., N C 55-0396 dihydrochloride described in Quesada et al., Drug Metab Dispos.
- TTA Merck T-type antagonist
- TTA-A2 Merck T-type antagonist
- TTA-A8 piperidines
- TTA-P1 and 4-aminomethyl-4-fluoropiperidine TTA-P2
- Additional selective T-type calcium channel small-molecule inhibitors include succinimide anticonvulsant derivatives (e.g., ethosuximide, phensuximide, and mesuximide also known as methsuximide, and an active metabolite, N-desmethylmethsuximide also known as (alpha)-methyl-(alpha)-phenyl-succinimide), and R isomer of efonidipine.
- T- type calcium channel small-molecule inhibitors include trimethadione, its active metabolite dimethadione, ABT-639 of Abbott, TTL-1 177 of Tau Therapeutics also known as TH-1 177, , KYSO5044, , and, and kurtoxin.
- T-type calcium channel small-molecule modulators may be selected from the group consisting of those described in the patents and published patent applications listed in Giordanetto et al, "T-type calcium channels inhibitors: a patent review," Expert Opin Ther Pat, 21 :85-101, 201 1 (hereby incorporated by reference), including WO2004035000, WO9304047,
- WO200707852 WO2008033447, WO2008033456, WO2008033460, WO2008033464, WO2008033465, WO2008050200, WO20081 17148, WO2009056934, EP1568695, WO2008007835, KR754325,
- T-type calcium channel small-molecule modulators for use in accordance with the present invention may be or include agents or compounds that are not in and of themselves selective for T-type calcium channels.
- agents or compounds include, for instance, anandamide, antrafenine, benidipine, efonidipine, flunarizidine, fluspiriline, haloperidol, lomerizine, penfluridol, phenytoin, pimozide, U-92032, zonisamide (see, for example, Biton, Clin Neuropharmacol. 30:230, 2007; Matar et al., Epilepsy Res. 83:224, 2009).
- T-type calcium modulators in accordance with the present invention are or include peptides or polypeptides.
- such peptides share structural homology (e.g., one or more conserved sequence elements) with one or more subunits of the relevant T- type calcium channel (e.g., al, ⁇ 2 ⁇ , ⁇ , and/or ⁇ subunit(s)) and/or transmembrane domains of the T-type calcium channel (e.g., TM1, TM2, TM3, TM4, TM5, and TM6).
- Non-limiting examples of peptide modulators include je TMla, LGLLVAIV; je TMla
- the present invention also relates to pharmaceutical compositions that contain one or more T-type calcium channel modulator(s) or a combination of a T-type calcium channel modulator and a second therapeutic agent (e.g., a combination of a T-type calcium channel modulator and a calcium channel modulator, an immunosuppressant, or an anticancer agent).
- a second therapeutic agent e.g., a combination of a T-type calcium channel modulator and a calcium channel modulator, an immunosuppressant, or an anticancer agent.
- Such compositions can be formulated for use in a variety of drug delivery systems.
- One or more physiologically acceptable excipients or carriers can also be included in the composition for proper formulation. Suitable formulations for use in the present invention are found in Remington 's The Science & Practice of Pharmacy, University of the Sciences in Philadelphia, PA, 21st ed., 2005. For a brief review of methods for drug delivery, see, e.g., Langer, Science 249: 1527-1533
- compositions are formulated for parenteral, intranasal, topical, oral, or local administration, such as by a transdermal means, for prophylactic and/or therapeutic treatment.
- the pharmaceutical compositions can be administered parenterally (e.g., by intravenous, intramuscular, or subcutaneous injection), or by oral ingestion, or by topical application or intraarticular injection at areas affected by the vascular or cancer condition. Additional routes of administration include intravascular, intra-arterial, intratumor, intraperitoneal, intraventricular, intraepidural, as well as nasal, ophthalmic, intrascleral, intraorbital, rectal, topical, or aerosol inhalation administration.
- compositions for parenteral administration that comprise the above mention agents dissolved or suspended in an acceptable carrier, preferably an aqueous carrier, e.g., water, buffered water, saline, PBS, and the like.
- an acceptable carrier preferably an aqueous carrier, e.g., water, buffered water, saline, PBS, and the like.
- the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, detergents and the like.
- compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered.
- the resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
- the pH of the preparations typically will be between 3 and 1 1 , more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5.
- compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the above mentioned agent or agents, such as in a sealed package of tablets or capsules.
- compositions in solid form can also be packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment.
- compositions containing an effective amount can be administered for prophylactic or therapeutic treatments.
- an effective amount e.g., compositions containing a unit dose amount appropriate for administration in an established effective dosing regimen
- compositions containing a unit dose amount appropriate for administration in an established effective dosing regimen can be administered for prophylactic or therapeutic treatments.
- compositions can be administered to a patient with a clinically determined predisposition or increased susceptibility to development of an autoimmune disease, an infectious disease, a T cell-mediated disease, or a cancer.
- compositions as described herein patient subject according to a dosing regimen that delivers an amount sufficient to delay, reduce, or preferably prevent the onset of clinical disease.
- compositions are administered to a subject (e.g., a human) already suffering from an autoimmune disease, an infectious disease, other T cell-mediated disease, or a cancer in an amount sufficient to cure or at least partially arrest the symptoms of the condition and its complications.
- a subject e.g., a human
- An amount adequate to accomplish this purpose is defined as a
- therapeutically effective dose an amount of a compound sufficient to substantially improve some symptom associated with a disease or a medical condition.
- an agent or compound which decreases, prevents, delays, suppresses, or arrests any symptom of the disease or condition would be therapeutically effective.
- a therapeutically effective amount of an agent or compound is not required to cure a disease or condition but will provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered, or prevented, or the disease or condition symptoms are ameliorated, or the term of the disease or condition is changed or, for example, is less severe or recovery is accelerated in an individual.
- compositions according to the present invention include a combination of a compound or formulation of the present invention in association with a pharmaceutically acceptable excipient, as described herein, and another therapeutic or prophylactic agent known in the art.
- formulated agents can be packaged together as a kit.
- kits that contain, e.g., two pills, a pill and a powder, a suppository and a liquid in a vial, two topical creams, etc.
- a kit can include optional components that aid in the administration of the unit dose to patients, such as vials for reconstituting powder forms, syringes for injection, customized IV delivery systems, inhalers, etc.
- the unit dose kit can contain instructions for preparation and administration of the compositions.
- kits may be manufactured as a single use unit dose for one patient, multiple uses for a particular patient (at a constant dose or in which the individual compounds may vary in potency as therapy progresses); or the kit may contain multiple doses suitable for administration to multiple patients ("bulk packaging").
- the kit components may be assembled in cartons, blister packs, bottles, tubes, and the like.
- compositions in accordance with the present invention, and/or active agents included therein may comprise and/or otherwise be associated with a targeting entity or moiety that assists in localizing the composition and/or agent, after delivery, to a site of interest (e.g., to immune cells having active T-type calcium channels).
- a targeting entity or moiety that assists in localizing the composition and/or agent, after delivery, to a site of interest (e.g., to immune cells having active T-type calcium channels).
- a targeting entity or moiety that assists in localizing the composition and/or agent, after delivery, to a site of interest (e.g., to immune cells having active T-type calcium channels).
- a targeting entity or moiety that assists in localizing the composition and/or agent, after delivery, to a site of interest (e.g., to immune cells having active T-type calcium channels).
- localization may be restricted to the periphery, and/or to non-neuronal and/or non-CNS locations, by which is meant areas of the body outside
- compositions of the invention can be administered in combination therapy, i.e., combined with other agents (e.g., immunosuppressants, other ion channel modulators, anticancer agents, anti-inflammatory agents, and/or pain relievers) depending on the condition to be treated.
- agents e.g., immunosuppressants, other ion channel modulators, anticancer agents, anti-inflammatory agents, and/or pain relievers
- useful immunosuppressants include, but are not limited to, calcineurin inhibitors (e.g., cyclosporin A (SANDIMMUNE ® ), cyclosporine G tacrolimus (PROGRAF ® , PROTOPIC ® )), mTor inhibitors (e.g., sirolimus (RAPAMUNE ® , NEORAL ® ), temsirolimus (TORISEL ® ), zotarolimus, and everolimus (CERTICAN ® )), fingolimod (GILENYATM), myriocin, alemtuzumab (CAMPATH ® , MABCAMPATH ® , CAMPATH- 1 H ® ), rituximab (RITUXAN ® , MABTHERA ® ), an anti-CD4 monoclonal antibody (e.g., HuMax-CD4), an anti-LFAl monoclonal antibody (e.g., HuMax
- Patent Publication 2006/02807308 monabatacept (ORENCIA ® ), belatacept, indolyl-ASC (32-indole ether derivatives of tacrolimus and ascomycin), azathioprine (AZASAN ® , IMURAN ® ), lymphocyte immune globulin and anti-thymocyte globulin [equine] (ATGAM ® ), mycophenolate mofetil (CELLCEPT ® ), mycophenolate sodium
- TREXALL ® 6-mercaptopurine
- PURINETHOL ® 6-mercaptopurine
- 15-deoxyspergualin Gusperimus
- LF 15-0195 15-deoxyspergualin
- bredinin brequinar
- muromonab-CD3 ORTHOCLONE ®
- Cyclosporine A (CsA; CAS No. 59865- 13-3; U.S. Patent No. 3,737,433) and its analogs may be used as an immunosuppressant.
- CsA Cyclosporine A
- Cyclosporines and their formulations are described, for example, in 2004 Physicians' Desk Reference ® (2003) Thomson Healthcare, 58th ed., and U.S. Patent Nos. 5,766,629; 5,827,822; 4,220,641 ; 4,639,434; 4,289,851 ; 4,384,996; 5,047,396;
- Tacrolimus (FK506) is a macrolide which exerts effects largely similar to CsA, both with regard to its molecular mode of action and its clinical efficacy (Liu, Immunol. Today 14:290-5, 1993; Schreiber et al., Immunol. Today, 13: 136-42, 1992); however, these effects are exhibited at doses that are 20 to 100 times lower than CsA (Peters et al., Drugs 46:746-94, 1993). Tacrolimus and its formulations are described, for example, in 2004 Physicians' Desk Reference ® (2003) Thomson Healthcare, 58th ed., and U.S. Patent Nos.
- Sirolimus is an immunosuppressive lactam macrolide produceable, for example, by Streptomyces hygroscopicus. Numerous derivatives of sirolimus and its analogs and their formulations are known and described, for example, in 2004 Physicians' Desk Reference ® (2003) Thomson Healthcare, 58th ed., European Patent EP 0467606; PCT Publication Nos. WO 94/02136, WO 94/09010, WO 92/05179, WO 93/1 1 130, WO 94/02385, WO 95/14023, and WO 94/02136, and U.S.
- useful antioxidants include, but are not limited to, vitamin D, calcitriol, calcidiol, or other vitamin D receptor binder, quercetin or other flavonoid, resveratrol or other sirtuin modulator.
- useful anticancer agents include, but are not limited to: chemotherapeutic agents (e.g., arsenic trioxide, cisplatin, carboplatin, chlorambucil, melphalan, nedaplatin, oxaliplatin, triplatin tetranitrate, satraplatin, imatinib, nilotinib, dasatinib, and radicicol), immunomodulatory agents (e.g., methotrexate, leflunomide, cyclophosphamide, cyclosporine A, minocycline, azathioprine, antibiotics (e.g., tacrolimus), methylprednisolone, corticosteroids, steroids, mycophenolate mofetil, rapamycin, mizoribine, deoxyspergualin, brequinar, T cell receptor modulators, and cytokine receptor modulators), antiangiogenic agents (e.g., arsenic trioxide
- mitotic inhibitors e.g., paclitaxel, vinorelbine, docetaxel, abazitaxel, ixabepilone, larotaxel, ortataxel, tesetaxel, vinblastine, vincristine, vinflunine, and vindesine
- nucleoside analogs e.g., gemcitabine, azacitidine, capecitabine, carmofur, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, fluorouracil, mercaptopurine, pentostatin, tegafur, and thioguanine
- DNA intercalating agents e.g., doxorubicin, actinomycin, bleomycin, mitomycin, and plicamycin
- topoisomerase inhibitors e.g., irinotecan, aclarubicin, amrubicin
- useful pain relievers include, but are not limited to: acetaminophen/paracetomol, non-steroidal anti-inflammatory drugs, COX-2 inhibitors, opiates, morphinomimetics, flupirtine, tricyclic antidepressants, (e.g., amitriptyline), nefopam, and
- anticonvulsants e.g., carbamazepine, gabapentin, and pregabalin
- dual LOX/COX inhibitors cannabinoid receptor antagonists
- neurokinin antagonists e.g., IL-12 receptor
- PAR2 receptor antagonists e.g., IL-12 receptor antagonists
- iNOS inhibitors e.g., IL-12 receptor antagonists
- vanilloid/TRPVl/capsaicin receptor antagonists calcitonin gene -related antagonists
- COX3 inhibitors glycine antagonists
- N-acetylcholine receptor antagonists e.g., N-acetylcholine receptor antagonists
- enkephalinase inhibitors e.g., enkephalinase inhibitors, FAAH inhibitors, and other T-type calcium channel inhibitors.
- T-type calcium modulators utilized in accordance with the present invention are not pain relievers (e.g., are not analgesics).
- such T-type calcium modulators lack significant effects (relative to an appropriate control) when administered to a model system for pain, and/or to one or more cells, tissues, organs or systems involved in or associated with pain or pain relief.
- T-type calcium modulators utilized in accordance with the present invention do or can have pain relief activity.
- such modulators are administered such that pain relief activity is not observed.
- T-type calcium channel modulators are delivered to subjects via a route, regimen, modality, and/or mechanism that does not achieve delivery of an effective amount (e.g., and amount sufficient to alter level and/or activity of a T-type calcium channel therein so that a significant biological effect is observed).
- T-type calcium modulators as described herein are utilized to relieve pain.
- the present invention provides methods of identifying patients likely to benefit from therapy with T-type calcium channel modulators as described herein, for example by directly or indirectly determining level and/or activity of a T-type calcium channels active in immune cells (e.g., in lymphocytes such as T cells such as na ' ive T cells and/or Thl7 cells) and/or of a relevant population of immune cells (e.g., lymphocytes and in particular T cells such as Thl7 cells or other cells with active T-type calcium channels) in the subject by analyzing a sample obtained from the subject.
- immune cells e.g., in lymphocytes such as T cells such as na ' ive T cells and/or Thl7 cells
- a relevant population of immune cells e.g., lymphocytes and in particular T cells such as Thl7 cells or other cells with active T-type calcium channels
- the present invention provides methods of assessing development, progression and/or treatment (e.g., responsiveness to therapy) of a relevant lymphocyte- associated disease, disorder or condition, in a subject for example by determining level and/or activity of a T-type calcium channel in or on immune cells (e.g., lymphocytes and in particular T cells such as naive T cells and/or Thl7 cells) and/or of Thl7 cells in the subject by analyzing a sample obtained from the subject.
- the sample is obtained prior to, concurrent with, or subsequent to administration of one or more doses of a T-type calcium channel modulator as described herein.
- such analyzing is performed on a plurality of samples from the subject, wherein different samples in the plurality were obtained at different points in time.
- one or more doses of a T-type calcium channel modulator as described herein may be administered between such different points in time.
- a decrease in level and/or activity of the relevant T-type calcium channel (e.g., of a CaV3.1 channel) and/or of Thl7 cells is indicative of slowed progression and/or effective treatment of the disease, disorder, or condition.
- the invention provides methods for assessing the treatment of a lymphocyte-associated disease, disorder, or condition as described herein, by administering a selective T-type calcium channel modulator to a subject suffering from or susceptible to the disease, disorder, or condition and determining whether, after such
- the frequency and/or severity of clinical exacerbations was reduced, extent of disease progression was delayed or prevented, and/or frequency and/or magnitude of one or more doses of a concomitant therapy (e.g., of another selective T-type calcium channel modulator, antioxidant, immunosuppressant, or anticancer agent) was reduced.
- a concomitant therapy e.g., of another selective T-type calcium channel modulator, antioxidant, immunosuppressant, or anticancer agent
- a sample obtained from a subject includes peripheral immune cells.
- a sample obtained from a subject includes tissue (e.g., spleen, bone marrow).
- tissue e.g., spleen, bone marrow.
- T-type calcium channel active in immune cells e.g., in lymphocytes such as T cells such as na ' ive T cells and/or Thl7 cells
- well established technologies for determining protein levels include, for example, ELISA assays and/or other direct binding assays.
- technologies for determining levels of nucleic acids encoding proteins include hybridization-based
- T-type calcium channels include, for example, whole-cell patch-clamp electrophysiology, calcium assays (e.g., FLIPR).
- FCM flow cytometry
- RORgT transcription factor
- RT-PCR RT-PCR
- detection e.g., by intracellular staining
- IL-17 secreted protein
- a targeting construct was designed to knockout the pore region of CaV3.1 by using neomycin cassette to replace the exons 1 1 to 13.
- the targeting construct was transfected into 129/SvJ embryonic stem (ES) cells.
- Targeted ES clones were identified by southern blotting and used in the generation of germline chimeras.
- Heterozygous germ line mice (129/SvJ) were interbred to obtain homozygous mice.
- Male germline chimeras were also backcrossed with female C57BL/6 mice for three generations. Homologous recombination was verified by southern blotting, PCR and immunoblotting. Wild type and CaV3.1 knock out littermates (6-8 weeks) were used for phenotypic analysis. Animals were maintained at and the full barrier facility of the Center of Life Sciences which is fully accredited by AAALAC and the U.S. Department of Agriculture.
- mice were dissected from wild type and CaV3.1-/- and CaV3.1 ⁇ mice. Cells in suspension were recovered. T cells were negatively enriched from pooled splenocytes and lymph node cells using a mouse pan T isolation kit (Miltenyi Biotec). CD4+ T cells were enriched using a mouse CD4+ T cell isolation kit (Miltenyi Biotec). All antibodies were purchased from BD Pharmingen. All recombinant cytokines were from PeproTech.
- Mouse CaV3.1 had the following sequences:
- Rabbit polyclonal antibodies with reactivity to this sequence were generated by Invitrogen. This antibody was tested on human embryonic kidney cells (HEK 293) transfected with either a myc tagged cDNA for CaV3.1, or the empty vector. This anti-CaV3.1, or an anti-myc mAb, immunoprecipitated and immunoblotted a band of the expected size, about 250kD, from HEK293 cells transfected with CaV3.1, but not from HEK293 cells transfected with the empty vector ( Figures 5A-5C).
- IP immunoprecipitation
- Digidata 1440A (Axon Instruments). Only cells with tight seals (>16 GO) were selected to break in. Cells were maintained at a -90 mV holding potential during experiments. Immediately after establishing the whole-cell patch clamp configuration, voltage steps (10 mV increments from a holding potential of - 90 mV up to +50 mV) lasting 250 ms were applied every 2 s. The liquid-junction potential offset was around 4.3 mV and was corrected. Bath solution: 120 mM tetraethylammonium chloride, 10 mM CsCl, 10 mM CaCl 2 , 10 mM HEPES (pH adjusted to 7.4 with CsOH).
- Pipette solution 105 mM Cs- methanesulfonate, 10 mM Cs- 1 ,2-te-(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid (Cs-BAPTA), 5 mM CaCl 2 , 8 mM MgCl 2 , and 10 mM HEPES (pH adjusted to 7.2 with CsOH).
- Calculated buffered intracellular Ca 2+ concentration is 150 nM using Maxchel software available online at
- FLIPR Fluorometric Imaging Plate Reader Assay
- BSA 0.5% BSA were loaded with 2 mM Indo-1 mixed with Pluronic F-127 at 37°C for 45 minutes.
- the cells were washed and resuspended in HBSS buffer containing 1.25 mM Ca, 1 mM Mg and 0.5% BSA, then labeled with anti-CD4-FITC on ice for 30 min, and then washed and loaded with biotinylated anti-CD3 (10 ⁇ g/mL).
- the CD4+ cells were gated and analyzed on a Becton Dickinson LSRII with
- OVA ovalbumine
- Mice were then euthanized with an overdose of pentobarbital and bronchoalveolar lavage (BAL) performed with PBS.
- BAL cells were pelleted, counted, and analyzed after Cytospin and Diff- Quik staining.
- MOG myelin oligodendrocyte glycoprotein
- CFA emulsion Hooke Laboratories
- mice spleen was dissected from wild type and CaV3.1 ⁇ mice. Cells in suspension were recovered. Pooled splenocytes were cultured for 5 days in 96-well plates coated with anti-CD3 (145-2cl 1, 10 ⁇ g/mL) and soluble anti-CD28 (10 ⁇ g/mL) in the presence of 2.5 ng/mL human TGF-beta, 20 ng/mL IL-6, 10 ng/mL IL-23, 10 ⁇ g/mL anti-IFN- ⁇ , and 10 ⁇ g/mL anti-IL-4 (murine, unless otherwise specified). CD4+ IL-17+ cell counts were performed.
- Example 1 CaV3.1 is expressed on the surface of CD4+ T cells
- This anti-CaV3.1 antibody was used to assay lysates of CD4+ T cells by immunoprecipitation and immunoblotting.
- CaV3.1 protein was detected as a band of the expected size (-250 kD), which was absent after immunoprecipitation with normal IgG ( Figure 1C). Therefore, CaV3.1 message and full- length CaV3.1 protein are indeed expressed in T cells.
- mice with a constitutive deletion of CaV3.1 were generated by homologous recombination ( Figures 5B-5C and
- Example 3 CaV3.1 is a functional calcium channel in T cells [00209]
- CaV3.1 in T cells acts as a functional channel, and if so whether it displays similar properties to that of CaV3.1 channels in other tissues.
- Whole-cell voltage- clamp recordings were conducted in primary splenic CD4+ T cells from wild-type mice. Without exception, currents displayed a uniquely T-type channel profile (summary data in Figure 2A, raw data in Figure 2B, Figure 2C, and Figures 7A-7C), with an activation threshold at -70 mV, a symmetric current/voltage (I/V) relationship, and rapid inactivation. The magnitude of the T-type current is significant, exceeding that of CRAC channels.
- Example 4 Ca V3.1 does not play a role in T cell maturation
- Example 5 Ca V3.1 deficient mice are protected against experimental autoimmune encephalomyelitis (EAE)
- EAE encephalomyelitis
- Thl7 cells are considered to be the major effector T cell population in EAE pathogenesis.
- naive T cells were isolated from 4 WT mice spleen and lymph nodes. The naive CD4+ T cells were skewed to Thl7 cells for 3, 6, 12, 24, 48 and 96 hours. Total RNA was isolated and Cav3.1 was detected by RT-PCR using Taqman primers and probes. As shown in Figure 13, Cav3.1 mRNA levels were observed to drop between 12 and 24 hr following initiation of differentiating naive T cells to Thl7 cells. Without wishing to be bound by any particular theory, we propose that one possible explanation for this observation is that Cav3.1 may play the role of a differentiation "switch.”
- TTA-A2 a potent and selective T-type calcium channel antagonist known as TTA-A2
- T-type calcium channel antagonist inhibited T- type calcium current as a function of antagonist concentration.
- TTA-A2 electrophysiological measurements of T-type calcium current in these cells was potently inhibited by TTA-A2, in a concentration-dependent manner.
- T-type calcium channel modulator significantly impacted differentiation of Thl7 cells.
- Naive CD4+ T cells were pre-treated with TTA-A2 for 24 hours. Pre-treated cells were then differentiated to Thl7 cells for 4 days with continued drug treatment for 1 day. Then, after 4 days, intracellular cytokine staining was performed for IL-17F, a marker of Thl7 cell differentiation.
- IL-17F a marker of Thl7 cell differentiation.
- 61.4 ⁇ 4.7 percent of untreated cells stained positive for IL-17F whereas only 33.7 ⁇ 5.8 percent of TT A- A2 -treated cells stained positive.
- splenocytes were surface stained with anti-CD4-FITC, anti-CDld/aGalcer-PE, anti-TCRab-APC, anti-NKl .1 -APC-cy7 to analyze the proportion of invariant NKT (iNKT) cells.
- iNKT invariant NKT
- iNKT cells have been observed by others to be protective in autoimmune diseases including multiple sclerosis (see, for example, Subleski et al. Immunotherapy 3(10): 1167-1 184. Oct 201 1), without wishing to be bound by any particular theory, enhancement of the iNKT population following T-type calcium channel inhibition could be an additional mechanism contributing to the amelioration of EAE symptoms and potentially of autoimmune diseases in general.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention features methods and compositions relevant to modulating voltage-operated calcium channels, in particular CaV3.1 calcium channels, active in or on immune cells (e.g., lymphocytes such as T cells and in particular nave T cells and Th17 cells).
Description
MODULATING VOLTAGE-OPERATED CALCIUM CHANNELS ON IMMUNE CELLS
Cross-Reference to Related Applications
[0001] This application claims priority to U.S. Provisional Application Serial No. 61/691,006, filed on August 20, 2012, and U.S. Provisional Application Serial No. 61/739,861, filed on December 20, 2012, the disclosures of which are hereby incorporated in their entirety.
Government License Rights
[0002] This invention was made with government support under Grant No. 5R37GM53950, awarded by the National Institutes of Health. The government has certain rights in the invention.
Background of the Invention
[0003] Undesirable or inappropriate lymphocyte activity contributes to a variety of diseases, disorders, and conditions, including particularly various inflammatory, infectious, and/or proliferative diseases, disorders, and/or conditions such as autoimmune disorders and cancer. There is a need to identify therapeutic modalities effective for the treatment of such diseases, disorders, and/or conditions, as well as a need for technologies that can identify, characterize, monitor and/or evaluate relevant lymphocyte components and/or activities.
Summary
[0004] The present invention encompasses the finding that T-type voltage-gated calcium channels operate on immune cells (e.g., T lymphocytes). The present invention further demonstrates that modulation of such T-type voltage-gated calcium channels can impact immune cell development, differentiation, and/or activity.
[0005] Among other things, the invention provides systems (e.g., compositions and methods) for identifying, characterizing, and/or using appropriate modulating agents that are selective T-type calcium channel modulators. In some embodiments, such modulating agents modulate T-type calcium channels active in or on immune cells.
[0006] In some embodiments, modulating agents are selective for (e.g., exhibit preferential activity with respect to) T-type calcium channels in cells when membrane potential is relatively depolarized. For example, in some embodiments, such modulating agents exhibit preferential activity for cells when membrane potential is above about -70 mV, for example in the range of about -55 mV to about -65 mV, or about -55 mV to about -60 mV, as is observed with resting T cells whose average resting
membrane potentials can range from -60 mV to -55 mV, a range which is depolarized relative to the approximate average resting potential of neurons (-70 mV) and cardiac muscle (-90 mV).
[0007] In some embodiments, modulating agents are selective and/or specific for T-type calcium channels (e.g., for one or more of Cav3.1, Cav3.2, or Cav3.3 channels) as compared with other calcium channels, and/or for T-type calcium channels on immune cells as compared with T-type calcium channels on other cell types. In some embodiments, modulating agents are selective and/or specific for a particular T-type calcium channel as compared with other T-type calcium channels (e.g., for Cav3.1 channels as compared with Cav3.2 and/or Cav3.3 channels), even in some instances as compared with other T-type calcium channels in or on immune cells. In some embodiments, modulating agents are or comprise inhibitors.
[0008] In some embodiments, the invention provides methods identifying and/or characterizing one or more agents for activity as a selective T-type calcium channel modulator by contacting the agent with a system comprising a T-type calcium channel active on lymphocyte cells; and detecting a selective and/or specific effect (e.g., relative to absence of the agent and/or to level or type of activity of the agent with respect to one or more other calcium channels and/or to one or more calcium channels on other cell types) of the agent on level or activity of the T-type channel. In some such embodiments, the system comprises lymphocyte cells on which the T-type calcium channel is active.
[0009] In some embodiments, relevant immune cells are or comprise T lymphocytes (i.e, T cells). In some particular embodiments, relevant immune cells are or comprise Thl7 cells. In some particular embodiments, relevant immune cells are or comprise naive T cells. In some embodiments, the relevant immune cells (e.g., T cells) are present in a tissue or organ. In some such embodiments, the tissue or organ is or comprises the spleen. In some such embodiments, the tissue or organ is or comprises bone marrow.
[0010] The present invention provides compositions comprising modulating agents as described herein, as well as methods of using them (e.g., including diagnostic and/or therapeutic methods), or of otherwise diagnosing, monitoring, and/or treating certain lymphocyte -related diseases, disorders, and/or conditions. In some embodiments, such diseases, disorders, and/or conditions may be selected from inflammatory, autoimmune, infectious, and/or proliferative diseases, disorders, or conditions.
[0011] In some embodiments, the invention features a method of treating a subject suffering from or susceptible to a relevant lymphocyte -related diseases, disorder, or condition, the method including administering to the subject a selective T-type calcium channel modulator in an amount sufficient to treat the disease, disorder, or condition. In some embodiments, the lymphocyte-related disease, disorder, or condition (and/or those aspects of it treated by administration of a T-type calcium
channel modulator [e.g., a selective T-type calcium modulator] as described herein) involves cells, tissues, organs and/or systems other than the CNS; in some such embodiments, it does not significantly involve CNS cells, tissues, organs and/or systems. In some particular embodiments, neurons are not involved.
[0012] In some embodiments, provided methods reduce the frequency of clinical exacerbations, and/or delay or prevent disease progression, rather than reduce the degree (e.g., severity and/or frequency of incidence of) of pain or of other clinical manifestations (e.g., fatigue) associated with the particular relevant disease, disorder, or condition.
[0013] In some embodiments, provided treatment methods further include administering to the subject a second agent, wherein the selective T-type calcium channel modulator and the second agent together are present in an amount sufficient to treat the condition. In some embodiments, provided treatment methods further include administering to the subject a second agent that reduces the frequency or severity, and/or delays onset, of one or more symptoms or manifestations of the disease, disorder, or condition that is not significantly affected by administration of the selective T-type calcium channel modulator alone; in some such embodiments, the one or more symptoms or manifestations is or comprises pain.
[0014] In some embodiments, the invention features a method for assessing development, progression and/or treatment of a relevant lymphocyte-associated disease, disorder or condition, in a subject, for example by determining level and/or activity of a T-type calcium channel in or on immune cells (e.g., T cells such as Thl7 cells) and/or of Thl7 cells in the subject by analyzing a sample obtained from the subject. In some embodiments, the sample is obtained prior to, concurrent with, or subsequent to administration of one or more doses of a T-type calcium channel modulator as described herein. In some embodiments, such analyzing is performed on a plurality of samples from the subject, wherein different samples in the plurality were obtained at different points in time. In some embodiments, one or more doses of a T-type calcium channel modulator as described herein may be administered between such different points in time. In some embodiments, a decrease in level and/or activity of the relevant T-type calcium channel (e.g., of a CaV3.1 channel) and/or of Thl7 cells is indicative of slowed progression and/or effective treatment of the disease, disorder, or condition. In some embodiments, the invention provides methods for assessing the treatment of a lymphocyte-associated disease, disorder, or condition as described herein, by administering a selective T-type calcium channel modulator to a subject suffering from or susceptible to the disease, disorder, or condition and determining whether, after such
administering, the frequency and/or severity of clinical exacerbations was reduced, extent of disease progression was delayed or prevented, and/or frequency and/or magnitude of one or more doses of a
concomitant therapy (e.g., of another selective T-type calcium channel modulator, antioxidant, immunosuppressant, or anticancer agent) was reduced.
[0015] As noted above, in some embodiments, the present invention contemplates combination therapy of a modulating agent (e.g., a T-type calcium channel blocker, and particularly a selective T-type calcium channel modulator as described herein) with at least one additional therapeutic agent (i.e., at least one second agent). In some embodiments of the invention, the second agent is or comprises another selective T-type calcium channel modulator, an antioxidant, an immunosuppressant, or an anticancer agent. In some embodiments, the second agent is or comprises a pain reliever (e.g., an analgesic).
[0016] In some embodiments, the antioxidant is selected from the group consisting of: vitamin
D, calcitriol, calcidiol, or other vitamin D receptor binder, quercetin or other flavonoid, resveratrol or other sirtuin modulator.
[0017] In some embodiments, the immunosuppressant is selected from the group consisting of: a calcineurin inhibitor, tacrolimus, an mTor inhibitor, fingolimod, myriocin, alemtuzumab, rituximab, an anti-CD4 monoclonal antibody, an anti-LFAl monoclonal antibody, an anti-LFA3 monoclonal antibody, an anti-CD45 antibody, an anti-CD 19 antibody, monabatacept, belatacept, indolyl-ASC; azathioprine, lymphocyte immune globulin and anti-thymocyte globulin [equine], mycophenolate mofetil,
mycophenolate sodium, daclizumab, basiliximab, cyclophosphamide, prednisone, prednisolone, leflunomide, FK778, FK779, 15-deoxyspergualin, busulfan, fludarabine, methotrexate, 6-mercaptopurine, 15-deoxyspergualin, LF 15-0195, bredinin, brequinar, and muromonab-CD3.
[0018] In some embodiments, the anticancer agent is selected from the group consisting of: a chemotherapeutic agent, an antiangiogenic agent, a mitotic inhibitor, a nucleoside analog, a DNA intercalating agent, and a topoisomerase analog.
[0019] Alternatively or additionally, in some embodiments, a modulating agent (e.g., a T-type calcium channel modulator, and particularly a selective T-type calcium modulator) is administered in combination with a pain reliever such as, for example, acetaminophen/paracetomol, one or more nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, opiates, morphinomimetics, flupirtine, tricyclic antidepressants, (e.g., amitriptyline), nefopam, anticonvulsants (e.g., carbamazepine, gabapentin, pregabalin), dual LOX/COX inhibitors, cannabinoid receptor antagonists, neurokinin antagonists, PAR2 receptor antagonists, iNOS inhibitors, vanilloid/TRPVl/capsaicin receptor antagonists, calcitonin gene- related antagonists, COX3 inhibitors, glycine antagonists, N-acetylcholine receptor antagonists, enkephalinase inhibitors, FAAH inhibitors, and/or other T-type calcium channel inhibitors.
[0020] In some embodiments of the invention, the lymphocyte-related disease, disorder or condition is a T cell-mediated disease, disorder, or condition such as, for example, allergic asthma, allergy
(e.g., bee venom allergy or food allergy), erythematosus, alopecia areata, atherosclerosis, bipolar disease, graft-versus-host disease, hay fever, rejection of a transplanted organ or tissue, schizophrenia, T cell lymphoma expressing ICOS. In some embodiments, the the lymphocyte-related disease, disorder or condition is a T cell-mediated disease, disorder, or condition such as, for example, allergic asthma, allergy (e.g., bee venom allergy or food allergy), erythematosus, alopecia areata, atherosclerosis, graft-versus- host disease, hay fever, rejection of a transplanted organ or tissue, T cell lymphoma expressing ICOS. In some embodiments, a T cell-mediated disease, disorder or condition is a Thl7-mediated autoimmune disease.
[0021] In some such embodiments, the lymphocyte-related disease, disorder or condition is an autoimmune disease, for example selected from the group consisting of: amyotrophic lateral sclerosis, multiple sclerosis, rheumatoid arthritis, systemic lupus, psoriasis, diabetes mellitus type 1 , sympathetic ophthalmia, thrombocytopenia, inflammatory bowel disease (Crohn's disease, ulcerative colitis), Grave's disease, Hajimoto's thyroiditis, Sjogren's syndrome, autoimmune aplastic anemia, autoimmune cardiomyopathy, autoimmune enteropathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune myocarditis, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune urticaria, and autoimmune uveitis, acute disseminated encephalomyelitis, ankylosing spondylitis, dermatomyositis, eosinophilic fasciitis, fibromyalgia, Goodpasture's syndrome, Guillain-Barre syndrome, Miller-Fisher syndrome, Hashimoto's
encephalopathy, idiopathic thrombocytopenic purpura, inflammatory myopathy, Kawasaki's disease, Lambert-Eaton myasthenic syndrome, myasthenia gravis, neuromyelitis optica (Devic's disease), neuromyotonia, osteoarthritis, pemphigus vulgaris, pernicious anaemia, polymyositis, primary biliary cirrhosis, progressive inflammatory neuropathy, psoriatic arthritis, Raynaud phenomenon, relapsing polychondritis, restless leg syndrome, sarcoidosis, scleroderma, stiff person (man) syndrome, temporal (giant cell) arteritis, transverse myelitis, undifferentiated connective tissue disease, vasculitis, vitiligo, Wegener's granulomatosis, and combinatios thereof.
[0022] In some embodiments, the lymphocyte -related disease, disorder or condition is an infectious disease, for example selected from the group consisting of: lower respiratory infections, HIV/AIDS, diarrheal diseases, tuberculosis, malaria, measles, pertussis, tetanus, meningitis, syphilis, hepatitis B, tropical diseases, and combinations thereof.
[0023] In some embodiments, the lymphocyte -related disease, disorder or condition is a, for example selected from multiple myeloma, T cell leukemia and T cell lymphoma.
[0024] In some embodiments, the modulating agent is or comprises a selective T-type calcium channel modulator that selectively targets T-type calcium channels. In some embodiments, the selective T-type calcium channel modulator selectively targets CaV3.1. In some embodiments, the selective T-type calcium channel modulator selectively targets CaV3.1 in T cells.
[0025] In some embodiments, the modulating agent is or comprises a selective T-type calcium channel modulator that modulates T cell differentiation.
[0026] In some embodiments, the modulating agent is or comprises a selective T-type calcium channel modulator that does not preferentially cross the blood-brain barrier (i.e., the T-type calcium channel modulator has a CSF:plasma concentration ratio less than one). In some embodiments, the modulating agent is or comprises a selective T-type calcium channel modulator that does not substantially cross the blood brain barrier (e.g., the T-type calcium channel modulator is not detected above background in a CNS sample such as a CSF sample). In some embodiments, the modulating agent is or comprises a selective T-type calcium channel modulator that is preferentially distributed to part or all of the immune system, such as for example to bone marrow, thymus, lymphatic system, lymph nodes, spleen, and/or mucosal and cutaneous lymphoid tissues in the gastrointestinal tract, respiratory system, genitourinary system, and/or skin.
[0027] In some embodiments, modulating agent is or comprises a selective T-type calcium channel modulator selected from the group consisting of: ethosuximide, phensuximide, and
methsuximide, methyl-phenyl-succinimide, R isomer of efonidipine, trimethadione, dimethadione, mibefradil, TTA-A2, TTA-A8, TTA-Pl, TTA-P2, TTA-Q3, TTA-Q6, MK-8998, Z941, Z944, ABT-639, TTL-1 177, KYSO5044, N C 55-0396 dihydrochloride, kurtoxin, and combinations thereof.
[0028] In some embodiments of the invention, the modulating agent is or comprises a selective
T-type calcium channel modulator that is an anti-T-type calcium channel antibody, an RNAi agent, a small molecule modulator, or peptide modulator. In some particular embodiments, the modulating agent is a selective T-type calcium channel blocker that is administered according to a dosing regimen that is sufficient to treat a particular lymphocyte-related disease, disorder or condition (e.g., multiple sclerosis) in that its use in a population of subjects suffering from multiple sclerosis shows a statistically significant correlation with a reduction in the frequency and/or severity, and/or with a delay in onset, of one or more symptoms or manifestations of the disease, disorder, or condition, across the population.
Definitions
[0029] Activator: By "activator" is meant an agent whose presence in a system comprising a T- type calcium channel or gene correlates with increased expression and/or activity of the T-type calcium channel as compared with that observed under otherwise comparable conditions in its absence. In some embodiments, an activator acts by direct interaction (i.e., binding) with a T-type calcium channel. In some embodiments, an activator acts by indirect effect (e.g., on expression or activity of a gene or transcript encoding a T-type calcium channel, or on a protein regulator thereof. In some embodiments, activators can include reversible activators (e.g., that reversibly interact with a T-type calcium channel or regulator thereof). In some embodiments, inhibitors can comprise irreversible inhibitors, for example which covalently modify the T-type calcium channel or regulator thereof. In some embodiments, activators can be agonists and/or positive allosteric regulators of T-type calcium channels or regulators thereof.
[0030] Administration: As used herein, the term "administration" refers to the administration of a composition to a subject. Administration may be by any appropriate route. For example, in some embodiments, administration may be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal and vitreal.
[0031] Amino acid: As used herein, the term "amino acid," in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds. In some embodiments, an amino acid has the general structure H2N- C(H)(R)-COOH. In some embodiments, an amino acid is a naturally-occurring amino acid. In some embodiments, an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. "Standard amino acid" refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. "Nonstandard amino acid" refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid, including a carboxy- and/or amino-terminal amino acid in a polypeptide, can contain a structural modification as compared with the general structure above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, and/or substitution as compared with the general structure. In some embodiments, such modification may, for example, alter the circulating half life of a polypeptide containing the modified amino acid as compared with one containing an otherwise identical
unmodified amino acid. In some embodiments, such modification does not significantly alter a relevant activity of a polypeptide containing the modified amino acid, as compared with one containing an otherwise identical unmodified amino acid. As will be clear from context, in some embodiments, the term "amino acid" is used to refer to a free amino acid; in some embodiments it is used to refer to an amino acid residue of a polypeptide.
[0032] Amount sufficient: By "amount sufficient" of an agent (e.g., a modulating agent) it is meant an amount of the agent sufficient to effect a beneficial or desired result (e.g., treatment of a relevant disease, disorder or conditionas described herein). In some embodiments, the beneficial or desired result is or comprises increase or reduction in level and/or activity of T-type calcium channels on immune cells and/or of Thl7 cells and/or of iNKT cells, as compared to that observed under otherwise comparable conditions absent the agent. In some embodiments, an amount sufficient is an amount that, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, is effective to achieve treatment of the disease, disorder, and/or condition (e.g., is effective to reduce the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition). Those of ordinary skill in the art will appreciate that an amount can be considered to be an "amount sufficient" even when it does not in fact achieve successful treatment upon administration to a particular individual. Rather, so long as the relevant amount provides a particular desired outcome in a significant number of subjects when administered to a population thereof, it may be considered an "amount sufficient". It is specifically understood that particular subjects may, in fact, be "refractory" to therapy so that the desired outcome is not observed even after administration of the amount sufficient. To give but one example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable. In some
embodiments, reference to amount sufficient may be a reference to an amount as measured in one or more relevant tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc). Those of ordinary skill in the art will appreciate that, in some embodiments, an amount sufficient may be formulated and/or administered in a single dose. In some embodiments, an amount sufficient may be formulated and/or administered in a plurality of doses, for example, as part of a therapeutic regimen.
[0033] Analog: As used herein, the term "analog" refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an "analog" shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, an analog a substance that can be generated from the reference substance by chemical manipulation of the reference
substance. In some embodiemnts, an analog is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance. In some embodiments, an analog is or can be generated through performance of a synthetic process different from that used to generate the reference substance.
[0034] Animal: As used herein, the term "animal" refers to any member of the animal kingdom.
In some embodiments, "animal" refers to humans, at any stage of development. In some embodiments, "animal" refers to non-human animals, at any stage of development. In some embodiments, the non- human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically-engineered animal, and/or a clone.
[0035] Antibody: As used herein, the term "antibody" refers to a polypeptide that includes canonical immunoglobulin sequence elements sufficient to confer selective and/or specific binding to a particular target antigen. As is known in the art, intact antibodies as produced in nature are approximately 150 kD tetrameric agents comprised of two identical heavy chain polypeptides (about 50 kD each) and two identical light chain polypeptides (about 25 kD each) that associate with each other into what is commonly referred to as a "Y-shaped" structure. Each heavy chain is comprised of at least four domains (each about 1 10 amino acids long) an amino-terminal variable (VH) domain (located at the tips of the Y structure), followed by three constant domains: CHI, CH2, and the carboxy-terminal CH3 (located at the base of the Y's stem). A short region, known as the "switch", connects the heavy chain variable and constant regions. The "hinge" connects CH2 and CH3 domains to the rest of the antibody. Two disulfide bonds in this hinge region connect the two heavy chain polypeptides to one another in an intact antibody. Each light chain is comprised of two domains - an amino-terminal variable (VL) domain, followed by a carboxy-terminal constant (CL) domain, separated from one another by another "switch". Intact antibody tetramers are comprised of two heavy chain-light chain dimers in which the heavy and light chains are linked to one another by a single disulfide bond; two other disulfide bonds connect the heavy chain hinge regions to one another, so that the dimers are connected to one another and the tetramer is formed.
Naturally-produced antibodies are also glycosylated, typically on the CH2 domain. Each domain in a natural antibody has a structure characterized by an "immunoglobulin fold" formed from two beta sheets (e.g., 3-, 4-, or 5-stranded sheets) packed against each other in a compressed antiparallel beta barrel. Each variable domain contains three hypervariable loops known as "complement determining regions" (CDRl, CDR2, and CDR3) and four somewhat invariant "framework" regions (FR1, FR2, FR3, and FR4). When natural antibodies fold, the FR regions form the beta sheets that provide the structural framework for the
domains, and the CDR loop regions from both the heavy and light chains are brought together in three- dimensional space so that they create a single hypervariable antigen binding site located at the tip of the Y structure. Amino acid sequence comparisons among antibody polypeptide chains have defined two light chain (κ and λ) classes, several heavy chain (e.g., μ, γ, α, ε, δ) classes, and certain heavy chain subclasses (al, a2, γΐ, γ2, γ3, and γ4). Antibody classes (IgA [including IgAl, IgA2], IgD, IgE, IgG [including IgGl, IgG2, IgG3, IgG4], IgM) are defined based on the class of the utilized heavy chain sequences. For purposes of the present invention, in certain embodiments, any polypeptide or complex of polypeptides that includes sufficient immunoglobulin domain sequences as found in natural antibodies can be referred to and/or used as an "antibody", whether such polypeptide is naturally produced (e.g., generated by an organism reacting to an antigen), or produced by recombinant engineering, chemical synthesis, or other artificial system or methodology.. In some embodiments, an antibody is monoclonal; in some embodiments, an antibody is monoclonal. In some embodiments, an antibody has constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, an antibody sequence elements are humanized, primatized, chimeric, etc, as is known in the art.
Moreover, the term "antibody" as used herein, will be understood to encompass (unless otherwise stated or clear from context) can refer in appropriate embodiments to any of the art-known or developed constructs or formats for capturing antibody structural and functional features in alternative presentation. For example, in some embodiments, the term can refer to bi- or other multi-specific (e.g., zybodies, etc) antibodies, Small Modular ImmunoPharmaceuticals ("SMIPsTM"), single chain antibodies, cameloid antibodies, and/or antibody fragments. In some embodiments, an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally. In some embodiments, an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload [e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc], or other pendant group [e.g., poly-ethylene glycol, etc]
[0036] Antibody fragment: As used herein, an "antibody fragment" includes a portion of an intact antibody, such as, for example, the antigen-binding or variable region of an antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; triabodies; tetrabodies; linear antibodies; single-chain antibody molecules; and CDR-containing moieties included in multi-specific antibodies formed from antibody fragments. Those skilled in the art will appreciate that the term "antibody fragment" does not imply and is not restricted to any particular mode of generation. An antibody fragment may be produced through use of any appropriate methodology, including but not limited to cleavage of an intact antibody, chemical synthesis, recombinant production, etc..
[0037] Anticancer: By "anticancer" is meant an agent or compound that reduces, prevents, or interferes with uncontrolled growth of cells, invasion and/or metastasis.
[0038] Anti-T-t pe Calcium Channel Antibody: By "anti-T-type calcium channel antibody" is meant an antibody (e.g., murine monoclonal antibody, chimeric, humanized monoclonal antibody, or human monoclonal antibody) that selectively and/or specifically binds to a T-type calcium channel. In some embodiments, an anti-T-type calcium channel antibody may prevent binding of the T-type calcium channel to its natural ligand, preventing downstream signaling events, and/or stimulate the immune system to attack the T-type calcium channel to which it is bound, including in some embodiments by killing cells that express the T-type calcium channel.
[0039] Approximately: As used herein, the term "approximately" and "about" is intended to encompass normal statistical variation as would be understood by those of ordinary skill in the art as appropriate to the relevant context. In certain embodiments, the term "approximately" or "about" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 1 1%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
[0040] Associated with: Two events or entities are "associated" with one another, as that term is used herein, if the presence, level and/or form of one is correlated with that of the other. For example, a particular entity (e.g., polypeptide) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and/or form correlates with incidence of and/or susceptibility of the disease, disorder, or condition (e.g., across a relevant population). In some embodiments, two or more entities are physically "associated" with one another if they interact, directly or indirectly, so that they are and remain in physical proximity with one another. In some embodiments, two or more entities that are physically associated with one another are covalently linked to one another; in some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another but are non-covalently associated, for example by means of hydrogen bonds, van der Waals interaction, hydrophobic interactions, magnetism, and combinations thereof.
[0041] Biologically active: As used herein, the phrase "biologically active" refers to a substance that has activity in a biological system (e.g., in a cell (e.g., isolated, in culture, in a tissue, in an organism), in a cell culture, in a tissue, in an organism, etc.). For instance, a substance that, when administered to an organism, has a biological effect on that organism, is considered to be biologically active. It will be appreciated by those skilled in the art that often only a portion or fragment of a biologically active
substance is required (e.g., is necessary and sufficient) for the activity to be present; in such circumstances, that portion or fragment is considered to be a "biologically active" portion or fragment.
[0042] Characteristic sequence element: As used herein, the phrase "characteristic sequence element" refers to a sequence element found in a polymer (e.g., in a polypeptide or nucleic acid) that represents a characteristic portion of that polymer. In some embodiments, presence of a characteristic sequence element correlates with presence or level of a particular activity or property of the polymer. In some embodiments, presence (or absence) of a characteristic sequence element defines a particular polymer as a member (or not a member) of a particular family or group of such polymers. A
characteristic sequence element typically comprises at least two monomers (e.g., amino acids or nucleotides). In some embodiments, a characteristic sequence element includes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, or more monomers (e.g., contiguously linked monomers). In some embodiments, a characteristic sequence element includes at least first and second stretches of continguous monomers spaced apart by one or more spacer regions whose length may or may not vary across polymers that share the sequence element.
[0043] Combination therapy: As used herein, the term "combination therapy" refers to those situations in which a subject is simultaneously exposed to two or more therapeutic agents. In some embodiments, such agents are administered simultaneously; in some embodiments, such agents are administered sequentially; in some embodiments, such agents are administered in overlapping regimens.
[0044] Comparable: The term "comparable", as used herein, refers to two or more agents, entities, situations, sets of conditions, etc that may not be identical to one another but that are sufficiently similar to permit comparison therebetween so that conclusions may reasonably be drawn based on differences or similarities observed. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc to be considered comparable.
[0045] Corresponding to: As used herein, the term "corresponding to" is often used to designate the position/identity of a residue in a polymer, such as an amino acid residue in a polypeptide or a nucleotide residue in a nucleic acid. Those of ordinary skill will appreciate that, for purposes of simplicity, residues in such a polymer are often designated using a canonical numbering system based on a reference related polymer, so that a residue in a first polymer "corresponding to" a residue at position 190 in the reference polymer, for example, need not actually be the 190th residue in the first polymer but rather corresponds to the residue found at the 190th position in the reference polymer; those of ordinary skill in the art readily appreciate how to identify "corresponding" amino acids, including through use of one or more commercially-available algorithms specifically designed for polymer sequence comparisons.
[0046] Decreased Level of Activity: By "decreased level of activity" of CaV3.1 is meant a decrease in CaV3.1 gene expression, protein expression, or activity (e.g., permeability to Ca2+, channel opening, and/or up-regulation of gene expression), as compared to a control or reference (e.g., from a normal cell or normal tissue). In some embodiments, such decrease is at least 2-fold, e.g., from about 2- fold to about 150-fold, e.g., from 5-fold to 150-fold, from 5-fold to 100-fold, from 10-fold to 150-fold, from 10-fold to 100-fold, from 50-fold to 150-fold, from 50-fold to 100-fold, from 75-fold to 150-fold, or from 75-fold to 100-fold, as compared to a control or a normal reference sample. Decrease level of activity of ion channels can be determined using any useful methods known in the art.
[0047] Derivative: As used herein, the term "derivative" refers to a structural analogue of a reference substance. That is, a "derivative" is a substance that shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, a derivative is a substance that can be generated from the reference substance by chemical manipulation. In some embodiemnts, a derivative is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance.
[0048] Designed: As used herein, the term "designed" refers to an agent (i) whose structure is or was selected by the hand of man; (ii) that is produced by a process requiring the hand of man; and/or (iii) that is distinct from natural substances and other known agents.
[0049] Docking: As used herein, the term "docking" refers to orienting, rotating, translating a chemical entity in the binding pocket, domain, molecule or molecular complex or portion thereof based on distance geometry or energy. Docking may be performed by distance geometry methods that find sets of atoms of a chemical entity that match sets of sphere centers of the binding pocket, domain, molecule or molecular complex or portion thereof. See Meng et al. J. Comp. Chem. 4: 505-524 (1992). Sphere centers are generated by providing an extra radius of given length from the atoms (excluding hydrogen atoms) in the binding pocket, domain, molecule or molecular complex or portion thereof. Real-time interaction energy calculations, energy minimizations or rigid-body minimizations (Gschwend et al., J. Mol.
Recognition 9: 175- 186 (1996)) can be performed while orienting the chemical entity to facilitate docking. For example, interactive docking experiments can be designed to follow the path of least resistance. If the user in an interactive docking experiment makes a move to increase the energy, the system will resist that move. However, if that user makes a move to decrease energy, the system will favor that move by increased responsiveness. (Cohen et al., J. Med. Chem. 33:889-894 (1990)). Docking can also be performed by combining a Monte Carlo search technique with rapid energy evaluation using molecular affinity potentials. See Goodsell and Olson, Proteins: Structure, Function and Genetics 8: 195-202 (1990).
Software programs that carry out docking functions include but are not limited to MATCHMOL (Cory et al., J. Mol. Graphics 2: 39 (1984); MOLFIT (Redington, Comput. Chem. 16: 217 (1992)) and DOCK (Meng et al., supra).
[0050] Dosage form: As used herein, the term "dosage form" refers to a physically discrete unit of a therapeutic agent for administration to a subject. Each unit contains a predetermined quantity of active agent. In some embodiments, such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen).
[0051] Dosing regimen: As used herein, the term "dosing regimen" refers to a set of unit doses
(typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).
[0052] Engineered: In general, the term "engineered" refers to the aspect of having been manipulated by the hand of man. For example, a polynucleotide is considered to be "engineered" when two or more sequences, that are not linked together in that order in nature, are manipulated by the hand of man to be directly linked to one another in the engineered polynucleotide. For example, in some embodiments of the present invention, an engineered polynucleotide comprises a regulatory sequence that is found in nature in operative association with a first coding sequence but not in operative association with a second coding sequence, is linked by the hand of man so that it is operatively associated with the second coding sequence. Comparably, a cell or organism is considered to be "engineered" if it has been manipulated so that its genetic information is altered {e.g., new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or deletion mutation, or by mating protocols). As is common practice and is understood by those in the art, progeny of an engineered polynucleotide or cell are typically still referred to as "engineered" even though the actual manipulation was performed on a prior entity.
[0053] Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence {e.g., by
transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and/or 3' end formation); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
[0054] Fragment: A "fragment" of a material or entity as described herein has a structure that includes a discrete portion of the whole, but lacks one or more moieties found in the whole. In some embodiments, a fragment consists of such a discrete portion. In some embodiments, a fragment consists of or comprises a characteristic structural element or moiety found in the whole. In some embodiments, a polymer fragment comprises or consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 1 10, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more monomeric units (e.g., residues) as found in the whole polymer. In some embodiments, a polymer fragment comprises or consists of at least about 5%, 10%, 15%, 20%, 25%, 30%, 25%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the monomeric units (e.g., residues) found in the whole polymer. The whole material or entity may in some embodiments be referred to as the "parent" of the whole.
[0055] Homology: As used herein, the term "homology" refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% similar (e.g., containing residues with related chemical properties at corresponding positions). For example, as is well known by those of ordinary skill in the art, certain amino acids are typically classified as similar to one another as "hydrophobic" or "hydrophilic"amino acids, and/or as having "polar" or "non-polar" side chains. Substitution of one amino acid for another of the same type may often be considered a
"homologous" substitution. Typical amino acid categorizations are summarized below:
Alanine Ala A nonpolar neutral 1.8
Arginine Arg R polar positive -4.5
Asparagine Asn N polar neutral -3.5
Aspartic acid Asp D polar negative -3.5
Cysteine Cys C nonpolar neutral 2.5
Glutamic acid Glu E polar negative -3.5
Glutamine Gin Q polar neutral -3.5
Glycine Gly G nonpolar neutral -0.4
Histidine His H polar positive -3.2
Isoleucine He [ nonpolar neutral 4.5
Leucine Leu L nonpolar neutral 3.8
Lysine Lys K polar positive -3.9
Methionine Met M nonpolar neutral 1.9
Phenylalanine Phe F nonpolar neutral 2.8
Proline Pro P nonpolar neutral -1.6
Serine Ser S polar neutral -0.8
Threonine Thr Γ polar neutral -0.7
Tryptophan Trp w nonpolar neutral -0.9
Tyrosine Tyr Y polar neutral -1.3
Valine Val V nonpolar neutral 4.2
Ambiguous Amino Acids 3-Letter 1-Letter
Asparagine or aspartic acid Asx B
Glutamine or glutamic acid Glx Z
Leucine or Isoleucine Xle J
Unspecified or unknown amino acid Kaa
As will be understood by those skilled in the art, a variety of algorithms are available that permit comparison of sequences in order to determine their degree of homology, including by permitting gaps of designated length in one sequence relative to another when considering which residues "correspond" to one another in different sequences. Calculation of the percent homology between two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-corresponding sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position; when a position in the first sequence is occupied by a similar nucleotide as the corresponding position in the second sequence, then the molecules are similar at that position. The percent homology between the two sequences is a function of the number of identical and similar positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. Representative algorithms and computer programs useful in determining the percent homology between two nucleotide sequences include, for example, the algorithm of Meyers and Miller (CABIOS, 1989, 4: 1 1 - 17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent homology between two nucleotide sequences can, alternatively, be determined for example using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.
[0056] Identity: As used herein, the term "identity" refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be "substantially identical" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. As will be understood by those skilled in the art, a variety of algorithms are available that permit comparison of sequences in order to determine their degree of homology, including by permitting gaps of designated length in one sequence relative to another when considering which residues "correspond" to one another in different sequences.
Calculation of the percent identity between two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-corresponding sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences.
Representative algorithms and computer programs useful in determinng the percent identity between two nucleotide sequences include, for example, the algorithm of Meyers and Miller (CABIOS, 1989, 4: 1 1- 17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined for example using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.
[0057] Immune Cells: As will be understood by those skilled in the art, immune cells are cells involved in the immune system. In many embodiments, immune cells consist of or comprise
lymphocytes (e.g., T lymphocytes or B-lymphocytes). In many embodiments, immune cells consist of or comprise T lymphocytes (i.e., T cells). In some embodiments, immune cells relevant to the present invention consist of or comprise Thl7 cells. In some embodiments, immune cells relevant to the present invention consist of or comprise naive T cells. In some embodiments, immune cells relevant to the present invention consist of or comprise iNKT cells. In some embodiments, immune cells are utilized in vitro. In some embodiments, immune cells are utilized in vivo. In some embodiments, immune cells are provided and/or utilized in context of a tissue or organ. In some embodiments, such a tissue or organ is or comprises a primary lymphoid organ (e.g., spleen), for example in which T- cell differentiation occurs. In some embodiments, such a tissue or organ is or comprises bone marrow. In some embodiments, immune cells consist of or comprise peripheral immune cells. In some embodiments, immune cells are not and/or do not include peripheral immune cells.
[0058] Immunosuppressant: By "immunosuppressant" is meant an agent or compound that induces immunosuppression, (i.e., it reduces, e.g., prevents or interferes with the development of an immunological response, e.g., cellular or humoral).
[0059] Inhibitor: By "inhibitor" is meant an agent whose presence in a system comprising a T- type calcium channel or gene correlates with reduced expression and/or activity of the T-type calcium channel as compared with that observed under otherwise comparable conditions in its absence. In some embodiments, an inhibitor acts by direct interaction (i.e., binding) with a T-type calcium channel. In some embodiments, an inhibitor acts by indirect effect (e.g., on expression or activity of a gene or transcript encoding a T-type calcium channel, or on a protein regulator thereofln some embodiments, inhibitors can include reversible inhibitors (e.g., competitive inhibitors, uncompetitive inhibitors, mixed inhibitors, non-competitive inhibitors). In some embodiments, inhibitors can comprise irreversible inhibitors, for example which covalently modify the T-type calcium channel or regulator thereof.
[0060] Ion Channel Blocker: By "ion channel blocker" is meant an agent or compound that disrupts the movement of ions (e.g., Na2+, Ca2+, K+, and CI") through ion channels (e.g., voltage-gated calcium channels, e.g., L-type, P-type/Q-type, N-type, R-type, or T-type, e.g., ligand-gated calcium channels, e.g., IP3 receptor, ryanodine receptor, two-pore channels, cation channels of sperm, or store- operated channels, e.g., voltage-gated potassium channels, calcium-activated potassium channels, two- pore domain potassium channels, voltage-gated sodium channels, and/or chloride channels).
[0061] Isolated: As used herein, the term "isolated" refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) designed, produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which they were initially associated. In some embodiments, isolated agents are about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is "pure" if it is substantially free of other components. In some embodiments, as will be understood by those skilled in the art, a substance may still be considered "isolated" or even "pure", after having been combined with certain other components such as, for example, one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such embodiments, percent isolation or purity of the substance is calculated without including such carriers or excipients. In some embodiments, isolation involves or requires disruption of covalent bonds (e.g., to isolate a polypeptide domain from a longer polypeptide and/or to isolate a nucleotide sequence element from a longer oligonucleotide or nucleic acid).
[0062] Isomer: As is known in the art, many chemical entities (in particular many organic molecules and/or many small molecules) can exist in a variety of structural and/or optical isomeric forms. In some embodiments, as will be clear to those skilled in the art from context, depiction of or reference to a particular compound structure herein is intended to encompass all structural and/or optical isomers thereof. In some embodiments, as will be clear to those skilled in the art from context, depiction of or reference to a particular compound structure herein is intended to encompass only the depicted or referenced isomeric form. In some embodiments, compositions including a chemical entitiy that can exist in a variety of isomeric forms include a plurality of such forms; in some embodiments such compositions include only a single form. For example, in some embodiments, compositions including a chemical entity that can exist as a variety of optical isomers (e.g., stereoisomers, diastereomers, etc) include a racemic population of such optical isomers; in some embodiments such compositions include only a single optical isomer and/or include a plurality of optical isomers that together retain optical activity.
[0063] Modulator: The term "modulator" is used to refer to an entity whose presence in a system in which an activity of interest is observed correlates with a change in level and/or nature of that activity as compared with that observed under otherwise comparable conditions when the modulator is absent. In some embodiments, a modulator is an activator, in that activity is increased in its presence as compared with that observed under otherwise comparable conditions when the modulator is absent. In some embodiments, a modulator is an inhibitor, in that activity is reduced in its presence as compared with otherwise comparable conditions when the modulator is absent. In some embodiments, a modulator interacts directly with a target entity whose activity is of interest. In some embodiments, a modulator interacts indirectly (i.e., directly with an intermediate agent that interacts with the target entity) with a target entity whose activity is of interest. In some embodiments, a modulator affects level of a target entity of interest; alternatively or additionally, in some embodiments, a modulator affects activity of a target entity of interest without affecting level of the target entity. In some embodiments, a modulator affects both level and activity of a target entity of interest, so that an observed difference in activity is not entirely explained by or commensurate with an observed difference in level.
[0064] Modulates T Cell Differentiation: By "modulates T cell differentiation" is meant that the agent or compound affects upstream or downstream signaling events that are involved in
differentiation of na'ive T cell into T-helper (Th) cells. The agent or compound may affect activation of antigen-presenting cells (APCs), the gene or protein expression of cytokine receptors (e.g., IL23R, IL22R, IL4R, IL12R, or IL17), cytokines (e.g., IL4, IL23, IL22, IL17, or IL12), interferon receptors (e.g., IFNGR1, or IFNGR2), and interferons (e.g., IFN, IL17, etc). Modulation of T cell differentiation may also be an effect on gene or protein expression of STAT4, STAT6, T-bet, or GAT A3. The term modulate
can include inhibition or activation of these or other upstream and/or downstream signaling molecules and/or events.
[0065] Nucleic acid: As used herein, the term "nucleic acid," in its broadest sense, refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from context, in some embodiments, "nucleic acid" refers to individual nucleic acid residues (e.g., nucleotides and/or nucleosides); in some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, a "nucleic acid" is or comprises RNA; in some embodiments, a "nucleic acid" is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. For example, in some embodiments, a nucleic acid is, comprises, or consists of one or more "peptide nucleic acids", which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention. Alternatively or additionally, in some embodiments, a nucleic acid has one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine). In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5- methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5- fluorouridine, C5-iodouridine, C5 -propynyl-uridine, C5 -propynyl-cytidine, C5-methylcytidine, 2- aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)- methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, a nucleic acid comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'- deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a nucleic acid includes one or more introns. In some embodiments, nucleic acids are prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), reproduction in a recombinant cell or system, and chemical synthesis. In some embodiments, a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140,
150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long.
[0066] Peptide modulator: By "peptide modulator" is meant an peptide that modulates T-type calcium channel active in lymphocyte cells as described herein, sometimes compared to a control or reference (e.g., baseline). In some embodiments, a peptide modulator is or comprises an endogenous or synthetic peptide that has structural homology or conserved sequences to the subunits of the T-type calcium channel (e.g., al, α2δ, β, and/or γ subunit(s)) and/or transmembrane domains of the T-type calcium channel (e.g., TM1, TM2, TM3, TM4, TM5, and TM6) that are effective in activating and/or inhibiting T-type calcium channel activity (e.g., low voltage-activated calcium current, high voltage- activated calcium current, calcium flux across the plasma membrane, and alteration of surface expression).
[0067] Pharmaceutically acceptable: The term "pharmaceutically acceptable" as used herein, refers to agents that, within the scope of sound medical judgment, are suitable for use in contact with tissues of human beings and/or animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[0068] Pharmaceutical composition: By "pharmaceutical composition" is meant a composition containing an active agent as described herein, formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gel cap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other formulation described herein.
[0069] Polypeptide: The term "polypeptide", as used herein, generally has its art-recognized meaning of a polymer of at least three amino acids, linked to one another by peptide bonds. In some embodiments, the term is used to refer to certain functional classes of polypeptides, such as, for example, autoantigen polypeptides, nicotinic acetylcholine receptor polypeptides, alloantigen polypeptides, etc. For each such class, the present specification provides several examples of amino acid sequences of known exemplary polypeptides within the class; in some embodiments, such known polypeptides are reference polypeptides for the class. In such embodiments, the term "polypeptide" refers to any member of the class that shows significant sequence homology or identity with a relevant reference polypeptide. In many embodiments, such member also shares significant activity with the reference polypeptide. For example, in some embodiments, a member polypeptide shows an overall degree of sequence homology or
identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more and/or includes at least one region (i.e., a conserved region, often including a characteristic sequence element) that shows very high sequence identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99%. Such a conserved region usually encompasses at least 3-4 and often up to 20 or more amino acids; in some embodiments, a conserved region encompasses at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15 or more contiguous amino acids. In some embodiments, a useful polypeptide as described herein may comprise or consist of a fragment of a parent polypeptide. In some embodiments, a useful polypeptide as described herein may comprise or consist of a plurality of fragments, each of which is found in the same parent polypeptide in a different spatial arrangement relative to one another than is found in the polypeptide of interest (e.g., fragments that are directly linked in the parent may be spatially separated in the polypeptide of interest or vice versa, and/or fragments may be present in a different order in the polypeptide of interest than in the parent), so that the polypeptide of interest is a derivative of its parent polypeptide.
[0070] Protein: As used herein, the term "protein" refers to a polypeptide (i.e., a string of at least two amino acids linked to one another by peptide bonds). Proteins may include moieties other than amino acids (e.g., may be glycoproteins, proteoglycans, etc.) and/or may be otherwise processed or modified. Those of ordinary skill in the art will appreciate that a "protein" can be a complete polypeptide chain as produced by a cell (with or without a signal sequence), or can be a characteristic portion thereof. Those of ordinary skill will appreciate that a protein can sometimes include more than one polypeptide chain, for example linked by one or more disulfide bonds or associated by other means. Polypeptides may contain L-amino acids, D-amino acids, or both and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, e.g., terminal acetylation, amidation, methylation, etc. In some embodiments, proteins may comprise natural amino acids, non- natural amino acids, synthetic amino acids, and combinations thereof. The term "peptide" is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids. In some embodiments, proteins are antibodies, antibody fragments, biologically active portions thereof, and/or characteristic portions thereof.
[0071] Reference: The term "reference" is often used herein to describe a standard or control agent or value against which an agent or value of interest is compared. In some embodiments, a reference agent is tested and/or a reference value is determined substantially simultaneously with the testing or determination of the agent or value of interest. In some embodiments, a reference agent or value is a historical reference, optionally embodied in a tangible medium. Typically, as would be understood by
those skilled in the art, a reference agent or value is determined or characterized under conditions comparable to those utilized to determine or characterize the agent or value of interest.
[0072] Refractory: As used herein, the term "refractory" refers to any subject that does not respond with an expected clinical efficacy following the administration of provided compositions as normally observed by practicing medical personnel.
[0073] RNAi Agen By "R Ai agent" is meant any agent or compound that exerts a gene silencing effect by hybridizing a target nucleic acid. RNAi agents include any nucleic acid molecules that are capable of mediating sequence-specific RNAi (e.g., under stringent conditions), for example, a short interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically- modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and Dicer-substrate RNA
(DsiRNA).
[0074] Sample: As used herein, the term "sample" typically refers to a biological sample obtained or derived from a source of interest, as described herein. In some embodiments, a source of interest comprises an organism, such as an animal or human. In some embodiments, a biological sample comprises biological tissue or fluid. In some embodiments, a biological sample may be or comprise bone marrow; blood; blood cells; ascites; tissue or fine needle biopsy samples; cell-containing body fluids; free floating nucleic acids; sputum; saliva; urine; cerebrospinal fluid, peritoneal fluid; pleural fluid; feces; lymph; gynecological fluids; skin swabs; vaginal swabs; oral swabs; nasal swabs; washings or lavages such as a ductal lavages or broncheoalveolar lavages; aspirates; scrapings; bone marrow specimens; tissue biopsy specimens; surgical specimens; feces, other body fluids, secretions, and/or excretions; and/or cells therefrom, etc. In some embodiments, a biological sample is or comprises cells obtained from an individual. In some embodiments, obtained cells are or include cells from an individual from whom the sample is obtained. In some embodiments, obtained cells are or include microbial cells of an individual's microbiome. In some embodiments, a sample is a "primary sample" obtained directly from a source of interest by any appropriate means. For example, in some embodiments, a primary biological sample is obtained by methods selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of body fluid (e.g., blood, lymph, feces etc.), etc. In some embodiments, as will be clear from context, the term "sample" refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane. Such a "processed sample" may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to
techniques such as amplification or reverse transcription of mRNA, isolation and/or purification of certain components, etc.
[0075] Selective: An agent that is "selective" is one that produces a desired effect on one target entity and/or in one cell, one compartment of the body, while to a lesser degree influencing and/or creating adverse effects on other potential target entities (in some embodiments including subtype and/or variants of the target entity) and/or in other cells, tissues, organs, and/or compartments of the body. In some embodiments, a selective agent is an agent that acts specifically and/or preferentially on a particular target or set of targets. In some embodiments, selectivity can be determined by binding kinetics (e.g., degree of interaction between an agent with its target and/or with a particular cell, cell type, tissue, organ, and/or compartment of the body). In some embodiments, an agent is selective if it shows an elevated affinity and/or decreased dissociation constant (KD) of 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30- fold, 100-fold, or 200-fold for its target (and/or for a particular cell, cell type, tissue, organ, and/or compartment of the body) as compared with for a non-target competitor. In some embodiments, an agent is selective if it exerts a particular biologic effect on its target (and/or on or in a particular cell, cell type, tissue, organ, and/or compartment of the body) at a dose that is lower (e.g., by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more) than is required for the agent to exert an analogous effect on a potential alternative target (or particular cell, cell type, tissue, organ, and/or compartment of the body ), and/or for an alternative comparable reference agent to exhibit an analogous effect on the target (and/or on or in the particular cell, cell type, tissue, organ, and/or compartment of the body). In some embodiments, selectivity can also be a measure of local accumulation of an agent in association with the target entity and/or on or in the particular cell, cell type, tissue, organ, and/or compartment of the body compared to accumulation in association with other potential target entities and/or target and/or cells, cell types, tissues, organs, and/or compartments of the body. In some embodiments, a selective agent demonstrates an increase in accumulation that is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% at or with the target entity and/or on or in the particular cell, cell type, tissue, organ, and/or compartment of the body as compared with an alternative comparable reference entity and/or cell, cell type, tissue, organ, and/or compartment of the body In some embodiments, selectivity can be based on efficacy and/or potency of an agent. In some embodiments, an agent that is selective shows an efficacy or potency that is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% more than that of a reference agent with respect to a particular activity or event.
[0076] Small molecule: As used herein, the term "small molecule" means a low molecular weight organic and/or inorganic compound. In general, a "small molecule" is a molecule that is less than
about 5 kilodaltons (kD) in size. In some embodiments, a small molecule is less than about 4 kD, 3 kD, about 2 kD, or about 1 kD. In some embodiments, the small molecule is less than about 800 daltons (D), about 600 D, about 500 D, about 400 D, about 300 D, about 200 D, or about 100 D. In some
embodiments, a small molecule is less than about 2000 g/mol, less than about 1500 g/mol, less than about 1000 g/mol, less than about 800 g/mol, or less than about 500 g/mol. In some embodiments, a small molecule is not a polymer. In some embodiments, a small molecule does not include a polymeric moiety. In some embodiments, a small molecule is not a protein or polypeptide (e.g., is not an oligopeptide or peptide). In some embodiments, a small molecule is not a polynucleotide (e.g., is not an oligonucleotide). In some embodiments, a small molecule is not a polysaccharide. In some embodiments, a small molecule does not comprise a polysaccharide (e.g., is not a glycoprotein, proteoglycan, glycolipid, etc.). In some embodiments, a small molecule is not a lipid. In some embodiments, a small molecule is a modulating agent. In some embodiments, a small molecule is biologically active. In some embodiments, a small molecule is detectable (e.g., comprises at least one detectable moiety). In some embodiments, a small molecule is a therapeutic.
[0077] Small Molecule Modulator. By "small molecule modulator" is meant any small molecule (e.g., naturally occurring, or synthesized organic and/or inorganic compound) that modulates a T-type calcium channel active in lymphocyte cells as described herein, sometimes compared to a control or reference (e.g., baseline). In some embodiments, such increase or decrease is by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, as compared to the control or reference. Small molecule modulators can be activators or inhibitors and can be identified and/or characterized by any useful methods or can be known in the art.
[0078] Solid form: As is known in the art, many chemical entities (in particular many organic molecules and/or many small molecules) can adopt a variety of different solid forms such as, for example, amorphous forms and/or crystalline forms (e.g., polymorphs, hydrates, solvates, etc). In some embodiments, such entities may be utilized in any form, including in any solid form. In some embodiments, such entities are utilized in a particular form, for example in a particular solid form.
[0079] Specific: The term "specific", when used herein with reference to an agent or entity having an activity, is understood by those skilled in the art to mean that the agent or entity discriminates between potential targets or states (i.e., acts preferentially with respect to one or more potential target or state as compared with another). For example, an agent is said to bind "specifically" to its target if it binds preferentially with that target in the presence of competing alternative targets. In some
embodiments, the agent or entity does not detectably bind to the competing alternative target under conditions of binding to its target. In some embodiments, the agent or entity binds with higher on-rate,
lower off-rate, increased affinity, decreased dissociation, and/or increased stability to its target as compared with the competing alternative target(s).
[0080] Stable: The term "stable," when applied to compositions herein, means that the compositions maintain one or more aspects of their physical structure and/or activity over a period of time under a designated set of conditions. In some embodiments, the period of time is at least about one hour; in some embodiments the period of time is about 5 hours, about 10 hours, about one (1) day, about one (1) week, about two (2) weeks, about one (1) month, about two (2) months, about three (3) months, about four (4) months, about five (5) months, about six (6) months, about eight (8) months, about ten (10) months, about twelve (12) months, about twenty- four (24) months, about thirty-six (36) months, or longer. In some embodiments, the period of time is within the range of about one (1) day to about twenty-four (24) months, about two (2) weeks to about twelve (12) months, about two (2) months to about five (5) months, etc. In some embodiments, the designated conditions are ambient conditions (e.g., at room temperature and ambient pressure). In some embodiments, the designated conditions are physiologic conditions (e.g., in vivo or at about 37 °C for example in serum or in phosphate buffered saline). In some embodiments, the designated conditions are under cold storage (e.g., at or below about 4 °C, -20 °C, or -70 °C). In some embodiments, the designated conditions are in the dark.
[0081] Subject: By "subject" it is meant a mammal (e.g., a human, in some embodiments including prenatal human forms). In some embodiments, a subject is suffering from a relevant disease, disorder or condition. In some embodiments, a subject is susceptible to a disease, disorder, or condition. In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder or condition. In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition. In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. In some embodiments, a subject is an individual to whom therapy is administered.
[0082] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term
"substantially" is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0083] Suffering from: An individual who is "suffering from" a disease, disorder, or condition has been diagnosed with and/or exhibits or has exhibited one or more symptoms or characteristics of the disease, disorder, or condition.
[0084] Susceptible to: An individual who is "susceptible to" a disease, disorder, or condition is at risk for developing the disease, disorder, or condition. In some embodiments, such an individual is known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition does not display any symptoms of the disease, disorder, or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition has not been diagnosed with the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition is an individual who has been exposed to conditions associated with development of the disease, disorder, or condition. In some embodiments, a risk of developing a disease, disorder, and/or condition is a population-based risk (e.g., family members of individuals suffering from allergy, etc.
[0085] Symptoms are reduced: According to the present invention, "symptoms are reduced" when one or more symptoms of a particular disease, disorder or condition is reduced in magnitude (e.g., intensity, severity, etc.) and/or frequency. For purposes of clarity, a delay in the onset of a particular symptom is considered one form of reducing the frequency of that symptom.
[0086] T cells: By "T cells" is meant a group of white blood cells that play a role in immune responses and contain a T cell receptor at the cell surface. T cells maybe of the subset of helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, and/or gamma delta T cells.
[0087] Therapeutic agent: As used herein, the phrase "therapeutic agent" refers to any agent that has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect, when administered to a subject. In some embodiments, an agent is considered to be a therapeutic agent if its administration to a relevant population is statistically correlated with a desired or beneficial therapeutic outcome in the population, whether or not a particular subject to whom the agent is administered experiences the desired or beneficial therapeutic outcome.
[0088] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" means an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and/or condition. In some embodiments, a therapeutically effective amount is one that reduces the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition. Those of ordinary skill in the art will appreciate that the term
"therapeutically effective amount" does not in fact require successful treatment be achieved in a particular individual. Rather, a therapeutically effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment. It is specifically understood that particular subjects may, in fact, be "refractory" to a "therapeutically effective amount." To give but one example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable. In some embodiments, reference to a therapeutically effective amount may be a reference to an amount as measured in one or more relevant tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc). Those of ordinary skill in the art will appreciate that, in some embodiments, a therapeutically effective amount may be formulated and/or administered in a single dose. In some embodiments, a therapeutically effective amount may be formulated and/or administered in a plurality of doses, for example, as part of a dosing regimen.
[0089] Therapeutic regimen : A "therapeutic regimen", as that term is used herein, refers to a dosing regimen whose administration across a relevant population is correlated with a desired or beneficial therapeutic outcome.
[0090] Three dimensional representation: As used herein, the term " three dimensional representation" refers to converting the lists of structure coordinates into structural models or graphical representation in three-dimensional space. In some embodiments, the three dimensional structure may be displayed or used to performing computer modeling or fitting operations. In some embodiments, the structure coordinates themselves, without the displayed model, may be used to perform computer-based modeling and fitting operations.
[0091] Treating: By "treating" it is meant obtaining beneficial or desired results, such as clinical results. Beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or manifestations of a disease, disorder, or condition;
diminishment of extent of disease, disorder, or condition; stabilization (i.e., not worsening) of a state of disease, disorder, or condition; prevention of spread of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable. In general, treating involves administering an agent as described herein, according to a therapeutic regimen that partially or completely alleviates, ameliorates, relieves, inhibits, delays onset of, reduces severity of, and/or reduces frequency, incidence or severity of one or more symptoms, features, and/or causes of a relevant disease, disorder, and/or condition. Such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs
of the disease, disorder, and/or condition. Alternatively or additionally, such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition. In some embodiments, treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject who is susceptible to the disease, disorder, or condition in that s/he is known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
[0092] T-t pe Calcium Channel Modulator: By "T-type calcium channel modulator" it is meant an agent that increases or decreases a level and/or activity of a T-type calcium channel, for example by altering one or more of gene expression (including transcription, post-transcriptional processing, transcript localization or packaging, etc), protein expression (including translation, folding, degradation, post-translational processing or modification, localization, etc), and/or activity (e.g., ability to transport calcium across the plasma membrane, to achieve membrane polarization, and/or to initiate or maintain downstream signaling), compared to an appropriate control or reference. In some embodiments, such increase or decrease is a change of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, as compared to the control or reference. T-type calcium channel modulators include activators or inhibitors of T-type calcium channels. T-type calcium channel modulators can be identified, tested, and/or characterized by any useful methods in the art and/or described herein.
[0093] T-t pe Calcium Channel: By "T-type calcium channel" is meant a type of voltage- operated calcium channel wherein the length of channel activation is transient and the channel contains an l subunit which determines the properties of the channel.
[0094] Voltage-Operated Calcium Channel: By "voltage-operated calcium channel" is meant a calcium channel activated by voltage, distinct from a ligand-gated calcium channel and synonymous with a voltage-activated calcium channel and a voltage-gated calcium channel.
Brief Description of the Drawing
[0095] Figures 1A-1E show CaV3.1 expression in T cells and localization to the plasma membrane. Figures 1A-B show CaV3.1 expression as measured by quantitative RT-PCR in CD4+ T cells isolated from murine lymph nodes, spleen and thymus, in EL-4 T cells, in murine splenic CD4+ T cells, cerebrum, and cerebellum. Figure 1C shows CaV3.1 protein detection in pooled splenic and lymph node CD4+ T cells as a band of the expected size (-250 kD) by cell lysis, immunoprecipitation and immunoblotting with an anti-CaV3.1 antibody (anti-CaV3.1). Figure ID shows CaV3.1 expression at the
surface of splenic CD4+ T cells by biotinylation of intacT cells followed by purification on avidin beads, then blotting with anti-CaV3.1 Ab (upper panel) or anti-GATA-3 as control for a strictly intracellular protein (lower panel). B indicates the biotinylated cell surface fraction isolated on avidin beads; N indicates the non-labeled flow-through fraction. Figure IE shows relative expression of the CaV3.1, CaV3.2, and CaV3.3 message in wild-type, CaV3.1 -/- and CaV3.1 ΔΤ mice. CaV3.1 deletion induces compensation with increased expression of CaV3.2 and CaV3.3 in CD4+ T cells, as assessed by quantitative RT-PCR.
[0096] Figures 2A-2E are results showing that the signature current for T-type channels is present in wild-type CD4+ T cells and reduced in constitutively CaV3.1 -/- CD4+ T cells. Figure 2A is a plot showing whole-cell patch clamp recordings of wild-type (WT) CD4+ cells (n= 17) and CaV3.1 -/- CD4+ T cells (n=19). Currents were activated using 10 mV voltage steps lasting 250 ms applied every 2 sec from a holding potential of -90 mV. Average I/V relationships are displayed. Recordings in both cell types were made in the absence or presence of the T-type channel inhibitor, mibefradil (1 μΜ). The bath solution contained 10 mM Ca2+. Only seal resistances greater than 16 GO were accepted for initiation of recordings. Figure 2B are representative recordings at the -30 mV voltage step displayed for all conditions. Currents were 13.3 ± 1.38 pA in wild-type versus 6.95 ± 1.10 pA in CaV3.1 -/- cells at -30 mV without mibefradil. Figure 2C is a plot showing the time constant (τ) of voltage-dependent inactivation of currents in CD4+ T cells elicited by voltage steps from a holding potential of -90 mV. Data represent means ± SEM from 7 wild-type and 8 CaV3.1 -/- cells. Figure 2D is a plot showing that store operated Ca2+ entry triggered by treatment with thapsigargin (TG; 2 μΜ) is unaffected in CaV3.1 deficient CD4+ cells. Cells were loaded with Fluo-4 AM and analyzed on a Flipr 96-well imaging system (means + SEM from 16 wells for each genotype from 3 independenT cell preparations). Figure 2E is a plot showing that calcium entry induced by TCR engagement is not affected by CaV3.1 deficiency. CD4+ T cells were stimulated with an anti-CD3 antibody and no differences in the amplitude or time course of calcium influx were observed between cells from wild-type and CaV3.1 ΔΤ animals. CD4+ T cells from CaV3.1 ΔΤ and wild-type littermates were loaded with indo-1 AM and biotinylated anti-CD3. The cells were analyzed by flow cytometry at baseline and after activation with streptavidin.
Representative of 3 experiments.
[0097] Figures 3A-3D show that CaV3.1 -/- and CaV3.1 ΔΤ animals are resistant to experimental autoimmune encephalomyelitis (EAE). Eight CaV3.1 -/- mice and seven wild-type littermates were immunized at day 0 with myelin oligodendrocyte glycoprotein (MOG), complete Freund adjuvant, and pertussis toxin. Figure 3A is a plot showing the EAE score and Figure 3B is a plot showing the body weight measured daily (means +/- SEM). Fourteen CaV3.1 ΔΤ mice and 16 wild-type
littermates were immunized at day 0. Premature euthanizations of four wild-type littermates of CaV3.1 ΔΤ mice are necessary due to complete paralysis. Figure 3C is a plot showing the EAE score and Figure 3D is a plot showing the body weight measured daily (means +/- SEM).
[0098] Figures 4A-4D show the reduction in Thl7 cell population and in RORyt expression in
CaV3.1 ΔΤ cells. In vitro Thl7 differentiation of splenocytes from wild-type (n=7) and CaV3.1 ΔΤ (n=6) mice after EAE induction. Differentiation entailed a 5-day treatment with Thl7-skewing conditions. Representative data are shown for wild-type in Figure 4A and CaV3.1 ΔΤ in Figure 4B. A summary plot is shown in Figure 4C, p=0.002. Figure 4D shows that RORyt expression induced by Thl7 skewing is decreased in CaV3.1 ΔΤ cells. Whole-cell lysates of pooled splenocytes are collected from wild-type (n=4) and CaV3.1 ΔΤ (n=4) mice. Representative of two experiments.
[0099] Figures 5A-5C shows that anti-CaV3.1 antibody recognizes CaV3.1. Figure 5A are blots showing full-length CaV3.1 or vector control myc -tagged cDNAs transiently transfected into 293 cells. Overexpressed proteins are detected in whole cell lysates via immunoprecipitation and
immunoblotting (IP) and immunobloting (blot) with anti-CaV3.1 or anti-myc. Figure 5B are blots showing the specificity of the anti-CaV3.1 antibody confirmed using cerebellum and cerebrum isolated from CaV3.1 -/- and wild-type littermate mice. Figure 5C is a blot showing that no shorter splice variant is present in cerebellum from CaV3.1 deficient mice. Total protein tissue lysates of cerebellum from wild-type and CaV3.1 -/- cerebellum were analyzed by immunoblotting with anti-CaV3.1 antibody or anti-GAPDH antibodies to verify equal protein loading.
[00100] Figures 6A-6C show the generation of constitutive CaV3.1 -deficient mice. Figure 6A are schematics showing a targeting construct designed to knockout the pore region of CaV3.1 using a neomycin cassette to replace exons 1 1 to 13. Figure 6B shows targeted disruption of the CaV3.1 gene verified by Southern blotting, and Figure 6C shows a PCR gel of genomic DNA isolated from candidate mice.
[00101] Figures 7A-7C show that the signature current for CaV3 channels is present in wild-type
CD4+ T cells and reduced in constitutively CaV3.1 -/- CD4+ T cells. Figures 7A-7B are plots showing the current/voltage (I/V) relationships of currents recorded from 17 wild-type cells and 19 CaV3.1-/- cells. Figure 7C is a graph showing peak currents (means ± SEM) recorded from 17 wild-type cells, and 19 CaV3.1-/- cells.
[00102] Figure 8 shows a plot of the voltage-dependent kinetics of activation. Time constant (τ) of voltage-dependent activation of currents in CD4+ T cells elicited by voltage steps from a holding potential of -90 mV. Data represent means ± SEM from 7 wild-type and 8 CaV3.1 -/- cells.
[00103] Figures 9A-9B show that thymic and splenic T cells isolated from CaV3.1 -/- mice display normal development and have similar rates of proliferation compared to wild-type cells.
Thymocytes and splenocytes were isolated from wild-type and CaV3.1 -/- mice and analyzed by flow cytometry for surface expression of various T cell specific antigens. Figure 9A are plots showing that the percent of CD4+ CD8+ and CD4+ CD8- thymocytes are indistinguishable between wild-type and CaV3.1 -/- mice. Figure 9B are plots showing that CD4+ cells from wild-type and CaV3.1 -/-spleens had similar rates of proliferation. Results are representative of 6 wild-type and 6 CaV3.1 -/- mice.
[00104] Figures 10A-10D show that CaV3.1 -/- mice are equally sensitive in an asthma model.
Figure 10A shows an anti-OVA serum IgE response in OVA immunized wild-type and CaV3.1 -/- mice induced with asthma by challenge with OVA or saline. Figure 10B shows pulmonary resistance (PR) after acetylcholine challenge, Figure IOC shows broncho-alveolar lavage cellularity, and Figure 10D shows lung inflammation are similar in wild-type and CaV3.1 -/- mice (n=20 each, of which 10 OVA, 10 saline).
[00105] Figures 11A-11B are histologic analyses of EAE mice showing minimal lesions in
CaV3.1 -deficient mice. Figure 11A is a histologic analysis by hematoxylin and eosin staining of spinal cords (upper panels) and cerebellum (lower panels) in wild- type (left) and CaV3.1 -/- (right) mice.
Figure 1 IB is a histologic analysis of spinal cords in wild-type (left) and CaV3.1 ΔΤ (right) mice.
Within each genotype the panel on the right is an enlarged view of the framed area in the left image. Characteristic perivascular inflammatory infiltrates were observed in both sets of wild-type animals.
[00106] Figure 12 shows a reduction in Thl7 cell population in EAE-na'ive CaV3.1 ΔΤ animals in in vitro experiments of Thl7 differentiation of naive splenocytes from wild-type and CaV3.1 ΔΤ mice (n=4 each, p=0.02).
[00107] Figure 13 shows an exemplary timecourse of mRNA expression of Cav3.1 during Thl7 differentiation at 3, 6, 12, 24, 48 and 96 hours.
[00108] Figure 14 depicts an exemplary dose response curve showing a T-type calcium channel antagonist, here TTA-A2, inhibiting T-type calcium current as a function of antagonist concentration.
[00109] Figure 15 shows an exemplary graph demonstrating the pharmacological effects of a T- type calcium channel modulator in an animal model of multiple sclerosis, EAE.
Detailed Description of Certain Embodiments
[00110] The present invention encompasses the recognition that the source of a problem in the development of therapeutic modalities for the treatment of lymphocyte-associated diseases, disorders and conditions is the limited knowledge of appropriate druggable targets active on immune (e.g., lymphocyte)
cells. The present invention solves this problem by identifying certain T-type calcium channels (e.g., Cav3.1 and/or Cav3.2 and/or Cav3.3 channels) as present and active on particular lymphocytes (e.g., T cells and specifically na'ive T cells and Thl7 cells). The present invention further specifically demonstrates ability of T-type calcium channel modulators (e.g., selective T-type calcium modulators as described herein) to impact level and/or activity of T-type calcium channels on immune cells in tissues and/or organs (e.g., spleen).
[00111] The present invention encompasses the specific recognition of a problem associated with treating diseases, disorders and conditions associated with activity of Thl7 cells. Thl7 cells are thought to play a key role in autoimmune diseases (such as multiple sclerosis, psoriasis, autoimmune uveitis, juvenile diabetes, rheumatoid arthritis, and Crohn's disease in particular), and specifically to play a role in inflammation and tissue injury in these conditions. Thl7 cell activity can cause severe autoimmune diseases, but is also important for maintaining anti-microbial immunity, particularly at epithelial / mucosal barriers. Thl7 cells produce cytokines (such as interleukin 22) which stimulate epithelial cells to produce anti-microbial proteins to clear out certain types of microbe (such as Candida and
Staphylococcus). Thus, insufficient Thl7 cell activity may leave the host susceptible to opportunistic infections. The present invention encompasses the recognition that one source of a problem associated with treating such diseases, disorders, and conditions associated with Thl7 cell activity is the substantial absence of identified targets involved Thl7 cell differentiation and/or activity. For example, the present invention appreciates that, while the Retinoic Acid Receptor gamma (RORy) transcription factor is known to participate in Thl7 cell differentiation and/or activity, it is difficult target safely and/or effectively. The present recognition defines and appreciates a need for draggable target(s) in or on na'ive T cells and/or Thl7 cells, preferably on the surface of such cells. The present invention solves this problem and addresses this need by demonstrating, among other things, that certain T-type calcium channels (e.g., Cav3.1 and/or Cav3.2 and/or Cav3.3 channels) are present and active on na'ive T cells and Thl7 cells, and furthermore are involved in Thl7 cell differentiation. The present invention therefore provides compositions and methods relevant to modulating (e.g., specifically modulating) T-type calcium channels active in na'ive T cells and Thl7 cells, and therefore unexpectedly provides technologies relevant to Thl7- associated diseases, disorders and conditions including, for example, multiple sclerosis, psoriasis, multiple myeloma, etc.
[00112] The present invention also specifically demonstrates that modulation of T-type calcium channel activity can achieve therapeutically relevant effects in models of lymphocyte-associated diseases disorders and conditions (e.g., in an EAE model of multiple sclerosis). The present disclosure particularly
establishes relevance of modulating Cav3.1 channels (whose activity is shown herein to be dominant relative to other T-type calcium channels such as, e.g., Cav3.2 and Cav3.3, at least on lymphocyte cells such as T cells, e.g., na'ive T cells and/or Thl7 cells).
[00113] Findings of the present invention are particularly surprising in light of the art-established perspective that, to the extent that calcium channels are present and active on T cells, the important calcium channels are calcium release-activated channels (CRAC) channels. CRAC channels are known to play a role in the activity of certain T cells; they are not believed to be involved in helper T cell differentiation (see, for example, Shaw et al Front Biosci (Elite Ed). 2012 Jan 1 ;4:2253, Jan 2012). The activity of CRAC channels is not voltage-dependent.
[00114] The inventive demonstration of T-type calcium channel activity on lymphocyte cells, is particularly valuable and beneficial because, prior to the present disclosure, T-type calcium channel activity was thought to be most relevant in CNS cells and events. Thus, although T-type calcium channel modulators have previously been pursued by others, efforts have typically been focused on agents that cross the blood brain barrier and/or that are effective in the treatment of CNS disorders such as epilepsy and pain (see, for example, Zhang et al Biochim Biophys Acta 1828(7): 1550, July 2013; Uslaner et al., Neuropharmacology 62(3): 1413, March 2012). T-type calcium channel modulators for use in accordance with the present invention, however, need not (and in many embodiments do not, or are administered such that they do not) cross the blood brain barrier and/or have any significant therapeutic effect with respect to pain, epilepsy, schizophrenia, and/or sleep disorders. The present invention therefore surprisingly establishes uses for T-type calcium channel modulators that do not cross the blood- brain barrier and/or do not have any significant therapeutic effect with respect to CNS disorders such as, for example, pain, epilepsy, schizophrenia, and/or sleep disorders. Indeed, in some embodiments, the present invention provides and/or utilizes T-type calcium channel modulators that do not reach and/or are not active with respect to CNS cells, and thus surprisingly teaches compositions and methods specific to non-CNS T-type calcium channels and/or to lymphocyte -related diseases, disorders or conditions that do not involve (or whose features that are treated herein do not involve) neurons and/or CNS cells, tissues, organs and/or systems. The present invention also surprisingly establishes methods and compositions for using T-type calcium channel modulators in non-CNS (e.g., peripheral) and/or non-neuronal settings, including particularly methods and compositions for peripheral (e.g., not-CNS targeted) delivery, including local delivery of such modulators.
[00115] The specific utility demonstrated herein for modulation of only the CaV3.1 subtype of T- type calcium channels is particularly surprising and unexpected in light of prior art focus on Cav3.2 modulation, which is thought to be relevant to treatment of pain, for example.
[00116] Still further, the invention surprisingly overcomes various challenges often associated with detection, characterization, and or modulation of voltage-dependent channels, and particularly of T- type voltage-gated calcium channels (e.g., Cav3.1 channels). For example, the technical difficulty that can be associated with electrophysiologically recording activity of such channels in cells is recognized in the field, which includes at least one published report of a researcher driven to fabricate
electrophysiological data, presumably in light of the challenges and significance associated with obtaining it (see Badou et al. Science 307: 1 17, 2005).
[00117] Specific surprising findings exemplified in the present disclosure include, for example the
CaV3.1 channel is expressed and functional as a channel in T cells, carrying the dominant current relative to the other T-type channels, CaV3.2 and CaV3.3. Further surprising findings include that targeted reduction of CaV3.1 channel expression in T cells inhibits the autoimmune response in the experimental autoimmune encephalomyelitis model. Still further surprising findings include that this targeted CaV3.1 deficiency leads to a lower proportion of Thl7 cells and a reduction in the expression of RORyt, a transcription factor critical to Thl7 differentiation, in CaV3.1 -deficient cells stimulated in Thl7-favoring conditions, whereas no effects of CaV3.1 deficiency were observed on TCR-mediated calcium entry. Still further surprising findings include demonstrated effects of T-type channel modulation in immune cells in organs, specifically spleen. These data provide, among other things, the first evidence of T-type calcium channels in immune cells, identify the unanticipated predominance of the CaV3.1 subtype, identify an unanticipated role for CaV3.1 in T cell differentiation into the Thl7 subset, and show the existence of a TCR-independent, CaV3.1 -mediated source of calcium influx in T cells that is active in the range of resting membrane potentials. The present invention thererefore establishes, among other things, that a potential therapeutic approach for autoimmune and other diseases and conditions is through T-type calcium channels of subtype CaV3.1.
Voltage-Gated Calcium Channels
[00118] Innumerable biological processes share calcium as a signaling molecule (e.g., as a second messenger). Calcium crosses cell membranes by passing through either ligand-gated or voltage-gated calcium channels. Voltage-operated calcium channels are subdivided into L, N, P/Q, R, and T types based on their sensitivity to particular blocking agents. T-type calcium channels are known to be preferentially expressed in dendrites, and are believed to be involved in synaptic integration (see, for example, Nelson et al. Curr Pharm. Des. 12:2189, 2006) and nociception (see, for example, Todorovic et al. Br,. J. Pharmacol. 163:484, 2011). Significant effort has been invested therefore in the development
of selective T-type calcium channel regulators for the treatment of pain (see summary in Todorovic et al., which is incorporated herein by reference in its entirety).
[00119] T-type calcium channels are uniquely characterized by their low activation thresholds. T- type currents typically activate at about -70 mV, and inactivate rapidly (τ of about 15-30 ms) (see, for example, review by Perez-Reyes Physiol Rev 88 : 1 17, 2003 , incorporated herein by reference in its entirety).
[00120] Most previous work on T-type calcium channels has focused on their roles in neuronal cells and pathways, including in pain signal transmission and in brain rhythms involved in sleep and in certain forms of epilepsy (see review by Cheong and Shin Physiol Rev 93:961, 2013). The present invention, by contrast, encompasses the insight that the T-type calcium channel activation threshold of about -70 mV is near the resting potential of lymphocytes, whose average membrane potential has been measured to be between -60 and -55 mV. The present inventors hypothesized that T-type calcium channels, if present in lymphocytes, could play important roles, potentially independent of T cell receptor engagement, and investigated the presence of, and potential roles for, T-type calcium channels in T cells, with a focus on CaV3.1. As described herein, the present invention establishes, among other things, that T-type calcium channels are in fact present and active on lymphocyte cells, and in particular on T cells such as naive T cells and Thl7 cells. Moreover, the present invention establishes that modulation of T- type calcium receptor activity, and particularly of CaV3.1 activity, is relevant in a certain lymphocyte- associated diseases, disorders and conditions, including particularly in multiple sclerosis.
Lymphocyte-Associated Diseases, Disorders and Conditions
[00121] Those skilled in the art will appreciate that a variety of diseases, disorders and conditions are associated with (e.g., caused by) lymphocyte cell (e.g., T cell) activity. For example, autoimmune diseases are typically attributable to action of lymphocytes against host cells, tissues, or components. Many inflammatory diseases, disorders, or conditions similarly are associated with and/or caused by lymphocyte activity. Certain infectious diseases may also be exacerbated by inappropriate or ineffective lymphocyte action; the same is true for a variety of cancers. For example, some cancers (e.g., T cell cancers) involve aberrant lymphocyte proliferation. Some cancers (as well as other diseases, disorders or conditions as would be appreciated by those skilled in the art) might effectively be inhibited or treated if lymphocytes could be stimulated or otherwise encouraged or supported to attack them. Those skilled in the art will readily recognize a variety of other contexts in which modulation (i.e., increase or decrease) in lymphocyte activity could achieve a desired therapeutic effect with respect to initiation, development,
progression, and/or severity of one or more diseases, disorders, or conditions. Any such disease, disorder or condition may be considered to be a lymphocyte-associated disease, disorder, or condition in certain embodiments of the present invention.
[00122] In some embodiments, lymphocyte -related diseases, disorders, or conditions (and/or those aspects of it treated by administration of a T-type calcium channel modulator [e.g., a selective T- type calcium modulator] as described herein) relevant to the present disclosure involve cells, tissues, organs and/or systems other than the CNS; in some such embodiments, such diseases, disorders, or conditions do not significantly involve CNS cells, tissues, organs and/or systems. In some particular embodiments, neurons are not involved. In some embodiments, however, neurons and/or one or more CNS cells, tissues, organs and/or systems is involved. In some embodiments, T-type calcium channel modulators utilized as described herein do not affect, and/or are administered so that an effective amount is not delivered to, neurons and/or to one or more CNS cells, tissues, organs and/or systems. In other embodiments, however, T-type calcium channel modulators utilized as described herein do affect, and/or are administered so that an effective amount is delivered to, neurons and/or to one or more CNS cells, tissues, organs and/or systems.
[00123] In some embodiments, lymphocyte -related diseases, disorders, or conditions (and/or those aspects of it treated by administration of a T-type calcium channel modulator [e.g., a selective T- type calcium modulator] as described herein) relevant to the present disclosure involve immune cells in the spleen.
[00124] In some embodiments, lymphocyte-associated diseases, disorders or conditions relevant to the present disclosure are autoimmune diseases, particularly diseases characterized by or associated with uncontrolled or inappropriate Thl7 activation, such as arthritis, multiple sclerosis, psoriasis, and lupus. Non-limiting examples of autoimmune diseases include, acute disseminated encephalomyelitis (ADEM), Addison's disease, agammaglbulinemia, alopecia areata, amyotrophic lateral sclerosis, ankylosing spondylitis, antiphospholipid syndrome, antisynthetase syndrome, atopic allergy, atopic dermatitis, autoimmune aplastic anemia, autoimmune cardiomyophathy, autoimmune enteropathy, autoimmunehemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune
thrombocytopenic purpura, autoimmune urticaria, autoimmune uveitis, Balo concentric sclerosis, Behcet's disease, Berger's disease, Bickerstaff s encephalitis, Blau syndrome, bullous pemphigoid, Castleman's disease, celiac disease, Chagas disease, chronic inflammatory demyelinating
polyneuropathy, chronic recurrent multifocal osteomyelitis, chronic obstructive pulmonary disease,
Churg- Strauss syndrome, cicatricial pemphigoid, Cogan syndrome, cold agglutinin disease, complement component 2 deficiency, contact dermatitis, cranial arteritis, CREST syndrome, Crohn's disease, Cushing's syndrome, cutaneous leukocytoclastic vasculitis, Dego's disease, Dercum's disease, dermatitis herpetiformis, dermatomyositis, diabetes mellitus type 1, diffuse cutaneous systemic sclerosis, Dressier' s syndrome, drug-induced lupus, discoid lupus erythematosus, eczema, endometriosis, enthesitis-related arthritis, eosinophilic fasciitis, eosinophilic gastroenteritis, epidermolysis bullosa acquisita, erythema nodosum, erythroblastosis fetalis, essential mixed cryoglobulinemia, Evan's syndrome, fibrodysplasia ossificans progressive, fibrosing alveolitis, gastritis, gastrointestinal pemphigoid, gianT cell arteritis, glomerulonephritis, Goodpasture's syndrome, Grave's disease, Guillain-Barre syndrome, Hashimoto's encephalopathy, Hashimoto's thyroiditis, Henoch-Schonlein purpura, herpes gestationis, hidradenitis suppurativa, Hughes-Stovin syndrome, hypogammaglobulinemia, idiopathic inflammatory demyelinating diseases, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, IgA nephropathy, inclusion body myositis, chronic inflammatory demyelinating polyneuropathy, interstitial cystitis, juvenile idiopathic arthritis, Kawasaki's disease, Lambert-Eaton myasthenic syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, linear IgA disease, lupus erythematosus, Majeed syndrome, Meniere's disease, microscopic polyangiitis, mixed connective tissue disease, morphea, Mucha-Habermann disease, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica, neuromyotonia, ocular cicatricial pemphigoid, opsoclonus myoclonus syndrome, Ord's thyroiditis, palindromic rheumatism, PANDAS, paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria, Parry Romberg syndrome, Parsonage-Turner syndrome, pars planitis, pemphigus vulgaris, pernicious anaemia, perivenous encephalomyelitis, POEMS syndrome, polyarteritis nodosa, polymyalgia rheumatic, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, progressive inflammatory neuropathy, psoriatic arthritis, pyoderma gangrenosum, pure red cell aplasia, Rasmussen's encephalitis, raynaud phenomenon, relapsing polychondritis, Reiter's syndrome, restless leg syndrome, retroperitoneal fibrosis, rheumatic fever, Schnitzler syndrome, scleritis, scleroderma, serum sickness, Sjogren's syndrome,
spondyloarthropathy, stiff person syndrome, subacute bacterial endocarditis, Susac's syndrome, Sweet's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis, thrombocytopenia, Tolosa- Hunt syndrome, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease, undifferentiated spondyloarthropathy, vitiligo, and Wegener's granulomatosis.
[00125] In some embodiments, lymphocyte-associated diseases, disorders or conditions relevant to the present disclosure are not classically considered autoimmune diseases. Non-limiting examples include: allergic asthma, hay fever, bee venom, allergy, food allergy, sarcoidosis, ankylosing, spondylitis, erythematosus, inflammatory bowel disease (e.g., ulcerative colitis), vasculitis, T cell lymphoma
expressing ICOS, rejection of a transplanted organ or tissue, alopecia areata, atherosclerosis, bipolar disorder, schizophrenia, and graft-versus-host disease.
[00126] In some embodiments, lymphocyte-associated diseases, disorders or conditions relevant to the present disclosure are infectious diseases. Infectious diseases can be of fungal, viral, bacterial, and/or parasitic in origin. Examples of viral infectious diseases include, but are not limited to: HPV, AIDS, SARS, rabies, rubella, roseola, mumps, measles, norovirus, Lassa fever, yellow fever, poliomyelitis, conjunctivitis, viral hepatitis, dengue fever, common cold, influenza, viral meningitis, West Nile virus, viral pneumonia, viral encephalitis, smallpox, Colorado tick fever, viral gastroenteritis, roseola sixth disease, hepes simplex, cytomegalovirus infection, and Ebola haemorrhagic fever. Examples of bacterial infectious diseases include, but are not limited to: stye, MRS A, E.coli, typhus, plague, tetanus, cholera, anthrax, syphilis, pink eye, impetigo, botulism, tularemia, trachoma, chalazion, listeriosis, diphtheria, gonorrhea, Chlamydia, shigellosis, scarlet fever, tuberculosis, legionellosis, typhoid fever, Lyme disease, bacterial meningitis, and pertussis whopping cough. Examples of fungal infectious diseases include, but are not limited to: candidiasis, aspergillosis, blastomycosis, histoplasmosis, cryptococcosis, tinea cruris, tinea capitis, and tinea pedis. Examples of parasitic infectious diseases include, but are not limited to: malaria, scabies, filariasis, amebiasis, ascariasis, babesiosis, pediculosis, trichinellosis, leishmaniasis, toxoplasmosis, trichomoniasis, Chagas disease, schistosomiasis, trypanosomiasis, and cryptosporidiosis.
[00127] In some embodiments, lymphocyte-associated diseases, disorders or conditions relevant to the present disclosure are cancers. Non-limiting examples of cancers include: bladder cancer, breast cancer, colon and rectal cancer, endometrial cancer, kidney or renal cell cancer, leukemia, lung cancer, melanoma, Non-Hodgkin lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer.
[00128] As discussed herein, the present disclosure specifically exemplifies effectiveness of T- type calcium channel modulation in models of multiple sclerosis. Those of ordinary skill in the art will appreciate that such findings have implications for a variety of other particular lymphocyte-associated diseases, disorders, and conditions including those known to be associated with Thl7 cells such as, for example, inflammatory bowel disease, multiple myeloma (see, for example, Noonan et al Blood
1 16:3554, 2010), and psoriasis, and also including relapsing-remitting multiple sclerosis in particular.
[00129] Those of ordinary skill in the art will also appreciate that animal models are available for a variety of lymphocyte-associated diseases, disorders and conditions; such models can be utilized to identify and/or characterize useful T-type calcium channel modulators as described herein, and particularly to assess their usefulness in treatment of the particular lymphocyte-associated diseases, disorders or conditions to which the particular model is relevant.
[00130] To give but a few examples of animal models, the present disclosure exemplifies mouse models for experimental autoimmune encephalomyelitis (EAE). Exemplary other relevant models include, for example, animal models of relapsing-remitting multiple sclerosis (see, for example, McRae et al., J. Neurommunol 38(3):229, June 1992), psoriasis (see, for example, van der Fits et al., J Immunol ; 182:5836, 2009) and inflammatory bowel disease (see, for example, Neurath et al. Cancer. Dig Dis 30(suppl 1):91, 2012).
T-type calcium channel modulators
[00131] The present invention provides, among other things, various methods and compositions that relate to and/or include T-type calcium channel modulators. In some embodiments, such T-type calcium channel modulators are active with respect to T-type calcium channels on immune cells (e.g., on T cells such as na'ive T cells and Thl7 cells). In some embodiments, such T-type calcium channel modulators are active with respect to T-type calcium channels in one or more primary lymphoid organs (e.g., the spleen). In some embodiments, such T-type calcium channel modulators are active with respect to T-type calcium channels in bone marrow.
[00132] In some embodiments, T-type calcium channel modulators for use in accordance with the present invention are selective T-type calcium channel modulators. In some embodiments, such modulators are selective and/or specific for (e.g., exhibit preferential activity with respect to) T-type calcium channels (e.g., for one or more of Cav3.1, Cav3.2, or Cav3.3 channels) as compared with other calcium channels, and/or for T-type calcium channels on immune cells (e.g., T cells such as na'ive T cells and/or Thl7 cells) as compared with T-type calcium channels on other cell types (e.g., on CNS cells). In some embodiments, such modulators are selective and/or specific for T-type calcium channels on certain immune cells (e.g., in primary lymphoid organs) as compared with other immune cells (e.g., peripheral immune cells). In some embodiments, such modulators are selective and/or specific for a particular T- type calcium channel as compared with other T-type calcium channels (e.g., for Cav3.1 channels as compared with Cav3.2 and/or Cav3.3 channels), even in some instances as compared with other T-type calcium channels in or on immune cells. In some embodiments, T-type calcium channel modulators are selective for T-calcium channels as compared with other voltage-gated channels (e.g., such as L-type, N- type, P/Q-type, and/or R-type calcium channels).
[00133] In some embodiments, T-type calcium channel modulators are selective for cells, tissues, organs and/or systems other than the CNS; in some such embodiments, T-type calcium channel modulators do not significantly involve CNS cells, tissues, organs and/or systems. In some particular
embodiments, T-type calcium channel modulators do not selectively or specifically impact neurons. In some embodiments, however, T-type calcium channel modulators do impact neurons and/or CNS cells, tissues, organs and/or systems if contacted therewith. In some embodiments of the present invention, such T-type calcium channel modulators are delivered to subjects via a route, regimen, modality, or mechanism that does not achieve delivery of an effective amount (e.g., and amount sufficient to alter level and/or activity of a T-type calcium channel therein so that a significant biological effect is observed).
[00134] In some embodiments, T-type calcium channel modulators are or comprise inhibitors. In some embodiments, T-type calcium channel modulators are or comprise activators.
[00135] In some embodiments, T-type calcium channel modulators as described herein have activities and/or are administered such that one or more effects (e.g., analgesia, pain relief) on neurons and/or CNS cells, tissues, organs and/or systems is not observed.
[00136] Among other things, T-type calcium channel modulators for use in accordance with the present invention may be identified and/or characterized with respect to their activity (including, for example, with respect to the specificity, magnitude, and/or nature of their effect(s), for example relative to one or more appropriate references or controls) on T-type calcium channels as described herein. In general, one or more candidate T-type calcium channel modulating agents is contacted with a system comprising in which one or more T-type calcium channels found in or on lymphocyte cells is active, and assessing impact of the agent on level and/or activity of the T-type calcium channel, typically relative to an appropriate reference or control (e.g., absence of the agent, presence of a different known modulator, specificity, magnitude, and/or nature of effect by the agent on a different calcium channel such as a different T-type calcium channel, for example active in or on different cells). Those skilled in the art will be aware of a variety of systems, including those described and/or exemplified herein, appropriate for such analyses.
[00137] In some embodiments, T-type calcium channel modulators are identified from collections or pools of candidate agents, for example including sets of candidate agents that are structural variants of one another. As will be apparent to those skilled in the art, in some embodiments, members of such collections or pools may be designed, for example, to share one or more structural features of a known T- type calcium channel modulator and/or to contain moieties in three dimensional space positioned appropriately for interaction with certain known target moieties (e.g., as determined with reference to three-dimensional structural models for example according to principles of structure based drug design).
[00138] In some embodiments, selective T-type calcium channel modulators may share certain structural attributes with agents or compounds that are not in and of themselves selective for T-type calcium channels. Of course, in many embodiments, agents or compounds that are not themselves
selective are nonetheless useful in various embodiments of the invention that require or benefit from selectivity, as such agents may be utilized in a way (e.g., via local delivery) that permits them to perform with appropriate selectivity and/or specificity in context (e.g., because they are not exposed to their own competing targets). Alternatively or additionally, such agents or compounds that are not in and of themselves selective for relevant T-type calcium channels may be used as references in the design, identification, and/or characterization of selective compounds that share one or more structural features with them.
Antibodies
[00139] In some embodiments, T-type calcium modulators in accordance with the present invention are or include antibodies or fragments thereof.
[00140] Antibodies against T-type calcium channels can be made, e.g., using any of the methods for making antibodies to membrane proteins known in the art. In one example, antibodies can be generated by immunization with whole cells over-expressing the target protein. Membrane proteins can be displayed in their native conformation without mechanical or detergent disruption. Typically, stable murine cells expressing a human membrane protein are used to immunize mice. Improvements to this approach can involve selecting cells that have the highest expression level of the membrane protein of interest. Alternatively, membrane proteins can be solubilized and reconstituted in its structurally intact form into phospholipid vesicles and used as an immunogen in mice. In another method, simple peptides can be effective immunogens for deriving antibodies against linear epitopes. A variation to this approach, known as chemical linkage of peptides onto scaffolds (CLIPS), uses peptides to recreate individual conformational epitopes for immunization and is described in Timmerman et al., J Mol Recognit 20:283- 299, 2007. By constraining linear epitope sequences using cysteine linkages to mimic certain structured conformations that better represent the native proteins. Conformational antibodies to, for example, follicle-stimulating hormone (FSH) and G-protein coupled receptor CXCR7 have been generated using this method. As an alternate, Integral Molecular (Philadelphia, PA) has developed a method of presenting native membrane protein immunogens as Lipoparticle (Willis et al., Biochemistry 47:6988-6990, 2008). Lipoparticles are virus-like particles that incorporate high concentrations of target membrane proteins in their native conformation. The particles are produced from mammalian cells by co-expressing the retroviral structural core polyprotein, Gag, along with a desired membrane protein. The lipoparticles are approximately 150 nm in diameter, therefore are readily suspended in aqueous solutions that can be used for inoculation. In any of the above methods monoclonal antibodies can then be produced by standard
hybridoma cell production. Once produced, monoclonal antibodies can also be tested for specific recognition by Western blot or immunoprecipitation analysis.
[00141] Antibodies selective and/or specific for the T-type calcium channel can be generated using the approach described in Naylor et al., The Open Drug Discovery Journal 1 :36-42, 2009. Briefly, the target T-type calcium channel (e.g., CaV3.1, Cav3.2, and Cav3.3) is selected and the amino acid sequence of the channel is obtained including information on any splice variants. A peptide, at least 20mer in length (e.g., 20mer, 25mer, 30mer, 35mer, 40mer, etc) based on the extracellular E3 loop, which maintains the position of the ion selectivity filter, is identified. The peptide sequence can be further selected to eliminate antigenicity and cross-species similarities (e.g., by comparing sequences between CaV3.1 , Cav3.2, and Cav3.3). An N- or C-terminal cysteine is added to the peptide if not naturally present in order to conjugate a support (e.g., KLH protein) to aide in affinity purification. The peptide is then used in standard immunization protocol, and antibody titre is determined by ELISA. Functional assays are then used to test the blocking activity of the antibody relative to controls such as preimmune antisera or peptide-adsorbed antibody. Antibodies with blocking effects are then tested for off-target effects on other ion transport mechanisms to validate any effects on cellular or tissue responses using independent methods (e.g., R Ai). Examples of polyclonal antibodies generated using this approach include, but are not limited to polyclonal antibodies targeted to the voltage-gated K+ channel Kvl .2 and Kv3.1, NESOpAb, targeted to voltage-gated sodium channel Navl.5, and D-III, pAb targeted to N- and P/Q- type voltage-gated calcium channels. Examples of monoclonal antibodies generated using the above approach include, but are not limited to the monoclonal antibody mAb56 targeted to the voltage-gated K+ channel, hEagl, and the anti-STIMl antibody targeted to the ion channel auxiliary protein STIM1.
Humanized antibodies
[00142] In some embodiments, antibodies for use in accordance with the present invention are humanized antibodies. Various methods for humanizing non-human antibodies are known in the art. For example, a humanized antibody can have one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies, where substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non- human species. In practice, humanized antibodies are typically human antibodies in which at least some
hypervariable region residues as well as other variable region residues are substituted by residues from analogous sites in rodent antibodies.
[00143] The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies can be important to reduce antigenicity. According to the so-called "best- fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework for the humanized antibody. Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies.
[00144] In some embodiments, it is further generally desirable that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to one method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.
Human antibodies
[00145] In some embodiments, antibodies for use in accordance with the present invention are human antibodies. Human antibodies can be constructed by combining Fv clone variable domain sequence(s) selected from human-derived phage display libraries with known human constant domain sequences(s). Alternatively, human monoclonal antibodies of the invention can be made by the hybridoma method. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described.
[00146] It is possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the
antibody heavy-chain joining region (JH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ- line mutant mice will result in the production of human antibodies upon antigen challenge.
[00147] Gene shuffling can also be used to derive human antibodies from non-human, e.g., rodent, antibodies, where the human antibody has similar affinities and specificities to the starting non- human antibody. According to this method, which is also called "epitope imprinting," either the heavy or light chain variable-region of a non-human antibody fragment obtained by phage display techniques as described herein is replaced with a repertoire of human V domain genes, creating a population of non- human chain/human chain scFv or Fab chimeras. Selection with antigen results in isolation of a non- human chain/human chain chimeric scFv or Fab where the human chain restores the antigen binding site destroyed upon removal of the corresponding non-human chain in the primary phage display clone, i.e., the epitope governs (imprints) the choice of the human chain partner. When the process is repeated in order to replace the remaining non-human chain, a human antibody is obtained. Unlike traditional humanization of non-human antibodies by CDR grafting, this technique provides completely human antibodies, which have no FR or CDR residues of non-human origin.
Antibody fragments
[00148] In some embodiments, antibodies for use in accordance with the present invention are or include anti-T-type calcium channel antibody fragments that comprise a portion of an intact antibody, preferably comprising the antigen binding region and/or one or more complement determining regions (CDRs) thereof. Examples of antibody fragments include Fab, Fab', F(ab')2 , and Fv fragments;
diabodies; linear antibodies; single-chain antibody molecules; and multi-specific antibodies formed from antibody fragments.
[00149] Papain digestion of antibodies produces two identical antigen-binding fragments, called
"Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')2 fragment that has two antigen- combining sites and is still capable of cross-linking antigen.
[00150] Fv is the minimum antibody fragment which contains a complete antigen-binding site. In one embodiment, a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. In a single-chain Fv (scFv) species, one heavy- and one light- chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure analogous to that in a two-chain Fv species. It is in this
configuration that the three hypervariable regions (HVRs) of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six HVRs confer antigen- binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three HVRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
[00151] The Fab fragment contains the heavy- and light-chain variable domains and also contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[00152] Single-chain Fv or scFv antibody fragments comprise the VH and VL domains of antibody, where these domains are present in a single polypeptide chain. Generally, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding.
[00153] Diabodies are antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies may be bivalent or bispecific.
[00154] Antibody fragments may be generated by traditional means, such as enzymatic digestion, or by recombinant techniques. In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead to improved access to solid tumors. Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies. However, these fragments can now be produced directly by recombinant hosT cells. Fab, Fv, and ScFv antibody fragments can all be expressed in and secreted from E. coli, thus allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments. In another approach, F(ab')2 fragments are isolated directly from recombinant hosT cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.
RNAi agents
[00155] In some embodiments, T-type calcium modulators in accordance with the present invention are or include one or more RNAi agent(s) that inhibit T-type calcium channel gene expression and/or activity in a cell in vitro or in vivo (e.g., in a subject). In some embodiments, such RNAi agents can be or include different types of double- stranded molecules that include either RNA:RNA or
RNA:DNA strands. These agents can be introduced to (including by expression within) cells in a variety of structures, including a duplex (e.g., with or without overhangs on the 3 '-terminus), a hairpin loop, or an expression vector that express one or more polynucleotides capable of forming a double-stranded polynucleotide alone or in combination with another polynucleotide.
[00156] Exemplary RNAi agents include siRNA, shRNA, DsiRNA, and miRNA agents.
Generally these agents are about 10 to about 40 nucleotides in length, and preferred lengths for particular RNAi agents include siRNA that are double-stranded RNA molecules of 16 to 30 nucleotides in length (e.g., 18 to 25 nucleotides, e.g., 21 nucleotides); shRNA that are single- stranded RNA molecules in which a hairpin loop structure is present and a stem length is between 19 to 29 nucleotides in length (e.g., 19 to 21 nucleotides or 25 to 29 nucleotides) or a loop size is between 4 to 23 nucleotides in length; DsiRNA that are double-stranded RNA agents of 25 to 35 nucleotides in length; and miRNA that are single- stranded RNA molecules of 17 to 25 nucleotides (e.g., 21 to 23 nucleotides) in length.
[00157] In some embodiments, an RNAi agent can have any useful nucleic acid sequence, including a nucleic acid sequence having one or more DNA molecules, RNA molecules, or modified forms (e.g., a modified backbone composition or 2'-deoxy, or 2'-0-methyl modifications) or
combinations thereof. Alternatively or additionally, in some embodiments an RNAi agent can contain one or more 5'- and/or 3 '-terminal modifications. In some embodiments, an RNAi agent can include blunt nucleotides at one or both termini; in some embodiments, an RNAi agent can include one or more overhanging nucleotides at one or both termini. Exemplary terminal modifications include a 5'- dideoxythymidine overhang, such as for siRNAi; a 3'-UU or 3'-dTdT overhang, such as for shRNA; one or more G-U mismatches between the two strands of the shRNA stem; or a single-stranded nucleotide overhang at the 3 '-terminal of the antisense or sense strand of 1 to 4 nucleotides (e.g., 1 or 2 nucleotides) for DsiRNA.
[00158] Methods of producing antisense and sense nucleotides, as well as corresponding duplexes or hairpin loops, are known in the art and can be readily adapted to produce an antisense oligonucleotide that targets a particular desired target nucleic acid sequence. RNAi agents include at least one antisense
nucleotide sequence that is directed to a target nucleic acid (e.g., a target gene, e.g., a T-type calcium channel gene). Antisense nucleotides are single strands of DNA or R A that are complementary to a chosen target sequence. In the case of antisense RNA, they prevent translation of complementary RNA strands by binding to it. Antisense DNA can be used to target antisense nucleotides contain from about 10 to about 40 nucleotides, more preferably about 15 to about 30 nucleotides. The antisense nucleotide can have up to 80%, 85%, 90%, 95%, 99%, or even 100% complementary to the desired target gene.
[00159] RNAi agents can include commercially available agents, such as those available from
OriGene Technologies (Rockville, MD), Santa Cruz Biotechnologies, Inc. (Santa Cruz, CA), Open Biosystems (Lafayette, CO), Invitrogen I (Carlsbad, CA), and Qiagen (Valencia, CA). RNAi agents can be designed to target a particular gene of interest using web-based prediction tools known in the art (e.g., Human siRNA Database (HuSiDa), and Genelink).
Small-molecule modulators
[00160] In some embodiments, T-type calcium modulators in accordance with the present invention are or include small molecules that alter level and/or activity of T-type calcium channels as described herein. In some embodiments, small-molecule modulators can include one or more compound(s) that enhance or inhibit the activity (e.g., membrane polarization, influx of calcium ions into the cell, and downstream signaling) of the channel by binding to the ¾ subunits (e.g., iG, iH, and ail) of various T-type calcium channels (e.g., CaV3.1, CaV3.2, CaV3.3). Alternatively or additionally, in some embodiments, small-molecule modulators can bind to other subunits that may make up the calcium channel, such as, the α2δ, β, and γ subunits, and to different states of the channels (e.g., depolarized (inactivated) state, and polarized (activated) state, hyperpolarized (closed) state, and open state).
[00161] In some embodiments, T-type calcium channel small-molecule modulators may be selected from the group consisting of diphenylbutylpiperidines derivatives (e.g., pimozide, penfluridol, clopimozide, and fluspirilene), butyrophenone derivatives (e.g., haloperidol, droperidol, benperidol, triperidol, melperone, lenperone, azaperone, and domperidone), and phenylpiperazine derivatives (e.g., antrafenine, aripiprazole, ciprofloxacin, dapiprazole, dropropizine, etoperidone, itraconazole, ketoconazole, levodropropizine, mepiprazole, naftopidil, nefazodone, niaprazine, oxypertine, posaconazole, trazodone, urpidil, and vesnarinone). Additional T-type calcium channel small-molecule inhibitors include dihydropyridine derivatives (e.g., manidipine, nilvadipine, benidipine, and efonidipine), flunarizine, anandamide, lomerizine, and phenytoin and zonisamide, and U-92032.
[00162] In some embodiments, selective T-type calcium channel small-molecule modulators may be selected from the group consisting of tetralol, tetralol derivatives (e.g., mibefradil), mibefradil derivatives (e.g., N C 55-0396 dihydrochloride described in Quesada et al., Drug Metab Dispos.
36: 1291-9, 2008), those such as the Merck T-type antagonist (TTA) phenyl acetamides TTA-A2 described by Uebele and coworkers (Uebele et al., J Clin Invest. 1 19: 1659-1667, 2009) and TTA-A8, piperidines such as TTA-P1 and 4-aminomethyl-4-fluoropiperidine (TTA-P2) described in Shipe et al., J. Med. Chem. 51 :3692-3695, 2008; Dreyfus et al., J. Neurosci. 30:99-109, 2010, quinazolinones such as TTA-Q3 and TTA-Q6, and MK-8998, and those such as Z941 and Z944 of Zalicus described in Tringham et al., Sci Transl Med 4: 121ra29, 2012. Additional selective T-type calcium channel small-molecule inhibitors include succinimide anticonvulsant derivatives (e.g., ethosuximide, phensuximide, and mesuximide also known as methsuximide, and an active metabolite, N-desmethylmethsuximide also known as (alpha)-methyl-(alpha)-phenyl-succinimide), and R isomer of efonidipine. Other selective T- type calcium channel small-molecule inhibitors include trimethadione, its active metabolite dimethadione, ABT-639 of Abbott, TTL-1 177 of Tau Therapeutics also known as TH-1 177, , KYSO5044, , and, and kurtoxin.
[00163] In some embodiments, T-type calcium channel small-molecule modulators may be selected from the group consisting of those described in the patents and published patent applications listed in Giordanetto et al, "T-type calcium channels inhibitors: a patent review," Expert Opin Ther Pat, 21 :85-101, 201 1 (hereby incorporated by reference), including WO2004035000, WO9304047,
WO2006098969, WO2009009015, WO2007002361, WO2007002884, WO2007120729,
WO2009054982, WO2009054983, WO2009054984, US20090270413, WO2008110008,
WO2009146539, WO2009146540, US8, 133,998, WO2010083264, WO2006023881, and
WO2006023883, and WO2005007124, WO2005009392, US2005245535, WO2007073497,
WO200707852, WO2008033447, WO2008033456, WO2008033460, WO2008033464, WO2008033465, WO2008050200, WO20081 17148, WO2009056934, EP1568695, WO2008007835, KR754325,
US7319098, US20100004286, EP1757590, KR2009044924, US2010094006, WO2009035307,
US20090325979, KR75758317, WO2008018655, US20080293786, and US20100056545, each of which is hereby incorporated by reference.
[00164] As noted above, in some embodiments, T-type calcium channel small-molecule modulators for use in accordance with the present invention may be or include agents or compounds that are not in and of themselves selective for T-type calcium channels. Particular non-limiting examples of such compounds include, for instance, anandamide, antrafenine, benidipine, efonidipine, flunarizidine,
fluspiriline, haloperidol, lomerizine, penfluridol, phenytoin, pimozide, U-92032, zonisamide (see, for example, Biton, Clin Neuropharmacol. 30:230, 2007; Matar et al., Epilepsy Res. 83:224, 2009).
Peptides
[00165] In some embodiments, T-type calcium modulators in accordance with the present invention are or include peptides or polypeptides. In some embodiments, such peptides share structural homology (e.g., one or more conserved sequence elements) with one or more subunits of the relevant T- type calcium channel (e.g., al, α2δ, β, and/or γ subunit(s)) and/or transmembrane domains of the T-type calcium channel (e.g., TM1, TM2, TM3, TM4, TM5, and TM6).
[00166] Non-limiting examples of peptide modulators include je TMla, LGLLVAIV; je TMla
SCR, LLILAVGV; γ4 TMla, LTTAGAFA; γ6 TMla G42T, LTLLVAIV; γ6 TMla L41FL43F,
FGFLVAIV; γ6 TMla V45FI47F, LGLLFAFV; γ6 TMlb, VGATLAVL; γ6 TMlb A50L, VGLTLAVL; γι TMla, VTLFFILA; yl TMla T12GI16A, VGLFFALA and any described in Chen et al., Mol. Pharm. 75: 1042-51, 2009.
Pharmaceutical compositions
[00167] The present invention also relates to pharmaceutical compositions that contain one or more T-type calcium channel modulator(s) or a combination of a T-type calcium channel modulator and a second therapeutic agent (e.g., a combination of a T-type calcium channel modulator and a calcium channel modulator, an immunosuppressant, or an anticancer agent). Such compositions can be formulated for use in a variety of drug delivery systems. One or more physiologically acceptable excipients or carriers can also be included in the composition for proper formulation. Suitable formulations for use in the present invention are found in Remington 's The Science & Practice of Pharmacy, University of the Sciences in Philadelphia, PA, 21st ed., 2005. For a brief review of methods for drug delivery, see, e.g., Langer, Science 249: 1527-1533, 1990.
[00168] In some embodiments, pharmaceutical compositions are formulated for parenteral, intranasal, topical, oral, or local administration, such as by a transdermal means, for prophylactic and/or therapeutic treatment. The pharmaceutical compositions can be administered parenterally (e.g., by intravenous, intramuscular, or subcutaneous injection), or by oral ingestion, or by topical application or intraarticular injection at areas affected by the vascular or cancer condition. Additional routes of administration include intravascular, intra-arterial, intratumor, intraperitoneal, intraventricular, intraepidural, as well as nasal, ophthalmic, intrascleral, intraorbital, rectal, topical, or aerosol inhalation administration. Sustained release administration is also specifically included in the invention, by such
means as depot injections or erodible implants or components. Thus, the invention provides compositions for parenteral administration that comprise the above mention agents dissolved or suspended in an acceptable carrier, preferably an aqueous carrier, e.g., water, buffered water, saline, PBS, and the like. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, detergents and the like.
[00169] In some embodiments, pharmaceutical compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 1 1 , more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5. Resulting
compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the above mentioned agent or agents, such as in a sealed package of tablets or capsules. In some embodiments, compositions in solid form can also be packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment.
[00170] In some embodiments, compositions containing an effective amount (e.g., compositions containing a unit dose amount appropriate for administration in an established effective dosing regimen) can be administered for prophylactic or therapeutic treatments. In prophylactic applications,
compositions can be administered to a patient with a clinically determined predisposition or increased susceptibility to development of an autoimmune disease, an infectious disease, a T cell-mediated disease, or a cancer.
[00171] In some embodiments, a pharmaceutical composition as described herein patient subject according to a dosing regimen that delivers an amount sufficient to delay, reduce, or preferably prevent the onset of clinical disease. In therapeutic applications, compositions are administered to a subject (e.g., a human) already suffering from an autoimmune disease, an infectious disease, other T cell-mediated disease, or a cancer in an amount sufficient to cure or at least partially arrest the symptoms of the condition and its complications. An amount adequate to accomplish this purpose is defined as a
"therapeutically effective dose," an amount of a compound sufficient to substantially improve some symptom associated with a disease or a medical condition. For example, in the treatment of an autoimmune disease, an infectious disease, a T cell-mediated disease, or cancer, an agent or compound which decreases, prevents, delays, suppresses, or arrests any symptom of the disease or condition would be therapeutically effective. A therapeutically effective amount of an agent or compound is not required to cure a disease or condition but will provide a treatment for a disease or condition such that the onset of
the disease or condition is delayed, hindered, or prevented, or the disease or condition symptoms are ameliorated, or the term of the disease or condition is changed or, for example, is less severe or recovery is accelerated in an individual.
[00172] The compounds and formulations of the present invention may be used in combination with either conventional methods of treatment or therapy or may be used separately from conventional methods of treatment or therapy. When the compounds and formulations of this invention are administered in combination therapies with other agents, they may be administered sequentially or concurrently to an individual. Alternatively, pharmaceutical compositions according to the present invention include a combination of a compound or formulation of the present invention in association with a pharmaceutically acceptable excipient, as described herein, and another therapeutic or prophylactic agent known in the art.In some embodiments, formulated agents can be packaged together as a kit. Non- limiting examples include kits that contain, e.g., two pills, a pill and a powder, a suppository and a liquid in a vial, two topical creams, etc. In some embodiments, such a kit can include optional components that aid in the administration of the unit dose to patients, such as vials for reconstituting powder forms, syringes for injection, customized IV delivery systems, inhalers, etc. Alternatively or additionally, the unit dose kit can contain instructions for preparation and administration of the compositions. In some embodiments, a kit may be manufactured as a single use unit dose for one patient, multiple uses for a particular patient (at a constant dose or in which the individual compounds may vary in potency as therapy progresses); or the kit may contain multiple doses suitable for administration to multiple patients ("bulk packaging"). The kit components may be assembled in cartons, blister packs, bottles, tubes, and the like.
[00173] In some embodiments, pharmaceutical compositions in accordance with the present invention, and/or active agents included therein, may comprise and/or otherwise be associated with a targeting entity or moiety that assists in localizing the composition and/or agent, after delivery, to a site of interest (e.g., to immune cells having active T-type calcium channels). To give but a few examples, localization may be restricted to the periphery, and/or to non-neuronal and/or non-CNS locations, by which is meant areas of the body outside the blood-brain-barrier. In some embodiments, localization may be confined to a specific organ such as the spleen.
Combination Therapy
[00174] Pharmaceutical compositions of the invention can be administered in combination therapy, i.e., combined with other agents (e.g., immunosuppressants, other ion channel modulators,
anticancer agents, anti-inflammatory agents, and/or pain relievers) depending on the condition to be treated.
Immunosuppressants
[00175] In some embodiments of the present invention, useful immunosuppressants include, but are not limited to, calcineurin inhibitors (e.g., cyclosporin A (SANDIMMUNE®), cyclosporine G tacrolimus (PROGRAF®, PROTOPIC®)), mTor inhibitors (e.g., sirolimus (RAPAMUNE®, NEORAL®), temsirolimus (TORISEL®), zotarolimus, and everolimus (CERTICAN®)), fingolimod (GILENYA™), myriocin, alemtuzumab (CAMPATH®, MABCAMPATH®, CAMPATH- 1 H®), rituximab (RITUXAN®, MABTHERA®), an anti-CD4 monoclonal antibody (e.g., HuMax-CD4), an anti-LFAl monoclonal antibody (e.g., CD1 la), an anti-LFA3 monoclonal antibody, an anti-CD45 antibody (e.g., an anti- CD45RB antibody), an anti-CD19 antibody (see, e.g., U.S. Patent Publication 2006/0280738), monabatacept (ORENCIA®), belatacept, indolyl-ASC (32-indole ether derivatives of tacrolimus and ascomycin), azathioprine (AZASAN®, IMURAN®), lymphocyte immune globulin and anti-thymocyte globulin [equine] (ATGAM®), mycophenolate mofetil (CELLCEPT®), mycophenolate sodium
(MYFORTIC®), daclizumab (ZENAPAX®), basiliximab (SIMULECT®), cyclophosphamide
(ENDOXAN®, CYTOXAN®, NEOSAR™, PROCYTOX™, REVIMMUNE™), prednisone, prednisolone, leflunomide (ARAVA®), FK778, FK779, 15-deoxyspergualin (DSG), busulfan
(MYLERAN®, BUSULFEX®), fludarabine (FLUDARA®), methotrexate (RHEUMATREX®,
TREXALL®), 6-mercaptopurine (PURINETHOL®), 15-deoxyspergualin (Gusperimus), LF 15-0195, bredinin, brequinar, and muromonab-CD3 (ORTHOCLONE®).
[00176] Cyclosporine A (CsA; CAS No. 59865- 13-3; U.S. Patent No. 3,737,433) and its analogs may be used as an immunosuppressant. A number of other cyclosporins and their derivatives and analogs that exhibit immunosuppressive activity are known. Cyclosporines and their formulations are described, for example, in 2004 Physicians' Desk Reference® (2003) Thomson Healthcare, 58th ed., and U.S. Patent Nos. 5,766,629; 5,827,822; 4,220,641 ; 4,639,434; 4,289,851 ; 4,384,996; 5,047,396;
4,388,307; 4,970,076; 4,990,337; 4,822,618; 4,576,284; 5, 120,710; and 4,894,235.
[00177] Tacrolimus (FK506) is a macrolide which exerts effects largely similar to CsA, both with regard to its molecular mode of action and its clinical efficacy (Liu, Immunol. Today 14:290-5, 1993; Schreiber et al., Immunol. Today, 13: 136-42, 1992); however, these effects are exhibited at doses that are 20 to 100 times lower than CsA (Peters et al., Drugs 46:746-94, 1993). Tacrolimus and its formulations are described, for example, in 2004 Physicians' Desk Reference® (2003) Thomson Healthcare, 58th ed., and U.S. Patent Nos. 4,894,366; 4,929,61 1 ; and 5, 164,495.
[00178] Sirolimus (rapamycin) is an immunosuppressive lactam macrolide produceable, for example, by Streptomyces hygroscopicus. Numerous derivatives of sirolimus and its analogs and their formulations are known and described, for example, in 2004 Physicians' Desk Reference® (2003) Thomson Healthcare, 58th ed., European Patent EP 0467606; PCT Publication Nos. WO 94/02136, WO 94/09010, WO 92/05179, WO 93/1 1 130, WO 94/02385, WO 95/14023, and WO 94/02136, and U.S. Patent Nos. 5,023,262; 5,120,725; 5, 120,727; 5,177,203; 5,258,389; 5, 1 18,677; 5,1 18,678; 5, 100,883; 5,151,413; 5,120,842; and 5,256,790.
Antioxidants
[00179] In some embodiments of the present invention, useful antioxidants include, but are not limited to, vitamin D, calcitriol, calcidiol, or other vitamin D receptor binder, quercetin or other flavonoid, resveratrol or other sirtuin modulator.
Anticancer agents
[00180] In some embodiments of the present invention, useful anticancer agents include, but are not limited to: chemotherapeutic agents (e.g., arsenic trioxide, cisplatin, carboplatin, chlorambucil, melphalan, nedaplatin, oxaliplatin, triplatin tetranitrate, satraplatin, imatinib, nilotinib, dasatinib, and radicicol), immunomodulatory agents (e.g., methotrexate, leflunomide, cyclophosphamide, cyclosporine A, minocycline, azathioprine, antibiotics (e.g., tacrolimus), methylprednisolone, corticosteroids, steroids, mycophenolate mofetil, rapamycin, mizoribine, deoxyspergualin, brequinar, T cell receptor modulators, and cytokine receptor modulators), antiangiogenic agents (e.g., bevacizumab, suramin, and
etrathiomolybdate), mitotic inhibitors (e.g., paclitaxel, vinorelbine, docetaxel, abazitaxel, ixabepilone, larotaxel, ortataxel, tesetaxel, vinblastine, vincristine, vinflunine, and vindesine), nucleoside analogs (e.g., gemcitabine, azacitidine, capecitabine, carmofur, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, fluorouracil, mercaptopurine, pentostatin, tegafur, and thioguanine), DNA intercalating agents (e.g., doxorubicin, actinomycin, bleomycin, mitomycin, and plicamycin), topoisomerase inhibitors (e.g., irinotecan, aclarubicin, amrubicin, belotecan, camptothecin, daunorubicin, epirubicin, etoposide, idarubicin, mitoxantrone, pirarubicin, pixantrone, rubitecan, teniposide, topotecan, valrubicin, and zorubicin), folate antimetabolites (e.g., pemetrexed, aminopterin, methotrexate, pralatrexate, and raltitrexed), and other targeting agents (e.g., agents that target particular enzymes or proteins involved in cancer or agents that target particular organs or types of cancers), and combinations thereof.
Pain relievers
[00181] In some embodiments of the present invention, useful pain relievers include, but are not limited to: acetaminophen/paracetomol, non-steroidal anti-inflammatory drugs, COX-2 inhibitors, opiates, morphinomimetics, flupirtine, tricyclic antidepressants, (e.g., amitriptyline), nefopam, and
anticonvulsants (e.g., carbamazepine, gabapentin, and pregabalin), dual LOX/COX inhibitors, cannabinoid receptor antagonists, neurokinin antagonists, PAR2 receptor antagonists, iNOS inhibitors, vanilloid/TRPVl/capsaicin receptor antagonists, calcitonin gene -related antagonists, COX3 inhibitors, glycine antagonists, N-acetylcholine receptor antagonists, enkephalinase inhibitors, FAAH inhibitors, and other T-type calcium channel inhibitors.
[00182] As described herein, in some embodiments, T-type calcium modulators (e.g., selective T- type calcium modulators) utilized in accordance with the present invention are not pain relievers (e.g., are not analgesics). In some embodiments, such T-type calcium modulators lack significant effects (relative to an appropriate control) when administered to a model system for pain, and/or to one or more cells, tissues, organs or systems involved in or associated with pain or pain relief.
[00183] In some embodiments, T-type calcium modulators (e.g., selective T-type calcium modulators) utilized in accordance with the present invention do or can have pain relief activity. In some such embodiments, such modulators are administered such that pain relief activity is not observed. For example, in some embodiments, such T-type calcium channel modulators are delivered to subjects via a route, regimen, modality, and/or mechanism that does not achieve delivery of an effective amount (e.g., and amount sufficient to alter level and/or activity of a T-type calcium channel therein so that a significant biological effect is observed). In some embodiments, however, T-type calcium modulators as described herein are utilized to relieve pain.
Identifying Patients and/or Monitoring Therapy
[00184] The discoveries of the present invention provide a variety of technologies relating to identification and/or characterization of subjects in need of and/or receiving therapy for one or more lymphocyte-associated diseases disorders or conditions.
[00185] For example, in some embodiments, the present invention provides methods of identifying patients likely to benefit from therapy with T-type calcium channel modulators as described herein, for example by directly or indirectly determining level and/or activity of a T-type calcium channels active in immune cells (e.g., in lymphocytes such as T cells such as na'ive T cells and/or Thl7 cells) and/or of a relevant population of immune cells (e.g., lymphocytes and in particular T cells such as
Thl7 cells or other cells with active T-type calcium channels) in the subject by analyzing a sample obtained from the subject.
[00186] Analogously, in some embodiments, the present invention provides methods of assessing development, progression and/or treatment (e.g., responsiveness to therapy) of a relevant lymphocyte- associated disease, disorder or condition, in a subject for example by determining level and/or activity of a T-type calcium channel in or on immune cells (e.g., lymphocytes and in particular T cells such as naive T cells and/or Thl7 cells) and/or of Thl7 cells in the subject by analyzing a sample obtained from the subject. In some embodiments, the sample is obtained prior to, concurrent with, or subsequent to administration of one or more doses of a T-type calcium channel modulator as described herein. In some embodiments, such analyzing is performed on a plurality of samples from the subject, wherein different samples in the plurality were obtained at different points in time. In some embodiments, one or more doses of a T-type calcium channel modulator as described herein may be administered between such different points in time. In some embodiments, a decrease in level and/or activity of the relevant T-type calcium channel (e.g., of a CaV3.1 channel) and/or of Thl7 cells is indicative of slowed progression and/or effective treatment of the disease, disorder, or condition. In some embodiments, the invention provides methods for assessing the treatment of a lymphocyte-associated disease, disorder, or condition as described herein, by administering a selective T-type calcium channel modulator to a subject suffering from or susceptible to the disease, disorder, or condition and determining whether, after such
administering, the frequency and/or severity of clinical exacerbations was reduced, extent of disease progression was delayed or prevented, and/or frequency and/or magnitude of one or more doses of a concomitant therapy (e.g., of another selective T-type calcium channel modulator, antioxidant, immunosuppressant, or anticancer agent) was reduced.
[00187] In some embodiments, a sample obtained from a subject includes peripheral immune cells. In some embodiments, a sample obtained from a subject includes tissue (e.g., spleen, bone marrow). Those of ordinary skill in the art will be aware of appropriate sources of cells or tissue for analysis in different circumstances (e.g., peripheral blood for analysis of proportion of Thl7 cells vs other T cell subsets, for example with respect to inflammatory disease, disorders or conditions; bone marrow for analysis relevant to multiple myeloma, etc).
[00188] Those of ordinary skill in the art will be aware of a variety of technologies useful to obtain and/or process samples from subjects and/or to determine level and/or activity of a T-type calcium channel active in immune cells (e.g., in lymphocytes such as T cells such as na'ive T cells and/or Thl7 cells) and/or of a relevant population of immune cells in accordance with the present invention. To give but a few examples, well established technologies for determining protein levels include, for example,
ELISA assays and/or other direct binding assays. Technologies for determining levels of nucleic acids encoding proteins (e.g., as a proxy for level of encoded proteins) include hybridization-based
technologies, amplification technologies (e.g., using polymerase chain reaction), sequencing technologies (including for example genomic sequencing technologies), etc. Technologies for determining activity of T-type calcium channels include, for example, whole-cell patch-clamp electrophysiology, calcium assays (e.g., FLIPR). Technologies for determining relative populations of Thl7 cells as compared with other T cell subsets, for example, include flow cytometry (FCM, e.g., FACS), measurement of transcription factor (e.g., RORgT) expression levels (e.g., by RT-PCR), detection (e.g., by intracellular staining) of cells producing particular proteins (e.g., the cytokine, IL-17), and assessment (e.g., by ELISA) of secreted protein (e.g., IL-17) levels.
EXAMPLES
Experimental Methods
Generation of Ca V3.1 -/- animals
[00189] A targeting construct was designed to knockout the pore region of CaV3.1 by using neomycin cassette to replace the exons 1 1 to 13. The targeting construct was transfected into 129/SvJ embryonic stem (ES) cells. Targeted ES clones were identified by southern blotting and used in the generation of germline chimeras. Heterozygous germ line mice (129/SvJ) were interbred to obtain homozygous mice. Male germline chimeras were also backcrossed with female C57BL/6 mice for three generations. Homologous recombination was verified by southern blotting, PCR and immunoblotting. Wild type and CaV3.1 knock out littermates (6-8 weeks) were used for phenotypic analysis. Animals were maintained at and the full barrier facility of the Center of Life Sciences which is fully accredited by AAALAC and the U.S. Department of Agriculture.
Generation of CaV3.1 AT animals
[00190] To generate animals with a T cell-specific CaV3.1 deficiency, constitutive CaV3.1 -/- mice were crossed with a transgenic strain expressing Cre under the control of the Lck promoter (B6.Cg- Tg(Lck-cre) 1 Cwi N9 mice from Taconic). The resulting pups that were CaV3.1+/- and transgenic for lck-Cre were crossed with a strain with two floxed 1 G alleles obtained from Matthew Anderson. The resulting pups that were CaV3.1 floxed/- and transgenic for lck-Cre should have a CaV3.1 deficiency limited to T cells. Their littermates negative for Cre were used as control.
T cell preparation
[00191] Mouse thymus, spleen and lymph nodes were dissected from wild type and CaV3.1-/- and CaV3.1 ΔΤ mice. Cells in suspension were recovered. T cells were negatively enriched from pooled splenocytes and lymph node cells using a mouse pan T isolation kit (Miltenyi Biotec). CD4+ T cells were enriched using a mouse CD4+ T cell isolation kit (Miltenyi Biotec). All antibodies were purchased from BD Pharmingen. All recombinant cytokines were from PeproTech.
Quantitative real-time RT-PCR
[00192] Total RNA was extracted from different lymphoid tissues and cell types, then reverse transcribed. Multiplex quantitative real-time PCR was performed in ABI Prism 7700 Sequence Detector or 7500 Fast Real Time PCR System (Applied Biosystems). 18S control reagents were used to normalize the quantities of target genes.
Taqman primers and probes sequences
[00193] Mouse CaV3.1 had the following sequences:
5'- TGAGGCCAAGAGTTCCTTTGA -3' (sense) (SEQ ID NO: l)
5'- GAAGCCGACTTGCCATTACAG -3' (anti-sense) (SEQ ID NO:2)
6FAM TCGGAGCTCTGCCTCTGAACACCA TAMRA (probe) (SEQ ID NO: 3)
[00194] Sequences for mouse CaV3.2 were obtained from Life Technologies Mm00445382_ml .
Sequences for mouse CaV3.3 were obtained from Life Technologies MmOl 299033_ml.
Antibody generation
[00195] We designed a unique peptide located in the C terminus, CPGVEGPDSPDSPKPGA.
Rabbit polyclonal antibodies with reactivity to this sequence were generated by Invitrogen. This antibody was tested on human embryonic kidney cells (HEK 293) transfected with either a myc tagged cDNA for CaV3.1, or the empty vector. This anti-CaV3.1, or an anti-myc mAb, immunoprecipitated and immunoblotted a band of the expected size, about 250kD, from HEK293 cells transfected with CaV3.1, but not from HEK293 cells transfected with the empty vector (Figures 5A-5C).
CaV3.1 overexpression
[00196] The full-length cDNA encoding human CaV3.1 was subcloned into the pcDNA4TO- myc-his expression vector and transiently transfected into 293 cells. Control clones were generated in parallel with empty vector. CaV3.1 over-expression was verified by immunoblotting.
Immunoblotting and immunoprecipitation
[00197] Cells were lysed in RIPA buffer and protease inhibitors. The lysates were separated by
3-8% SDS-PAGE, then blotted with the polyclonal anti- CaV3.1 antibodies and visualized by ECL detection (GE Healthcare). For immunoprecipitation (IP), polyclonal anti-CaV3.1 antibody or irrelevant rabbit IgG was bound to Dynabeads (Invitrogen) and then incubated with RIPA cell lysates. IPs were resolved on SDS-PAGE gels and proteins were detected by immunoblotting with antibodies as indicated.
Cell surface protein isolation
[00198] Cell surface proteins were isolated and purified with The Cell Surface Protein Isolation
Kit (Thermo Scientific Pierce) according to the manufacturer's suggestions.
Electrophysiology
[00199] Whole-cell patch clamp recordings were carried out using an Axopatch 200B and
Digidata 1440A (Axon Instruments). Only cells with tight seals (>16 GO) were selected to break in. Cells were maintained at a -90 mV holding potential during experiments. Immediately after establishing the whole-cell patch clamp configuration, voltage steps (10 mV increments from a holding potential of - 90 mV up to +50 mV) lasting 250 ms were applied every 2 s. The liquid-junction potential offset was around 4.3 mV and was corrected. Bath solution: 120 mM tetraethylammonium chloride, 10 mM CsCl, 10 mM CaCl2, 10 mM HEPES (pH adjusted to 7.4 with CsOH). Pipette solution: 105 mM Cs- methanesulfonate, 10 mM Cs- 1 ,2-te-(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid (Cs-BAPTA), 5 mM CaCl2, 8 mM MgCl2, and 10 mM HEPES (pH adjusted to 7.2 with CsOH). Calculated buffered intracellular Ca2+ concentration is 150 nM using Maxchel software available online at
http://maxchelator.stanford.edu/. Clampfit 10.1 software was used for data analysis. Pipettes were pulled by a P-97 flaming/brown micropipette puller (Sutter Instrument Company) and polished with DMF1000 (World Precision Instruments). Resistances of filled pipettes ranged 2-3 ΜΩ.
Fluorometric Imaging Plate Reader Assay (FLIPR)
[00200] Cells were stained with fluo4 (4 μΜ) at 37 °C and 5% C02 for 1 h in cell culture medium, then washed with HBSS. The plate was then placed in the Fluorometric Imaging Plate Reader (FLIPR) instrument (Molecular Devices, Sunnyvale, CA, USA) where baseline fluorescence was recorded, then thapsigargin followed by calcium were added. Ca2+ entry was calculated relative to the baseline- subtracted signal derived from wells in Ca2+-free HBSS (F/F0).
Flow cytometric measurement of calcium flux
[00201] Splenocytes suspended in HBSS buffer containing 1.25 mM calcium, 1 mM magnesium,
0.5% BSA were loaded with 2 mM Indo-1 mixed with Pluronic F-127 at 37°C for 45 minutes. The cells were washed and resuspended in HBSS buffer containing 1.25 mM Ca, 1 mM Mg and 0.5% BSA, then labeled with anti-CD4-FITC on ice for 30 min, and then washed and loaded with biotinylated anti-CD3 (10 μg/mL). The CD4+ cells were gated and analyzed on a Becton Dickinson LSRII with
FACSDivasoftware using the violet and blue channels. After measuring the baseline for 2 min, streptavidin (20 μg/mL) was added.
Asthma model
[00202] Twenty wild type mice and 20 gender-matched CaV3.1 -/- littermates, aged 6-8 weeks, were immunized intraperitoneally (IP) with 50 mg of ovalbumine (OVA) and 1 mg of alum at day 0, 7 and 14. The mice were challenged intranasally with 100 mg of OVA or buffer at day 21, 22 and 23. At day 24 lung function was measured in anesthetized and ventilated mice using a Scireq FlexiVent pulmonary mechanics analyzer. The parameters measured were pulmonary resistance and dynamic compliance. Mice were then euthanized with an overdose of pentobarbital and bronchoalveolar lavage (BAL) performed with PBS. BAL cells were pelleted, counted, and analyzed after Cytospin and Diff- Quik staining. BAL fluids were analyzed for cytokine content by ELISA. The lungs were harvested and processed for histological analysis.
EAE model
[00203] Wild type and CaV3.1 -/- and CaV3.1 ΔΤ female littermates aged 10- 12 weeks were used. At day 0 they were injected with myelin oligodendrocyte glycoprotein (MOG)/CFA emulsion (Hooke Laboratories) containing 1 mg/mL MOG35-55 and 2 mg/mL killed mycobacterium tuberculosis H37R in an oil emulsion, into two sites in the upper and lower back (100 μΐ per site) subcutaneously. Within 2 hours of these injections the mice were injected IP with pertussis toxin (165 ng in 100 ml PBS). The toxin injection was repeated 24h later. Mice were weighed and score daily using the following standard scale. 0: Normal, no signs of neurological disease. 1 : Flaccid paralysis of the tail; partial or no tail muscle tone. Mouse is unable to curl tail around finger or pencil. No significant gait abnormalities. 2: Hind limb paresis, weak or wobbling gait, impaired righting reflex. 3: Bilateral hind limb paresis. Mouse drags its hind limbs over flat surface. Mouse exhibits incontinence. 4: Hind and forelimb paralysis. Mouse barely moves around. 5: Complete hind and complete front leg paralysis, no movement. Mice were observed up to day 30. Mice were euthanized at the end of the experiment or earlier if they displayed severe paralysis or lost 20% weight, and scored 5 for remainder of experiment. Results from independent experiments were pooled.
Thl 7 cell differentiation
[00204] To skew T cell differentiation towards the Thl 7 phenotype, mouse spleen was dissected from wild type and CaV3.1 ΔΤ mice. Cells in suspension were recovered. Pooled splenocytes were cultured for 5 days in 96-well plates coated with anti-CD3 (145-2cl 1, 10 μg/mL) and soluble anti-CD28 (10 μg/mL) in the presence of 2.5 ng/mL human TGF-beta, 20 ng/mL IL-6, 10 ng/mL IL-23, 10 μg/mL anti-IFN-γ, and 10 μg/mL anti-IL-4 (murine, unless otherwise specified). CD4+ IL-17+ cell counts were performed.
Statistical analyses
[00205] Continuous data were compared between genotypes by the Wilcoxon rank-sum test.
Example 1: CaV3.1 is expressed on the surface of CD4+ T cells
[00206] We first investigated whether CaV3.1 is expressed in T cells. To assess CaV3.1 gene expression, we performed quantitative RT-PCR in primary CD4+ T cells from murine lymph nodes, spleen, and thymus, as well as in the EL-4 T cell lymphoma line. CaV3.1 was expressed in all of these T
cell populations (Figure 1A), at expression levels lower than those observed in the brain (Figure IB). To assess CaV3.1 protein expression, we generated an antibody specific to CaV3.1, by selecting for antibodies reactive to a peptide unique to CaV3.1 among voltage-activated calcium channels. The specificity of this antibody was confirmed using multiple cell types from CaV3.1 -/- mice (Figures 5A). This anti-CaV3.1 antibody was used to assay lysates of CD4+ T cells by immunoprecipitation and immunoblotting. CaV3.1 protein was detected as a band of the expected size (-250 kD), which was absent after immunoprecipitation with normal IgG (Figure 1C). Therefore, CaV3.1 message and full- length CaV3.1 protein are indeed expressed in T cells.
[00207] To determine whether CaV3.1 is expressed at the plasma membrane in T cells, we performed surface biotinylation of murine CD4+ T cells followed by purification of biotinylated proteins on an avidin column. In the eluate of the avidin column a band of the expected size for CaV3.1 was identified after blotting with anti-CaV3.1, while blotting with an antibody against the strictly intracellular protein, Gata-3, was negative (Figure ID, lane B). In the flow-through, non-biotinylated fraction of the avidin column, both CaV3.1 and Gata-3 were detected (Figure ID, lane N). These results established that CaV3.1 is present on the surface of CD4+ T cells.
Example 2: Deletion of Ca V3.1 by homologous recombination
[00208] As tools for subsequent studies, we generated two strains of mice. Mice with a constitutive deletion of CaV3.1 were generated by homologous recombination (Figures 5B-5C and
Figures 6A-6C). These CaV3.1-/- mice were born with the expected frequency, did not display any gross abnormalities, developed normally, were of normal fertility, and could reach at least 17 months of age, findings similar to those reported for another strain of CaV3.1 -/- mice7. We also generated a mouse strain with a T cell-specific CaV3.1 deficiency ("CaV3.1 ΔΤ") through Cre-lox recombination, with Cre under the control of the Lck promoter. Using quantitative RT-PCR, we found a 60% reduction in CaV3.1 message in CD4+ T cells from CaV3.1 ΔΤ animals, as compared to the complete deficiency of message observed in cells from the constitutive CaV3.1 -/- animals (Figure IE). We found that CaV3.2 channels were also expressed in wild-type splenic CD4+ T cells, and that their expression was increased in CaV3.1 -/- cells; CaV3.3 expression was not detected in wild-type cells, but was detected in CaV3.1 -/- cells (Figure IE).
Example 3: CaV3.1 is a functional calcium channel in T cells
[00209] We next assessed whether CaV3.1 in T cells acts as a functional channel, and if so whether it displays similar properties to that of CaV3.1 channels in other tissues. Whole-cell voltage- clamp recordings were conducted in primary splenic CD4+ T cells from wild-type mice. Without exception, currents displayed a uniquely T-type channel profile (summary data in Figure 2A, raw data in Figure 2B, Figure 2C, and Figures 7A-7C), with an activation threshold at -70 mV, a symmetric current/voltage (I/V) relationship, and rapid inactivation. The magnitude of the T-type current is significant, exceeding that of CRAC channels. In cells from CaV3.1 -/- littermates, the current was markedly reduced (Figure 2A). Treatment with mibefradil, a T-type-selective calcium channel inhibitor, almost completely reduced the current in cells from both wild-type and CaV3.1 -/- animals. The incomplete reduction of T-type currents in CaV3.1 -/- cells is likely due to compensatory expression of CaV3.2 and CaV3.3 channels (Figure IE). The slight rightward shift in the current-voltage curve in cells from CaV3.1 -/- cells is consistent with the appearance of CaV3.3 channels, whose peak currents occur at slightly higher potentials. Taken together, these data demonstrate that multiple T-type calcium channel subtypes are expressed and functional as channels in T cells and mediate a substantial current with a low activation threshold. Based on single-channel recordings, we estimate that a population of 200 to 400 T- type channels are expressed per T cells. Given the fast inactivation kinetics of the wild-type current with a time constant less than 30 ms at -40 mV, together with the data generated in CaV3.1 -/- cells, we believe that CaV3.1 is the predominant T-type channel subtype in wild-type T cells (cf. inactivation time constants: CaV3.1 (30 ms); CaV3.2 (47 ms), CaV3.3 (137 ms)).
[00210] We then investigated whether calcium influx via CaV3.1 channels might regulate or mediate signaling downstream of TCRs. We first used a standard method for activating CRAC channels, treatment with thapsigargin, an inhibitor of sarco/endoplasmic reticulum Ca2+ ATPase. Calcium influx triggered by thapsigargin was indistinguishable in CD4+ T cells from wild-type and CaV3.1 -/- littermates (Figure 2D). We next stimulated CD4+ T cells with an anti-CD3 antibody and again found no differences in calcium influx between wild-type and CaV3.1 -deficient cells. We therefore observed no role for CaV3.1 in TCR-mediated signaling.
Example 4: Ca V3.1 does not play a role in T cell maturation
[00211] We also explored a potential role for CaV3.1 in T cell maturation. We compared CD4 and CD8 expression profiles between WT and CaV3.1 -/- thymocytes and found no differences in thymic development (Figure 9A). Analysis of CD25+ CD44+ cells among the CD4- CD8- cells, as well as of the TCRaP expression pattern, further indicated normal staging of the maturation of CaV3.1 -/-
thymocytes (Table 1). No significant differences in the expression of TCR, T cell co-stimulators, or T cell activation markers, including CD44, CD25, CD69, and CD62L, were observed between wild-type and CaV3.1 -/- CD4+ thymocytes, or in peripheral lymphocytes (Table 1). Nor were differences found in the rates of proliferation of naive CD4+ T cells (Figure 9B). Taken together, these results demonstrate that CaV3.1 does not play a role in the maturation of CD4+ or CD8+ T cells.
Table 1
Example 5: Ca V3.1 deficient mice are protected against experimental autoimmune encephalomyelitis (EAE)
[00212] To further investigate the role of CaV3.1, we conducted in vivo studies using two disease models, the Th2 -mediated asthma model, and the Thl7-mediated experimental autoimmune
encephalomyelitis (EAE) model. In the asthma model, wild-type and CaV3.1 -/- littermates were immunized with OVA and alum and challenged with OVA or saline. No differences were observed between animals across all parameters measured (Figures 10A-10D).
[00213] In the EAE model, animals were immunized with myelin oligodendrocyte glycoprotein peptide and followed for up to 32 days. With this protocol, all but one wild-type animal developed paresis, with some animals displaying remitting and relapsing symptoms. In contrast, CaV3.1 -/- mice were markedly resistant to EAE induction (Figures 3A-3D). In CaV3.1 -/- mice, paresis was delayed or absent (Figure 3A) and weight loss was reduced or did not occur (Figure 3B). Histology in wild-type mice showed multiple foci of inflammatory cells, in particular perivascularly, while such lesions were rare or absent in CaV3.1 -/- mice (Figures 11A-11B).
[00214] To assess whether the protection against EAE in constitutive CaV3.1 -/- mice was due to the absence of CaV3.1 in T cells, we conducted EAE studies using our CaV3.1 ΔΤ mice with the T cell-
specific CaV3.1 deficiency. Even with the partial (60%) reduction in CaV3.1 message in CaV3.1 ΔΤ cells, CaV3.1 ΔΤ mice were also found to have markedly reduced EAE signs. In this experiment, it was necessary to prematurely euthanize four of 16 wild-type mice due to complete paralysis.
[00215] As with the CaV3.1 -/- mice, in CaV3.1 ΔΤ mice, paresis was delayed or absent (Figure
3D), weight loss was reduced or did not occur (Figure 3E), and no cases of complete paralysis occurred. Histology in wild-type mice showed multiple foci of inflammatory cells, in particular perivascularly, while such lesions were rare or absent in CaV3.1 ΔΤ mice (Figures 11A-11B). In addition, it was observed that those animals (primarily CaV3.1 -/- mice) that displayed lower levels of EAE signs typically had enlarged spleens. Without wishing to be bound by any particular theory, we propose that one possible explanation for this observation is that inhibition of CaV3.1 channels in lymphocytes in the spleen (and other lymphoid organs) may lead to sequestration of these lymphocytes in these lymphoid organs.
Example 6: CaV3.1 is involved in Th 17 differentiation
[00216] The resistance of both CaV3.1 -/- and CaV3.1 ΔΤ animals to EAE led us to investigate a potential role in Thl7 cells for CaV3.1 channels, since Thl7 cells are considered to be the major effector T cell population in EAE pathogenesis. We used an in vitro system to differentiate splenocytes into Thl7 cells, consisting of TCR ligands, TGFB, IL-6, and other cytokine receptor ligands. From splenocytes harvested from EAE-induced mice, we observed a 71% reduction in the proportion of Thl7 cells in CaV3.1 ΔΤ versus wild-type animals (Figures 4A-4C). Similarly, from splenocytes from EAE-nai've mice, we observed a 47% reduction in the proportion of Thl7 cells in CaV3.1 ΔΤ versus wild-type animals (Figure 12).
[00217] We analyzed the expression in this Thl7 differentiation system of RORyt, a transcription factor critical to Thl7 differentiation. Splenocytes showed lower expression of RORyt in CaV3.1 ΔΤ cells versus wild-type cells (Figure 4D). Together with the lack of any observed interaction between CaV3.1 and either TCR-mediated calcium entry or CRAC channel modulation (Figures 2D-2E), these data suggest that CaV3.1 promotes T cell differentiation into the Thl7 subset, independently of TCR engagement.
[00218] We also assessed the timecourse of mRNA expression of Cav3.1 during the
differentiation of naive T cells in conditions favoring Thl7 differentiation. Naive CD4+ T cells were isolated from 4 WT mice spleen and lymph nodes. The naive CD4+ T cells were skewed to Thl7 cells for 3, 6, 12, 24, 48 and 96 hours. Total RNA was isolated and Cav3.1 was detected by RT-PCR using
Taqman primers and probes. As shown in Figure 13, Cav3.1 mRNA levels were observed to drop between 12 and 24 hr following initiation of differentiating naive T cells to Thl7 cells. Without wishing to be bound by any particular theory, we propose that one possible explanation for this observation is that Cav3.1 may play the role of a differentiation "switch."
Example 7: Pharmacological inhibition of T-type calcium channels
[00219] Using a potent and selective T-type calcium channel antagonist known as TTA-A2 (see
Kraus et al J. Pharmacol. Exp Ther. 335(2): 409, 2010), we demonstrated pharmacological effects of such a T-type calcium channel activator on immune cells (specifically, CD4+ T cells).
[00220] In particular, we demonstrated that such a T-type calcium channel antagonist inhibited T- type calcium current as a function of antagonist concentration. As shown in Figure 14,
electrophysiological measurements of T-type calcium current in these cells was potently inhibited by TTA-A2, in a concentration-dependent manner.
[00221] We also demonstrated that such a T-type calcium channel modulator significantly impacted differentiation of Thl7 cells. Naive CD4+ T cells were pre-treated with TTA-A2 for 24 hours. Pre-treated cells were then differentiated to Thl7 cells for 4 days with continued drug treatment for 1 day. Then, after 4 days, intracellular cytokine staining was performed for IL-17F, a marker of Thl7 cell differentiation. We found that 61.4 ± 4.7 percent of untreated cells stained positive for IL-17F, whereas only 33.7 ± 5.8 percent of TT A- A2 -treated cells stained positive. These data showed that TTA-2 significantly inhibited Thl7 cell differentiation.
[00222] Still further, we demonstrated pharmacological effects of such a T-type calcium channel modulator in an animal model of multiple sclerosis, EAE. As shown in Figure 15 (average EAE scores over time: green triangles = Control; blue diamonds = TTA-A2), onset of significant symptoms (as reflected by EAE score) was delayed in animals treated with TTA-A2 (oral route, 10 mg/kg bid).
Moreover, maximum EAE score was dramatically (more than 50%) reduced, and observed score was lower following disease initiation.
[00223] Furthermore, from both groups of these EAE mice, i.e., TT A- A2 -treated and vehicle- treated, splenocytes were surface stained with anti-CD4-FITC, anti-CDld/aGalcer-PE, anti-TCRab-APC, anti-NKl .1 -APC-cy7 to analyze the proportion of invariant NKT (iNKT) cells. We observed that the proportion (in percent) of iNKT cells was higher in EAE mice treated with TTA-A2 (5.81 ± 0.81 1) vs with vehicle (4.03 ± 1.44), p = 0.036. Since iNKT cells have been observed by others to be protective in autoimmune diseases including multiple sclerosis (see, for example, Subleski et al. Immunotherapy 3(10): 1167-1 184. Oct 201 1), without wishing to be bound by any particular theory, enhancement of the
iNKT population following T-type calcium channel inhibition could be an additional mechanism contributing to the amelioration of EAE symptoms and potentially of autoimmune diseases in general.
[00224] In conclusion, the data presented in this Example confirm that, as described herein, our results show for the first time that T-type calcium channels are expressed and functional as channels in T cells, in which CaV3.1 is the predominant subtype. Our results also show that CaV3.1 channels play a key role in Thl7 differentiation. The predominance of CaV3.1 in T cells and the marked effects of CaV3.1 inhibition on the autoimmune response in EAE, even in the face of some compensatory expression of other T-type calcium channels, suggest that therapeutic modulation of CaV3.1 -mediated signaling has the potential to rebalance T cell subsets in the context of autoimmune disease.
Other Embodiments
[00225] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.
[00226] All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
What is claimed is:
Claims
1. A method comprising steps of:
administering to a subject suffering from or susceptible to a lymphocyte-related disease, disorder, or condition a composition comprising a selective T-type calcium channel modulator in an amount sufficient to treat said disease, disorder, or condition.
2. The method of claim 1, wherein said selective T-type calcium channel modulator selectively targets CaV3.1.
3. The method of claim 1, wherein said selective T-type calcium channel modulator is a selective T- type calcium channel inhibitor which is ethosuximide, phensuximide, methsuximide, methyl- phenyl-succinimide, R isomer of efonidipine, trimethadione, dimethadione, mibefradil, TTA-A2, TTA-A8, TTA-P1, TTA-P2, TTA-Q3, TTA-Q6, MK-8998, Z941, Z944, ABT-639, TTL-1 177, KYSO5044, N C 55-0396 dihydrochloride, kurtoxin, or a derivative thereof, or is a selective T- type calcium channel inhibitor disclosed in Giordanetto F, Knerr L, Wallberg A. T-type calcium channels inhibitors: a patent review. Expert Opin Ther Pat. 21 :85-101, 201 1, or in any of WO2004035000, WO9304047, WO2006098969, WO2009009015, WO2007002361,
WO2007002884, WO2007120729, WO2009054982, WO2009054983, WO2009054984, US20090270413, WO20081 10008, WO2009146539, WO2009146540, US8,133,998,
WO2010083264, WO2006023881, or WO2006023883, or WO2005007124, WO2005009392, US2005245535, WO2007073497, WO200707852, WO2008033447, WO2008033456,
WO2008033460, WO2008033464, WO2008033465, WO2008050200, WO2008117148, WO2009056934, EP1568695, WO2008007835, KR754325, US7319098, US20100004286,
EP 1757590, KR2009044924, US2010094006, WO2009035307, US20090325979, KR75758317, WO2008018655, US20080293786, or US20100056545.
4. The method of claims 2 or 3, wherein said disease, disorder or condition is or comprises multiple sclerosis.
5. The method of claim 1, wherein said disease, disorder or condition is or comprises a Thl7- mediated autoimmune disease.
6. The method of claim 1, wherein said disease, disorder or condition is or comprises psoriasis.
7. The method of claim 1, wherein said disease, disorder or condition is or comprises multiple myeloma.
8. The method of claim 1, wherein said selective T-type calcium channel modulator selectively targets one or more T-type calcium channels in lymphocytes.
9. The method of claim 8, wherein said selective T-type calcium channel modulator selectively targets one or more T-type calcium channels in T cells.
10. The method of claim 8 or claim 9, wherein said selective T-type calcium channel modulator selectively targets CaV3.1.
1 1. The method of claim 9 or claim 10, wherein said selective T-type calcium channel modulator selectively targets one or more T-type calcium channels in naive T cells, Thl7 cells, and/or iNKT cells.
12. The method of any one of claims 9-1 1, wherein said selective T-type calcium channel modulator modulates T cell differentiation.
13. The method of claim 1, wherein said selective T-type calcium channel modulator is or comprises an anti-T-type calcium channel antibody, an RNAi agent, a small molecule, or a peptide.
14. The method of claim 13, wherein said selective T-type calcium channel modulator does not preferentially cross the blood brain barrier.
15. The method of claim 14, wherein said selective T-type calcium channel modulator does not substantially cross the blood brain barrier.
16. The method of claim 13, wherein said selective T-type calcium channel modulator is
preferentially distributed to part or all of the immune system, including bone marrow, thymus,
lymphatic system, lymph nodes, spleen, and/or mucosal and cutaneous lymphoid tissues in the gastrointestinal tract, respiratory system, genitourinary system, and/or skin.
17. The method of claim 1, wherein said disease, disorder or condition is an autoimmune disease is selected from the group consisting of: amyotrophic lateral sclerosis, multiple sclerosis, rheumatoid arthritis, systemic lupus, psoriasis, diabetes mellitus type 1 , sympathetic ophthalmia, thrombocytopenia, inflammatory bowel disease (Crohn's disease, ulcerative colitis), Grave's disease, Hajimoto's thyroiditis, Sjogren's syndrome, autoimmune aplastic anemia, autoimmune cardiomyopathy, autoimmune enteropathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune myocarditis, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune urticaria, and autoimmune uveitis, acute disseminated encephalomyelitis, ankylosing spondylitis,
dermatomyositis, eosinophilic fasciitis, fibromyalgia, Goodpasture's syndrome, Guillain-Barre syndrome, Miller- Fisher syndrome, Hashimoto's encephalopathy, idiopathic thrombocytopenic purpura, inflammatory myopathy, Kawasaki's disease, Lambert-Eaton myasthenic syndrome, myasthenia gravis, neuromyelitis optica (Devic's disease), neuromyotonia, osteoarthritis, pemphigus vulgaris, pernicious anaemia, polymyositis, primary biliary cirrhosis, progressive inflammatory neuropathy, psoriatic arthritis, Raynaud phenomenon, relapsing polychondritis, restless leg syndrome, sarcoidosis, scleroderma, stiff person (man) syndrome, temporal (giant cell) arteritis, transverse myelitis, undifferentiated connective tissue disease, vasculitis, vitiligo, Wegener's granulomatosis.
18. The method of claim 1, wherein said disease, disorder or condition is selected from the group consisting of: allergic asthma, hay fever, allergy, erythematosus, T cell lymphoma expressing ICOS, rejection of a transplanted organ or tissue, alopecia areata, atherosclerosis, and graft- versus-host disease.
19. The method of claim 1, wherein said disease, disorder or condition is selected from the group consisting of: erythematosus, T cell lymphoma expressing ICOS, rejection of a transplanted organ or tissue, alopecia areata, atherosclerosis, and graft-versus-host disease.
20. The method of claim 1, wherein said disease, disorder or condition is an infectious disease is selected from the group consisting of: lower respiratory infections, HIV/AIDS, diarrheal diseases, tuberculosis, malaria, measles, pertussis, tetanus, meningitis, syphilis, hepatitis B, and tropical diseases.
21. The method of claim 1 , wherein said disease, disorder or condition is a T cell cancer selected from the group consisting of T cell leukemia and T cell lymphoma.
22. The method of claim 1, wherein said amount sufficient is an amount sufficient to reduce the frequency of clinical exacerbations, and/or delay or prevent disease progression, rather than used to reduce the degree of pain or the degree of other clinical manifestations associated with said diseases or conditions.
23. The method of claim 1, wherein said method further comprises administering to said subject a second agent, and further wherein the amount sufficient is an amount of the selective T-type calcium channel modulator that is sufficient, when administered in combination with said second agent to treat said disease, disorder, or condition, which amount may be less than that required for the selective T-type calcium channel modulator to treat the disease, disorder or condition if administered alone.
24. The method of claim 23, wherein said second agent is or comprises another selective T-type calcium channel modulator, an antioxidant, an immunosuppressant, or an anticancer agent.
25. The method of claim 23, wherein said second agent is or comprises an immunosuppressant that is selected from the group consisting of: a calcineurin inhibitor, tacrolimus, an mTor inhibitor, fingolimod, myriocin, alemtuzumab, rituximab, an anti-CD4 monoclonal antibody, an anti-LFAl monoclonal antibody, an anti-LFA3 monoclonal antibody, an anti-CD45 antibody, an anti-CD 19 antibody, monabatacept, belatacept, indolyl-ASC; azathioprine, lymphocyte immune globulin and anti-thymocyte globulin [equine], mycophenolate mofetil, mycophenolate sodium, daclizumab, basiliximab, cyclophosphamide, prednisone, prednisolone, leflunomide, FK778, FK779, 15- deoxyspergualin, busulfan, fludarabine, methotrexate, 6-mercaptopurine, 15-deoxyspergualin, LF 15-0195, bredinin, brequinar, and muromonab-CD3.
26. The method of claim 23, wherein said second agent is or comprises an antioxidant that is selected from the group consisting of: vitamin D, calcitriol, calcidiol, or other vitamin D receptor binder, quercetin or other flavonoid, resveratrol or other sirtuin modulator.
27. The method of claim 23, wherein said second agent is or comprises an anticancer agent that is selected from the group consisting of: a chemotherapeutic agent, an antiangiogenic agent, a mitotic inhibitor, a nucleoside analog, a DNA intercalating agent, and a topoisomerase analog.
28. A method for assessing development, progression and/or treatment of a relevant lymphocyte- associated disease, disorder or condition in a subject, the method comprising:
determining a level and/or activity of a T-type calcium channel in or on immune cells (e.g., T cells such as naive T cells, Thl7, and/or iNKT cells) and/or of Thl7 cells and/or iNKT cells in the subject by:
analyzing a sample obtained from the subject.
29. The method of claim 28 wherein said immune cells are or comprise T cells.
30. The method of claim 29 wherein said immune cells are or comprise naive T cells, Thl7, and/or iNKT cells.
31. The method of claim 28 wherein said sample is obtained prior to, concurrent with, or subsequent to administration of one or more doses of a T-type calcium channel modulator.
32. The method of claim 28 wherein said step of analyzing is repeatedly performed, on a plurality of samples from the subject, wherein different samples in the plurality were obtained at different points in time.
33. The method of claim 32 further comprising one or more steps of administering a dose of a T-type calcium channel modulator, wherein different such steps of administering are performed between the different points in time.
34. A method for assessing the treatment of a lymphocyte-associated disease, disorder, or condition by:
administering a selective T-type calcium channel modulator to a subject suffering from or susceptible to the disease, disorder, or condition; and
determining whether, after such administering, the frequency and/or severity of clinical exacerbations was reduced, extent of disease progression was delayed or prevented, and/or frequency and/or magnitude of one or more doses of a concomitant therapy was reduced.
35. A method for identifying or characterizing an agent for activity as a selective T-type calcium channel modulator by:
contacting the agent with a system comprising lymphocyte cells on which a T-type calcium channel is active; and
detecting a specific effect of the agent on level or activity of the T-type channel.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261691006P | 2012-08-20 | 2012-08-20 | |
US61/691,006 | 2012-08-20 | ||
US201261739861P | 2012-12-20 | 2012-12-20 | |
US61/739,861 | 2012-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014031594A2 true WO2014031594A2 (en) | 2014-02-27 |
WO2014031594A3 WO2014031594A3 (en) | 2015-07-16 |
Family
ID=50150473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/055711 WO2014031594A2 (en) | 2012-08-20 | 2013-08-20 | Modulating voltage-operated calcium channels on immune cells |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014031594A2 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7195783B2 (en) * | 1999-07-09 | 2007-03-27 | Fx Life Sciences International Gmbh | Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
US20030232336A1 (en) * | 2000-06-06 | 2003-12-18 | Curtis Rory A. J. | Novel human ion channel and transporter family members |
CA2555319A1 (en) * | 2004-02-11 | 2005-08-25 | University Of Virginia Patent Foundation | Inhibiting cav3 isoforms and the .delta.25b splice variants for the diagnosis and treatment of cancer |
US20060003020A1 (en) * | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
WO2011032291A1 (en) * | 2009-09-18 | 2011-03-24 | Zalicus Pharmaceuticals Ltd . | Selective calcium channel modulators |
-
2013
- 2013-08-20 WO PCT/US2013/055711 patent/WO2014031594A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014031594A3 (en) | 2015-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2924071T3 (en) | Specific antibodies to human T-cell immunoglobulin and ITIM domain (TIGIT) | |
ES2918501T3 (en) | Human mesothelin chimeric antigen receptors and uses thereof | |
ES2765874T3 (en) | Anti-KIR antibodies for the treatment of inflammatory disorders | |
ES2972425T3 (en) | Antibody molecules for TIM-3 and their use | |
ES2824261T3 (en) | Compositions and procedures for the treatment of progressive multifocal leukoencephalopathy (PML) | |
KR101813482B1 (en) | Compositions and methods for treating or preventing lupus | |
US20190375844A1 (en) | Antibodies and polypeptides directed against cd127 | |
CA2922805A1 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
EP3652209A2 (en) | Agonist antibodies that bind human cd137 and uses thereof | |
JP2017517488A (en) | Treatment of cancer using an anti-CD19 chimeric antigen receptor | |
AU2013278843A1 (en) | LSR antibodies, and uses thereof for treatment of cancer | |
TW201412775A (en) | Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders | |
ES2830849T3 (en) | Assay and method for treating subjects with immune-mediated diseases | |
US20180044422A1 (en) | Treating solid tumor by targeting dectin-1 signaling | |
CA3091996A1 (en) | Inhibitors of pla2-g1b cofactors for treating cancer | |
BR112021011393A2 (en) | ANTI-IL-27 ANTIBODIES AND USES THEREOF | |
US20220389102A1 (en) | Hla class i sequence divergence and cancer therapy | |
TW201929907A (en) | Use of PILRA binding agents for treatment of a Disease | |
US20180028566A1 (en) | Gamma delta t cells as a target for treatment of solid tumors | |
TW202128752A (en) | Anti-il-27 antibodies and uses thereof | |
KR20220115572A (en) | Anti-B7-H3 monoclonal antibodies and methods of use thereof | |
KR20220042131A (en) | Anti-LRRC25 compositions and methods for modulating myeloid cell inflammatory phenotype, and uses thereof | |
WO2014031594A2 (en) | Modulating voltage-operated calcium channels on immune cells | |
ES2718226T3 (en) | Linear telescopic actuator | |
ES2867373B2 (en) | THERAPEUTIC TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A MONOCLONAL ANTIBODY AGAINST THE PRE-TCR RECEPTOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13830810 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct app. not ent. europ. phase |
Ref document number: 13830810 Country of ref document: EP Kind code of ref document: A2 |